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CHAPTER I 
INTRODUCTION 
The functions of biogenic amines in the living organism have been a subject 
of keen interest for many research workers in the past decades. Two of these 
amines, noradrenaline and acetylcholine, have been firmly established as 
"neurotransmitters" - substances responsible for the transmission of nerve 
impulses via synapses or from nerve fibres to the eventually responding en-
tity, the "effector" -, but for other amines like, for instance, histamine and 
serotonin the picture is not quite so clear. 
"In retrospect, serotonin made its debut to science in 1868, when it was 
noted that defibrinated blood caused vasoconstriction" (Page 3), but its chemi-
cal structure was only revealed in 1949 when it was shown that the vasocon-
strictive substance obtained from bovine serum, serotonin, was 5-hydroxy-
tryptamine (5-HT) (Rapport). 
In 1943 the Swiss chemist A.Hofmann unintentionally inhaled a minute quan-
tity of D-lysergic acid diethylamide (LSD). He first noticed a peculiar sense 
of vertigo and restlessness, followed by a strange state of "drunkenness* and 
exaggerated imagination. After about two hours the effect passed off and he 
felt quite normal (Page 4). The potent "hallucinogenic" properties of LSI>, dis-
covered so unintentionally, provided a great stimulus towards research on the 
actions of indole compounds in general and 5-HT and its antagonists in parti-
cular, since it was shown that LSD is a potent "specific" antagonist of 5-HT 
(Gaddum 2; Woolley 9, 10) and that 5-HT is present in the brain in relatively 
large quantities (Amin; Twarog). This, along with other indications, led Woolley 
and Shaw to suggest that 5-HT may play a role in the maintenance of normal 
mental function (Woolley 1,2). It seemed that, virtually for the first time since 
Thudichum published the first work on chemistry of the brain in 1884 (Thudi-
chum), an important role in this respect could be ascribed to a chemical sub-
stance. From 1947 until the publication of Erspamer's extensive review on 
5-HT, approximately 2,000 papers have been published on this subject (Ers-
pamer 1). As research in this field progressed, some of the first postulates 
on the fact that the hallucinogenic action of LSD arises from 5-HT antago-
nism came to be questioned. It was shown, for instance, that 2-bromo-LSD 
(BOL) could antagonize 5-HT even better, but did not produce any psychic 
symptoms. 
In the meantime other aspects of the actions of 5-HT have not been for-
gotten. There are very strong indications that this amine plays an important 
role in certain processes in the periphery, like, for instance, in the regula-
tion of intestinal motility (Bülbring 1, 2; Kosterlitz). This provides all the 
more reason for a keen interest in this field. 
Many chemical compounds have already been shown to possess antagonistic 
properties towards 5-HT. A number of research workers have synthesized 
and studied series of substituted tryptamines and 5-hydroxytryptamines in 
attempts to find potent and specific 5-HT antagonists and to learn more about 
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the pharmacological actions of the indole amines in general (Vane 1; Heinzel-
man 1; Brimblecombe; Chapman; Barlow; Bertaccini 1; Gyermek 4). 
These latter studies are of special interest, since it has been demonstrated 
that changes in the chemical structure of the other biological amines nor-
adrenaline, acetylcholine and histamine or closely related compounds, lead to 
potent and specific antagonists of the respective amines. Noradrenaline anta-
gonists have been found amongst the N-aralkyl substituted noradrenaline and 
p-sympatol derivatives (Ariens 1; Koopman); antihistaminic compounds have 
been found amongst the N-aralkyl substituted ß-2-pyridylethylamine deriv-
atives (Ariëns 2; van den Brink) and substitution on acetylcholine and struc-
turally related compounds has led to various antagonists of this amine (van 
Roseum 1; Koopman; Ellenbroek). It should be noted that in the cases of nor-
adrenaline, p-sympatol and 3-2-pyridylethylamine the N-aralkyl substituted 
compounds generally behave as potent antagonists. The only case where nearly 
analogous derivatives of 5-HT have been studied, indeed led to the discovery 
of 5-HT antagonists (Gyermek 4). It seemed worthwhile to synthesize and test 
some N-aralkyl substituted 5-hydroxytryptamines and tryptamines, as well as 
other 5-HT and tryptamine related compounds, to ascertain whether some spe-
cific antagonists could be obtained, but also to find out if some systematical 
changes of pharmacological properties could be found in homologous series of 
these compounds, as has been demonstrated for the other amines. 
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CHAPTER II 
BIOCHEMISTRY, DISTRIBUTION 
AND PHARMACOLOGY OF SEROTONIN 
Quite a large amount of papers have appeared on the biosynthesis, distribu-
tion and possible physiological significance of serotonin (5-hydroxytryptamine, 
5-HT) and a number of good reviews have been written on this subject (Gyer-
mek 1; Lewis 1, 2; Page 1; Cerletti 1; Cronheim; Garattini; Erspamer 1, 2). 
Papers summarizing various findings on 5-HT antagonism also appear from 
time to time (Gyermek 1, 2; Garattini; Erspamer 1) while new antagonists of 
this amine are regularly reported. 
It is the intention to present in this chapter a short introduction into the bio-
synthesis and metabolic breakdown, distribution and possible role of 5-HT, 
while the question of 5-HT antagonists shall also be discussed. 
1. BIOSYNTHESIS AND METABOLIC BREAKDOWN 
Evidence indicates that 5-HT is synthesized in the animal body from the 
amino acid L-tryptophan, firstly by 5-hydroxylation to L-5-hydroxytryptophan 
(5-HTP) and then by decarboxylation to 5-HT. Not much is known about the 
enzyme systems responsible for the 5-hydroxylation; it is possible that apart 
from highly specific L-tryptophan-S-hydroxylase, non-specific enzymes might 
also transform L-tryptophan into 5-HTP (Garattini; Erspamer 1). 
Thedecarboxylating enzyme of 5-HTP, the so-called 5-HTP decarboxylase, 
appears to be widely distributed throughout the mammalian body, contrasting 
sharply with the limited distribution of L-tryptophan-5-hydroxylase (West 2). 
So far only three types of mammalian tissue have been shown to hydroxylate 
L-tryptophan: the gastro-intestinal mucosa, nervous tissue (including the brain), 
and, only in rats and mice, the mast cells. It is possible that the relatively 
large amounts of 5-HT found in some tissues are not synthesized in these t is-
sues, but originate from elsewhere in the body. 
There is ample reason to assume that 5-HTP decarboxylase and the well-
known DOPA decarboxylase, the enzyme responsible for decarboxylating 3,4-
dihydroxyphenylalanine (DOPA) to dopamine, are identical. Udenfriend et al. 
(Udenfriend 5) even suggested the existence of a single decarboxylase 
capable of decarboxylating L-am ino acids, but this viewpoint is not generally 
accepted. 
The main channel of 5-HT breakdown in the mammalian body is oxidation 
to 5-hydroxyindoleacetaldehyde (5-HIA aldehyde) through catalysis by mono-
amine oxidase (MAO) followed by further oxidation to 5-hydroxyindoleacetic 
acid (5-HIAA) in the presence of aldehyde dehydrogenase (Sjoerdsma; Uden-
friend 6). The 5-HIAA is excreted in the urine, mostly in the unchanged form, 
but in some species partly as the glycine conjugate 5-hydroxyindoleaceturic 
acid (5-HIAUr) (Mclsaac). 
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After treating experimental animals with relatively large doses of 5-HT or 
5-HTP, the O-glucuronide or O-sulphate of 5-HT has been found in the urine 
(Mclsaac; Weissbach 1; Erspamer 4). 
Methylation of the phenolic OH-group in 5-HT, after acetylation of the amino 
group, appears to be the route of biosynthesis of the hormone melatonin (Axel-
rod; Wurtman). Melatonin is formed in the pineal gland where it probably ful-
fils a specific function (Lemer 1,2; Marczynski). 
The synthesis and main catabolic routes of 5-HT are schematically presented 
in figure 1. 
2. DISTRIBUTION 
a. G a s t r o - i n t e s t i n a l t r a c t 
Serotonin is apparently a normal constituent of the gastro-intestinal mucosa 
of all vertebrates (Erspamer 1 ; Garattini). It is highly probable that most of 
the gastro-intestinal 5-HT is stored in the so-called enterochromaffin cells, 
which probably owe their specific histochemical properties to their content of 
5-HT or closely related 5-hydroxyindole substances. In these cells 5-HT, as 
is the case in other tissues too, is contained in a particular granular fraction 
which is rich in adenosine triphosphate (ATP) (Prusoff 1, 2). 
It is generally assumed that a large fraction of the 5-HT found in the body 
is formed in the enterochromaffin cells of the intestinal tract (Erspamer 1). 
b. B lood 
The thrombocytes of mammals are relatively rich in 5-HT, while platelet-
free plasma contains only minute quantities (West 2; Weissbach 2; Garattini). 
The calculated half-life of platelet 5-HT is 24 to 48 hours, i.e. the platelets 
practically lose their 5-HT only when disintegrating (Udenfriend 7). The con-
siderable amounts of 5-HT in spleen tissue originate in the platelets and plate-
let fragments caught in the spleen. The 5-HT concentration of the spleen is 
particularly high in those animals (rabbit, ox, hen) of which the blood contains 
large amounts of this amine. The 5-HT found in blood components is probably 
of intestinal origin (Erspamer 1). 
c. M a s t c e l l s 
Only rat and mouse mast cells have been shown to contain important amounts 
of 5-HT, either under normal or pathological conditions. The amine is probably 
synthesized in these cells from L-tryptophan, and these cells show considerable 
5-hydroxytryptophane (5-HTP) decarboxylase activity (Schindler; Day 2). Sero-
tonin is contained in specific granules of the cells, clearly separable from other 
organelles in the cell (Hagen). 
d . O t h e r e x t r a c e r e b r a l t i s s u e s 
Serotonin is found in nearly all parenchymatous tissues of rats and mice. 
Although the 5-HT in these tissues may originate from mast cells, a correla-
tion between mast cell population and 5-HT concentration is not evident (Ers-
pamer 1). 
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Fig.l. Scheme of 5-HT metabolism In mammals. 
The 5-HT in the lungs, as shown for the rabbit lung, probably originates 
from thrombocytes (Waalkes). During anaphylactic shock, when circulating 
platelets are caught in the lung, the 5-HT content of this tissue may increase 
5- to 10-fold (Waalkes). 
Serotonin is also found in the sheep thyroid gland, but the origin of the amine 
in this tissue is unknown (Erspamer 1). 
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e. C e n t r a l n e r v o u s s y s t e m 
The discovery that 5-HT occurs in the brain was made by Twarog and Page 
(Twarog) and separately by Amin et al. (Amin). The distribution in the central 
nervous system closely follows that for catecholamines; the amine is prefer­
entially contained in specific areas of the brain, some of which are connected 
with the autonomic system or with the reticular activating system, making it 
highly probable that serotonin has a specific function in the brain (see table I). 
T A B L E I 
Regional distribution of 5-HT in the brain of the dog, cat and rabbit 
Brain s tem 
Medulla 
Pons 
Cerebellum 
Midbrain· 
Thalamus 
Hypothalamus 
Caudate nucleus 
5-HT content, in μg base per g fresh t i s sue 
Dog 
0.75 
0.55-0.62 
0.39-0.42 
0.07; 0.01 
0.97 
0.57-0.65 
1.75; 0.37 
0.72; 0.27 
Cat 
0.79 
0.55-1.2 
0.33-0.7 
0.27-0.30 
1.23-1.7 
0.43-1.1 
1.78-2.5 
1.6 
Rabbit 
0.45-0.57 
0.63 
0.12; 0.03 
0.83; 0.31 
0.39 
(After Erspamer 1), 
After removal of the whole gastro-intestinal tract of rats, the 5-HT content 
of their brains remain nearly normal (Bertaccini 2) showing that 5-HT is 
probably formed locally in the brain from L-tryptophan. 
Further evidence for the biosynthesis of 5-HT in the brain is given by the 
findings that rat and pigeon brain tissue is capable of hydroxylating [ З - С ^ ] 
tryptophan, both in v i v o and in v i t r o (Gal 1, 2; Graham-Smith). It has 
also been shown that intracerebrally injected L-tryptophan produces an in­
crease of the 5-HT content of rat brain (Consolo). 
Brain tissue is known to be capable of decarboxylating 5-hydroxytryptophan 
(5-HTP) (Gaddum 7; Kuntzman). 
There still is considerable uncertainty about the cellular distribution of 
5-HT within the brain tissue. Whittaker suggests that the amine is bound to 
particles, partly in a labile and partly in a relatively stable state, and that these 
particles can take up 5-HT from supernatant fluid; a process which is depen­
dent on adenosine triphosphate (ATP) (Whittaker 1, 2). It is suggested by the' 
same author that the amine occurs in the nerve endings. Other investigators 
agree that the amine is contained for 10-80% in granules in the body of nerve 
cells (Erspamer 1), but the possibility does exist that 5-HT is contained in 
glia cells and not in true nerve cells, at least in some areas (Lewis 2). 
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3. POSSIBLE ROLE OF SEROTONIN 
a. G a s t r o - i n t e s t i n a l t r a c t 
Since most of the 5-HT found in the living organism seems to originate from 
the gastro-intestinal mucosa, it seems probable that the amine fulfils some 
function in this region. Intravenous injections of 5-HT (0.4 - 1.5 mg base) given 
to human volunteers cause a sharp rise in intestinal tone in most cases; this 
effect is accentuated by prior administration of MAO inhibitors (Clifton; Hen-
drix). The increase in tone is inhibited by anticholinergic drugs and left un­
changed by hexamethonium (Clifton). With intravenous infusion of 5-HT at 
rates of 0.1 to 0.6 mg/min it was found that while stimulating the musculature 
of jejunum and ileum, epontaneous movement of the colon was inhibited (Schmid 
1). The stimulant action resulting from infused 5-HT exhibits tachyphylaxis 
(Haverback). 
On both rat and mouse, 5-HT causes an increase in intestinal motility, this 
also being the case with the dog and the rabbit (Brittain, Erspamer 1, 3). 
Much work has been done on the effect of 5-HT on the peristalsis of the gui­
nea-pig ileum. It has been postulated that 5-HT may stimulate intestinal mo­
tility by sensitizing the sensory receptors for intraluminal pressure, and that 
these receptors trigger the peristaltic reflex (Biilbring 1, 2; Lembeck 1). 
On the basis of its effects on the intestinal tract, it is often suggested that 
5-HT might, i n t e r a l i a , function as a hormone regulating intestinal motility 
(Lembeck 1; Erspamer 1) at least in some animal species. 
b. B l o o d and c i r c u l a t i o n 
The effect of 5-HT on systemic blood pressure varies greatly according 
to the animal species employed, anaesthetic used, route of administration and 
dose (Erspamer 1). It has been suggested that hypertensive effects might be 
due to a release of catecholamines from the adrenal medulla and vascular 
walls (Erspamer 1 ; Scarinci) and the hypotension due to a release of hist­
amine (Page 2). Results obtained on reserpinized animals, however, make the 
actual importance of a catecholamine release questionable (Erspamer 1). 
It is interesting to note that 5-HT, even in very small doses, causes a strong 
constriction in some vascular areas. The constrictive action of 5-HT on the 
pulmonary vessels of the dog, for instance, exceeds that of the other biogenic 
amines (Rose; Gillie). A strong constrictive effect is also produced in the ves­
sels of the human placenta; it has been suggested that 5-HT liberated from 
disintegrating thrombocytes may participate in the spontaneous closure of the 
umbilical artery after birth (Rodegra). 
Although it has often been claimed that 5-HT increases general capillary 
resistance in man and animal, experimental results are contradictory (Ers­
pamer 1). There is also no sufficient proof for the view that 5-HT released 
from disintegrating platelets causes a shortening in bleeding time or clotting 
time of blood. 
с B r o n c h i a l s m o o t h m u s c l e 
Aerosols containing 0.5 to 1% 5-HT given to guinea-pigs produce broncho­
constriction, but tolerance to 5-HT in this respect develops soon (Herxhei-
mer 1). The bronchoconstriction is antagonized by adrenaline, noradrenaline 
and D-lysergic acid diethylamide (LSD) (Herxheimer 1). Relaxation of medium 
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sized bronchioles after 5-HT treatment is, surprisingly, reported for a num­
ber of species (Brocklehurst). 
d. K i d n e y 
An antidiuretic action of 5-HT was first demonstrated by Erspamer (Erspa-
mer 5). The mechanism by which this action is brought about is still uncertain. 
An infusion of 5 μg/kg/mm 5-HT apparently causes a reduced glomerular fil­
tration in rats (Del Greco), but a 10 to 20 μg/kg/min infusion in dogs appears to 
cause a decrease in diuresis through an enhanced reabsorption of water (Spi-
nazzola). Some authors reported a decrease in renal blood flow following 5-HT 
administration in dogs (Abrahams 1, 2) while others noticed an increase (Spi-
nazzola). A contraction of the musculature of the ureter of the dog, preventing 
passage of fluid, is also produced by 5-HT. This effect lasts only 1 to 2 min­
utes and the flow of fluid is retarded for another period of 1 to 2 minutes 
(Abrahams 2). 
e. U t e r u s 
The isolated uterus of the rat contracts in the presence of 5-HT and is often 
used to evaluate this amine and its antagonists. The sensitivity of the rat uterus 
to 5-HT is the greatest during oestrus (Robson 1). Human uterus in v i t r o also 
contracts to 5-HT (Garrett) but attempts to exhibit an effect of 5-HT on this 
organ in v i v o have not met with success (Abrahams 3). In conscious-or an­
aesthetized dogs, however, an infusion of 1 μg/kg 5-HT or more, does pro­
duce uterine contractions (Abrahams 3). 
f. N e r v o u s s y s t e m 
( i) Autonomic ganglionic transmission 
Although there is no evidence that 5-HT is liberated in the ganglia on pre­
ganglionic stimulation, it is possible that changes in the 5-HT content of the 
ganglia can influence ganglionic transmission. Injection of 5-HT into the blood 
supply of the superior cervical ganglion of the cat augments both the response 
of the nictitating membrane and the action potentials in the postganglionic nerve, 
caused by submaximal stimulation of the preganglionic nerve. Direct stimula­
tion of the superior cervical ganglion by 5-HT has also been shown to occur 
(Trendelenburg 1, 2, 3). Facilitation of synaptic transmission in sympathetic 
ganglia of the rat may be caused by 5-HT (Hertzler). Stimulation of the in­
ferior mesenteric ganglia by 5-HT has been demonstrated (Gyermek 3) and 
this effect has been used in the evaluation of some 5-HT antagonists (Gyer­
mek 2, 4, 5, 6; Bindler). 
(ii) Central nervous system 
The effects of 5-HT on the central nervous system are difficult to assess. 
Like the catecholamines, 5-HT does not pass the blood-brain barrier easily 
when given peripherally, whereby peripheral effects, such as blood pressure 
changes, intestinal hypermotility etc., may obscure effects brought about by 
an action on the central nervous system. Some investigators reported that no 
detectable increase takes place in the brains of experimental animals when 
injecting 5-HT peripherally (Udenfriend 1 ; Southern; Erspamer 1), while others 
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concluded that at least in some animal species, 5-HT given peripherally does 
reach at least certain regions of the brain (Costa 1 ; Kärki 1 ; Mclsaac). The 
latter results were critisized by Erspamer (Erspamer 1) and do not seem to 
be generally accepted as conclusive. 
The reports that 5-HT when given peripherally to test animals produces, 
as central actions, mild sedation (Shore 1, 2; Chessin; Cronheim), potentiates 
barbiturate narcosis (Brodie; Shore 2; Sturtevant; Salmoiraghi;FaBtier; Brown), 
causes changes in the electrical activity of the brain (Rothballer; Monnier 1, 2), 
causes changes in conditioned reflexes, etc. have been rather severely criti-
sized (Erspamer 1) on the grounds that when 5-HT is administered at high dose 
levels, blood pressure may fall to shock levels, gastro-intestinal distress may 
disturb the animal, the vasoconstrictive effect on cerebral vessels can affect 
brain neurons through anoxia (Malcolm), etc. 
Feldberg and Sherwood (Feldberg) have shown that injection of 5-HT directly 
into the lateral cerebral ventricle of a conscious cat produces quiescence, but 
the animal appeared to be catatonic rather than drowsy. 
It has been demonstrated that peripheral administration of DL-5-hydroxy-
tryptophane (5-HTP) produces a conspicuous increase in the 5-HT level of 
various tissues, including the brain (Udenfriend 2, 3; Davidson; Green). When 
this 5-HT precursor is given to animals pretreated with monoamine oxidase 
(MAO) inhibitors, the increase of the level of 5-HT in the brain tissue is even 
more conspicuously enhanced (Erspamer 1; Green). Administration of MAO 
inhibitors alone also causes an increase in brain levels of 5-HT (Pletscher 
1, 2; Udenfriend 4; Green). 
In rats, treatment with 5-HTP in doses between 25 and 200 mg/kg did not 
produce observable central effects (Green), but after pretreatment with MAO 
inhibitors, 5-HTP could produce tremors, excitement or increased sponta-
neous activity in mice and rats (Bogdanski 1, Erspamer 6; Green). Divergent 
results have been reported concerning the effect of 5-HTP upon behaviour of 
other experimental animals; generally results obtained with low doses (5 to 
20 mg/kg) indicate towards a decrease in spontaneous activity in dogs, cats 
and rabbits (Bogdanski 1; Monnier 1; Lewis 2; Erspamer 1) while high doses 
(30-100 mg/kg) appear to cause excitement and disorientation (Udenfriend 2, 3; 
Bogdanski 1; Monnier 1; Costa 2). Erspamer (Erspamer 1, 3) reported that 
100 mg/kg 5-HTP reproducibly abolishes thè intraspeciflc aggressive behaviour 
in 50% of treated couples of male albino mice. 
From the resultsof5-HT antagonism studies, the idea arose that this amine 
plays a role in the maintenance of normal mental functions (Woolley 1, 2). This 
direction of thought was perhaps strongly stimulated when it was shown that 
a number of drugs acting as "hallucinogens" antagonize some actions of 5-HT 
and/or are structurally related to 5-HT. Lysergic acid diethylamide (LSD), 
which was later shown to be an antagonist of 5-HT (Gaddum 2), was described 
as an extremely powerful hallucinogenic compound (Stoll). Bufotenine, the 
Ν,Ν-dimethyl analogue of 5-HT, was found to produce hallucinogenic effects 
in man when given intravenously (Fabing); the O-phosphate of N,N-dimethyl-
4-hydroxytryptamme (psilocybine) (Isbell; Hollister), a-methyltryptamine 
(Murphree), N.N-dimethyltryptamine (Sai-Halasz), N,N-diethyltryptamine 
(Böszörmenyi) all have been shown to produce psychotic effects. 
After the observation that children suffering from phenylketonuria excrete 
less than 50% of the normal urinary amount of 5-HIAA (Pare 1), the view that 
a shortage of 5-HT might contribute to mental deficiency in patients with phe-
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nylketonuria was advanced. It has been shown that phenylketonuria can be in­
duced in mice by feeding a diet rich in phenylalanine and tyrosine from birth. 
These mice have a decreased maze-learning ability, and their brains have 
been shown to contain subnormal quantities of 5-HT (Woolley 3). Both in Phe­
nylketonurie patients having a mental deficiency, and in the Phenylketonurie 
mice, however, administration of 5-HTP could not improve the condition (Pare 
2; Woolley 3). 
In the case of schizophrenia, no significant differences in 5-HIAA excretion 
from that of normal subjects could be shown, with or without a tryptophan load, 
and no correlation between schizophrenia and positive indole colour reac­
tions was obvious (Erspamer 1; Leyton). 
To conclude, it seems fairly certain that 5-HT has some function in the 
central nervous system but, in spite of numerous studies, a lot still remains 
to be elucidated. 
g. S e r o t o n i n and i n t e s t i n a l t u m o u r s 
Carcinoid tumours in the intestinal tract originating from the argentaffin 
cells are accompanied by diarrhoea, colic, flushing of the skin and attacks 
of bronchoconstriction resembling asthma (Robson 2). A high concentration 
of 5-HT was found in portions of tumours removed from patients with these 
symptoms. The 5-HT level of the blood is raised and urinary excretion of 
5-HIAA is increased (Lembeck 2; Robson 2). 
Since intravenous infusion of 5-HT can cause intestinal colic and diarrhoea, 
flushing and bronchoconstriction, the symptoms accompanying these malignant 
carcinoid tumours may be due to a discharge of 5-HT from the tumour. Symp­
tomatic treatment with 5-HT antagonists, however, has not given satisfactory 
results. 
It has been suggested that 5-HT, given hypodermically as HCl salt, exhibits 
an inhibitory effect on transplanted tumours ih rats, while 5-HIAA causes sti­
mulation of the mitotic activity (Pukhalskaya). It is still very uncertain, how­
ever, whether 5-ЬТГ plays an active role, or whether the level of 5-HT is merely 
increased because of an increase in the amount of enterochromaffin cells being 
able to synthesize the amine. 
4. ANTAGONISTS OF SEROTONIN 
A number of compounds have been described as being able to antagonize 
effects induced by 5-HT, in in v i t r o as well as in in v i v o experiments. 
The simplest way of indicating drug antagonism is usually by making use of 
isolated organ systems. Serotonin possesses the ability to cause contraction 
of some isolated smooth muscle preparations like, for instance, the isolated 
rat uterus, guinea-pig ileum or rat gastric fundus. This spasmogenic ability 
is shared by some compounds closely related to 5-HT, notably tryptamine, 
an amine identical to 5-HT except for the 5-hydroxy group. 
It is generally assumed that 5-HT and tryptamine act on the same sites or 
"receptors", since the only structural difference between these two amines 
is the fact that 5-HT possesses a 5-hydroxy group while tryptamine lacks this 
group. It may therefore be expected that antagonists of 5-HT are also anta­
gonists of tryptamine (Gaddum 1,6). 
Various investigators have examined series of tryptamine and 5-HT deriv-
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atives possessing 5-HT-like activity (Vane 1; Heinzelman 1; Gyermek 4; 
Brimblecombe; Chapman; Barlow; Bertaccini 1). It seemed possible that the 
investigations of such series might provide some insight in the structure-
activity relationships governing the actions of 5-HT and related compounds, 
and might give some clue as to the direction in which 5-HT antagonists might 
be found. 
The structure-activity relationships for a number of these compounds as 
well as for a number of 5-HT antagonists will be discussed in the next chap­
ters . 
T A B L E II 
Relative anti-5-НТ potency of lysergic acid derivatives 
on the rat uterus preparation (LSD = 100) 
I)-Lyscrgic acid monomethylanude 
monoetfn lamide 
monoisoprop\ lamide 
monopropylamide 
monobuU Umide 
monoamylamide 
amide 
pirrohdide 
morphohde (LSM) 
D-Lysergic acid dimethylamide 
diethylamide (LSD) 
dusopropylamide 
dipropylamide 
dibutylamide 
Lumi-LSD 
L-L\sergic acid diethylamide 
L-Isolysergic acid diethylamide 
D-lsolysergic acid diethylamide 
6 
12 
20 
40 
65 
75 
5 
6 
8 
28 
100 
28 
50 
27 
D-Dihydrolvsergic acid 
chetln lamide (C 9 -C l u ) 70 
2-Bromo-LSD (DOL) 70 150 
2-Jodo-LSn 50 
1-A.cctyl-LSD (ALU) 200 
1-Oxy methyl-LSD (j() 
1-Methyl-LSD (MLD) 370 
1-Methyl-BOL (MOB) 530 
1-Methyl-D-ljsergic acid ethylamide 835 
pirrolidiclc' 130 
amide 100 
1-Methyl-D-lysergic acid butanol-
amide (UML) (Deseril®) 600-700 
Ergobasine 17 
1-Methyl ergobasine 400 
Methylergobasine (Methergme®) 60 
1-Methyl-methergine 2Î0 
LSD (D-Lysergic acid diethylamide) R 1 - —H 
R 2 = _ N ( C 2 H 5 ) 2 
UML (Methysergide) R 1 - — С Н 3 
R 2 = — N H - C H - C Η ,ΟΗ 
I 
С Н 2 - С Н з 
(after Erspamer 1) 
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a. L y s e r g i c a c i d d e r i v a t i v e s 
The antagonistic properties of the hallucinogenic drug lysergic acid die­
thylamide (LSD) was first demonstrated by Gaddum (Gaddum 2, 3). A large 
number of lysergic acid derivatives have been reported to possess anta­
gonistic properties towards 5-HT (Cerletti 2, 3; Doepfner; Rothlin 1, 2). 
The most important of them are listed in table II. 
It is interesting to note that compounds like BOL and UML, although being 
even more potent antagonists of 5-HT than LSD, and although being structur­
ally very closely related to the latter, do not exhibit hallucinogenic effects. 
This has been a strong argument to support the view that the hallucinogenic 
effect caused by LSD is not simply due to antagonism of 5-HT in the central 
nervous system (Cerletti 4; Rothlin 1; Marrazzi). The compound UML has been 
successfully used against migraine (Graham; Shekelle; Leigh) and one could 
well ask if 5-HT has some role to play in the migraine syndrome, since it is 
known to exhibit vasoconstriction on the blood vessels of the brain. 
The latest LSD related drug for which a strong anti-5-НТ action has been 
reported is 8 ß-carbobenzyloxyaminomethyl-2-methyl-10a-ergoline. Anta-
gonism towards 5-HT induced bronchospasm develops slower but lasts longer 
than with UML (Beretta). 
b. I n d o l e a m i n e d e r i v a t i v e s 
Anumberof gramine derivatives have been reported to be 5-HT antagonists 
on isolated organs (Erspamer 1, 7; Quadbeck; Gaddum 1, 4, 5). One of the 
most potent antagonists in this group is 5-benzyloxygramine (Gaddum4). In 
v i v o , however, the gramines did not prove to be usable compounds in this 
respect. 
7
 1 7 1 
tryplamine gramine 
\Voolley and Shaw have synthesized a number of aminoindoles and benzyl 
analogues of 5-HT and their ethers. These compounds have been shown to 
possess considerable anti-5-НТ activity (Woolley 2, 4, 5, 6, 7; Shaw 1). The 
best known compounds of this series are BAS, BAS-phenol and BAB. 
A 
? 0 S-OH -H BAS-phenoJ 
5-OCHj -CH3 BAB 
Woolley et al. have found that BAS, when injected into the left ventricle of 
the mouse brain, causes excitation (Woolley 8). Recently an amino acid ana­
logue of BAS, tested on the grounds that it would pass the blood-brain barrier 
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more readily than BAS itself, was shown not to produce excitation when in­
jected intraperitoneally, but a mild sedation (Leonard). This discrepancy may 
be due to enzymatic breakdown of the amino acid to compounds other than 
BAS. 
Psilocybine (the O-phosphate of 4-hydroxy-N,N -dimethyltryptamine), an 
alkaloid obtained from the hallucinogenic mushroom P s i l o c y b e m e x i c a ­
na Heim, and some compounds closely related to psilocybine have been des­
cribed as 5-HT antagonists (Wiedmann; Erspamer 1; Robson 2). It is inter­
esting to note that, although not as potent, psilocybine causes psychic symp­
toms reminiscent of those produced by LSD (Isbell; Erspamer 1). 
Gyermek (Gyermek 4) described the antagonistic properties towards 5-HT 
exhibited by a series of N-benzyl and substituted N-benzyl quaternary salts 
of Ν,Ν-dimethyltryptamine, Ν,Ν-diethyltryptamine and bufotenine. Some of 
these compounds exhibited marked antagonistic actions against neural effects 
of 5-HT; especially the compound N-(m-chlorobenzyl)bufoteninium bromide 
proved to be active in this respect. It was shown that generally compounds 
with a 5-OH group are more active than the corresponding tryptamine deriv­
atives, and that the Ν,Ν-dimethyl compounds are better antagonists than the 
Ν,Ν-diethyl ones. 
Melatonin has been shown to possess some 5-HT like properties, such as 
exerting an antidiuretic effect, causing vasoconstriction in the isolated rabbit 
ear preparation, contracting the isolated rat uterus etc., although 5-HT is 
much more potent in producing the same effects (Aruntyunyan). However, an 
anti-5-НТ action on the isolated rat duodenum has also lately been demonstrated 
for melatonin (Quastel). 
It has been reported that high concentrations of 5-HT or tryptamine, when 
left in contact with isolated smooth muscle for some time, inhibit the effect 
of subsequent applications of 5-HT (Gaddum 1). This auto-inhibitive effect can 
be demonstrated on most smooth muscle preparations used for the evaluation 
of 5-HT. 
The lysergic acid derivatives mentioned previously as well as the indole 
amine derivatives discussed here, are claimed to be rather specific antago­
nists of 5-HT. The same is claimed for the cinnamamides which are discussed 
under e. The other 5-HT antagonists mentioned in this chapter are rather un-
specific in the sense that they exhibit antagonism towards some other biolo­
gical amines just as well. 
с P h e n o t h i a z i n e s 
Chlorpromazine is the most potent 5-HT antagonist among the phenothiazines 
tested (Erspamçrl); this facet of its action was first reported by Gyermek 
(Gyermek 7, 8). The antagonism is, however, not specific, since chlorprom-
azine is known to antagonize the effects of other biological amines as well. 
d. A n t i h i s t a m i n i c d r u g s 
Cyproheptadine appears to possess the strongest anti-5-НТ activity among 
the antihistaminic drugs tested (Erspamer 1); antagonism towards 5-HT has 
been reported for some other antihistaminics, especially against the asthma-
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like condition produced by 5-HT in guinea-pigs (Schmid). 
e. M i s c e l l a n e o u s a n t a g o n i s t s 
Dibenamine and dibenzyline are powerful irreversible antagonists of 5-HT, 
especially in v i t r o (Gaddumó; Erspamer l).Isopropylnoradrenaline has been 
described as a very potent 5-HT antagonist on the rat colon and guinea-pig 
ileum (Jaques). Reserpine has been reported to possess anti-5-НТ potency in 
high concentrations (Kirpekar) and also papaverine (Herxheimer 2). 
Morphine, although low in potency in this respect, has been shown to anta­
gonize 5-HT on the isolated guinea-pig ileum (Gaddum 3,6). This antagonistic 
action towards 5-HT induced contractions of the ileum is shared by atropine 
(Gaddum 6; Leitch). The antagonism towards 5-HT exhibited by morphine and 
atropine is discussed further under section 5 of this chapter. 
A new class of 5-HT antagonists, cinnamamides, has recently been des­
cribed by Krapcho and his associates (Krapcho 1, 2; Rubin). The most potent 
compound of this series was 2,-(3-dimethylaminopropylthio) cinnamanilide 
(SQ 10,643). Dombro and Woolley reported some more serotonin antagonists of 
this class and tried to show that these compounds may be seen as structural 
analogues of 5-HT (Dombro). 
5. TWO TYPES OF SEROTONIN RECEPTORS 
The fact that the spasmogenic action of 5-HT on the guinea-pig ileum could 
be partially, but not fully, antagonized by morphine, the rest of the contrac­
tion being eliminated by dibenzyline, led Gaddum and Picarelli to postulate 
that there are two types of 5-HT receptors present in this organ (Gaddum 6). 
These were called M-receptors (those that could be blocked by morphine and 
were probably located in nervous tissue) and D-receptors (those that could 
be blocked by dibenzyline and were probably located in the smooth muscle). 
Compounds active as antagonists on the M-receptors were morphine, atropine, 
cocaine and methadone, while the D-receptors are blocked by dibenzyline, 
LSD, dihydroergotamine and 5-benzyloxygramine. The M-receptors in the 
guinea-pig ileum are different from the ganglionic cholinergic receptors, since 
they are not suppressed by hexamethonium or large blocking doses of nicotine 
(Rocha e Silva). Johnson also showed recently that 5-HT acts on receptors 
different from those of nicotine or dimethylphenylpiperazine (DMPP). The con­
tractile response to an action via the M-receptors was thought to result from a 
release of acetylcholine at the myoneural junction, since this effect could be po­
tentiated by an acetylcholine esterase inhibitor (Harry; Johnson). The release 
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of acetylcholine by 5-HT in the guinea-pig ileum has recently been demonstrated 
by Brownlee and Johnson (Brownlee). 
Gyermek (Gyermek 2) has stressed that in a study of 5-HT antagonists, 
particular attention should be paid to the fact that the various antagonists do 
not exhibit the same activity on D- and M-receptors. He uses the isolated rat 
uterus to study effects on the D-(musculotropic) receptors and the inferior 
mesenteric ganglion of the cat to study effects on the M-(neurotropic) ones. 
It is mentioned that compounds like, for instance, LSD, BOL, 5-benzyloxy-
gramine, BAS and cyproheptadine exhibit mainly a blockade on the musculo-
tropic receptors, while compounds like, for instance, cocaine, N-(m-chloro-
benzyl)bufoteninium bromide and morphine act mainly on the neurotropic r e -
ceptors. 
6. REMARKS 
It is striking to note in the literature the variety of compounds described 
as antagonists of 5-HT. Only those drugs which seem to be more or less 
generally accepted as antagonists of 5-HT have been summarized under sec-
tion 4 of this chapter, but even for some of these compounds the following may 
be true. 
In the pharmacological literature a procedure often used to establish whether 
a drug is an antagonist of some agonistic compound, is to produce a certain 
effect with a fixed dose of the agonist in some biological object, and then to 
ascertain whether this effect is decreased by the presence of the possible "an-
tagonist". If the effect produced by the agonist is indeed decreased by the pre-
sence of a reasonably low dose of the "antagonist", the latter compound is 
tested in the presence of other agonists to see whether it is a "specific antago-
nist" . Some more cautious investigators then determine whether the antagonism 
found also holds true on other biological systems, but rarely does anybody 
investigate the effects of the antagonist on the whole dose-response curve of 
an agonist. In this way little, if any, information is gained on the type of anta-
gonism involved. One rarely knows whether reported antagonists act on the 
same "active sites" or "receptors" as the agonist, thereby producing a "com-
petitive antagonism" (competing with the agonist for the same receptors) or 
whether the antagonist interferes with the effect produced by the agonist in 
some other way. 
When comparing "potencies" of various agonistic compounds, various authors 
compare the dose of one agonist which produces an effect of a certain magni-
tude with the dose of a second agonist which produces an effect of the same 
magnitude. The ratio between these two doses is then presented as a potency 
ratio. This type of comparison is, however, only of real value if the log dose-
response curves of both agonists are equal in height and parallel. When stu-
dying full dose-response curves one often finds compounds which are partial 
agonists. These compounds do not reach the same maximal effect as a full 
agonist, no matter how high the dose employed. The slope of the log dose-
response curve of a partial agonist differs from the slope of the log-dose 
response curve of a full agonist, the curves are not parallel and they may even 
cross. When giving a "potency ratio" in the way described above for a full 
agonist compared with a partial agonist, this ratio will differ for each different 
magnitude of the effect used. 
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Quantitative studies on drug "potencies" and "antagonism" in the way out-
lined here have a limited value and give very little insight into the actions of 
drugs on the receptor level. Since a drug as well as a biological object are 
both composed of molecules, the action of a drug with some part or parts of 
a biological object is essentially a chemical interaction. There are known laws 
that govern chemical interactions, and these laws apply to all interactions be-
tween molecules. It seems that the only logical way to approach a study where-
by a correlation between the molecular structure of a drug and its action is 
sought, is by trying to apply the laws that govern chemical interactions. This 
leads to the study of the whole concentration-response curves of various ago-
nists, and to the study of influences of various antagonists on the w h o l e con-
centration-response curves of agonists. The application of these principles 
on the action of drugs is approached in the next chapter. 
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CHAPTER III 
MOLECULAR BASIS 
FOR THE ACTIONS OF DRUGS 
The aim of this chapter is discussing in short those principles of molecular 
pharmacology applied in evaluating experimental results presented in the next 
chapter. A number of papers have appeared on this subject, therefore it did not 
seem essential to go into great detail here; the reader is referred to the lit-
erature for a broader overview (Ariens 3, 4, 5, 6, 7; Furchgott 2; Haefely 1, 2; 
van Rossum 7, 8; van den Brink). 
It is generally accepted that most drugs which are able to cause an effect 
interact with certain molecular complexes, molecules or parts of molecules 
in the biological object. These sites of interaction are called "receptors". 
Receptors on which drug interaction can result in an effect are called "spe-
cific receptors" for these drugs with respect to that specific effect. That com-
partment of the biological object in which the specific receptors are situated 
is called the "biophase". 
A drug may also interact with other receptors, for instance with "carrier" 
molecules in the body and be transported by them, or with indifferent binding 
sites (called "silent receptors"), etc.. 
When conducting a quantitative study on the actions of drugs on their recep-
tors, it is necessary to exclude factors that may complicate the ratio between 
the dose of a drug employed and the concentration of this drug in the biophase, 
as far as possible. This requirement makes the use of intact animals inad-
visable in such a study, since, when a drug is given to an animal, it is sub-
jected to various processes before and after it reaches the biophase. The drug 
has, for instance, to be distributed through the animal body by the body fluids; 
passive or active transport through biological membranes may take place; the 
drug may be subjected to metabolism which again may result in inactivation 
or activation, etc.. All these factors make it very difficult, if not impossible, to 
conduct a quantitative study on the action of drugs on their receptors in intact 
animals. To avoid these factors as far as possible, isolated organs (or parts of 
them), immersed in organ baths filled with a suitable fluid,are employed. Hereby 
the influence of "drug transference" (drug distribution and the processes, 
like drug metabolism, possibly taking place during drug distribution) is cut 
down to a minimum. 
Although this may not always be the case, it is assumed that when a drug 
is added to the bath fluid, a linear relationship exists between the drug con-
centration in the bath fluid and the concentration in the biophase when equi-
librium is reached. For the following discussion it is provisionally assumed 
that these concentrations are equal. 
It is postulated that the specific receptors are in some way connected with 
"effectors", in which some type of response "effectuation" is induced as a r e -
sult of interaction between these receptors and drugs which are able to "sti-
mulate" the latter. It is accepted that a drug or pharmacon has to have two 
properties to produce an effect on a receptor-effector system of which the 
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receptors are not yet occupied by another drug ("empty'receptors), namely 
"affinity" towards the receptors, and, once in interaction with these, the ability 
to start a chain of events, leading to an effect in the effector. This ability to 
induce the so-called •stimulus'' is called "intrinsic activity" (Ariens 8) or 
"efficacy" (Stephenson), and a drug possessing both receptor affinity and in­
trinsic activity is called an "agonist". A pharmacon possessing only affinity 
towards the receptors in question cannot induce an effect when interacting 
with empty receptors. When such a drug is employed in the presence of an 
agonist, however, it competes with the agonist for the occupation of the re­
ceptors and reduces or nihilates the effect of the agonist, whereby higher con­
centrations of the latter have to be used to produce the same amount of ago­
nist-receptor interactions. Because of this ability, a drug with affinity but 
lacking intrinsic activity is called a "competitive antagonist" (Ariens 3, 6, 7). 
The described situation can be schematically presented as follows: 
E 
I 
R 
Λ 
A В 
A and В are the agonist and competitive antagonist respectively, competing 
for occupation of the specific receptor R on which only A is able to induce ef­
fectuation in the effector E. 
In many cases drugs can antagonize the action of an agonist without compe­
ting for occupation of the specific receptors, but by acting on other receptors, 
whereby the effect brought about by an agonist is diminished. This can be 
schematically presented in the following way: 
E 
I R' 
? i 
A 
Here В has affinity for the receptor R'. Interaction of В with R' leads to a 
decrease in the effect produced by A through an interference somewhere on or 
between the stimulus formation and eventual effect brought about by interac­
tion of A with R. В does not compete with A for occupation of the letter's spe­
cific receptors, therefore В is called a non-competitive antagonist (Ariens 3, 
6,7). 
It is very probable that many types of non-competitive antagonists, acting 
on different receptors and therefore interfering at different points of the sti­
mulus-effect chain of the agonist, are included in this group. A special case of 
non-competitive antagonism could also result when a drug B, through occupa­
tion of its receptors R', causes a decrease in the affinity between A and R; 
A then also possibly decreasing the affinity between В and R' (Ariens 4, 7; 
van den Brink). 
Other examples of antagonism which are not competitive, but do also not 
fall within the outlined group of non-competitive antagonisms may be men­
tioned, e.g. chemical antagonism, physical antagonism.etc. (Ariens 4, 5, 7). 
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These, falling outside the scope of this investigation, will not be discussed 
here. 
1. RECEPTOR AFFINITY 
As stated, it is generally assumed that a drug acts via occupation of specific 
receptors. Although the exact nature of drug receptors is by no means claimed 
to be known, it is assumed that the receptors are in about the same order of 
size as the drug molecule, whereby, in the simplest case, a reversible bimo-
lecular reaction would take place between drug and receptor. This reaction can 
be written as: 
R + A : RA (1) 
k2 
where R is a receptor molecule, A a drug molecule and RA the drug-receptor 
complex; k^ and k2 are the rate constants. 
The receptors could be homogeneously distributed in the biophase as would 
be the case when the receptor is an enzyme, or could be located on the sur-
faces of biological membranes, for instance, "active parte" of protein mole-
cules. In the former case the law of mass action (Michaelis) can be applied 
to equation 1 in order to calculate an equilibrium constant, and in the latter 
case an equation analogous to the Langmuir adsorption isotherm (Langmuir) 
could be applied. It is assumed that all the individual receptors in question 
have the same affinity towards the drug molecules and that occupation of some 
receptors does not interfere in any way with the chance of interaction with 
unoccupied ones. 
The velocity of formation of RA is: 
Ä Q R A . Q R
 r . 
k r - — . [A] (2) it 
and the velocity of disintegration of RA is 
•
ÄQRA . QRA 
— - k r — (3) 
(In equations 2 and 3 k^ and k2 are the reaction rate constants, Q R is the quan-
tity of unoccupied receptors, QRA the quantity of receptors occupied by A, V 
the volume of the biophase and [A] the concentration of drug A in the biophat-
se). 
When a state of equilibrium has been reached, the velocity of formation of 
RA is equal to the velocity of disintegration of this complex, therefore 
д ^
А
 = ^
R A
. The equilibrium constant KA, being the dissociation constant 
of RA, can be given in the following equation: 
^ [A] k 2 V · ί Α > . . . 
K A =
 ir = - Q i ^ (4 ) 
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Equation 4 can be simplified to: 
Q R ΓΑ] 
K A
 • ^ІГ < 5 ) 
The total quantity of receptors, Or equals Q R + Q R A . therefore equation 5 can 
be written as: 
К д
 . ві^ШМ
 (6) 
The fraction of the total quantity of receptors occupied can now be given in the 
following equation: 
QM . __L_
 (7) 
Qr , . KA ( 7 ) 
[A] 
When using an isolated organ in an organ bath, it should be pointed out that 
in practice it can be assumed for most cases that the number of free drug 
molecules lost through binding to receptors does not cause a significant change 
in [A], since the volume of the bath is very much larger than the volume of the 
biophase and therefore contains a great excess of drug molecules which can 
diffuse into the biophase. 
Equation 7 is used to calculate receptor occupation of any drug, whether it 
is an agonist or an antagonist. 
It should be noted that the receptor affinity can also be expressed by an af-
ki 1 
finity constant, -j-^ от1Гь ^1 e Q u a t i o n 4 · ti:iÍB being the association constant of 
the drug-receptor complex. The letter К is used to indicate an affinity con­
stant in some papers on drug interaction, while К is used here to indicate a 
dissociation constant. This distinction should be kept in mind when comparing 
calculations of different papers. 
2. INTRINSIC ACTIVITY 
Intrinsic activity has already been defined as the ability of a drug to cause 
a stimulus when occupying its receptors. This ability is ascribed only to ago­
nists. If it is assumed that the stimulus is linearly related to the quantity of 
receptors occupied by the agonist, it can be stated that: 
SA = aQRA (8) 
In this equation 8д is the stimulus produced by the concentration [A] of the 
agonist whereby QRA is the quantity of receptors occupied. The factor a ex­
presses the intrinsic activity of drug A. In the same way, the maximal stimulus 
possible on the system, S
m
, produced by a drug with a maximal intrinsic activ­
ity, a
m
, when all the receptors are occupied, is expressed as: 
Sm = a
m
Q
r
 (9) 
Since the nature of intrinsic activity is not known, it is always given as a 
relative value, the "relative intrinsic activity", a. This expresses the in-
trineic activity of a drug in relation to a maximal intrinsic activity on the re­
ceptor-effector system in question (Ariens 3, 6, 7; van Rossum 7; van den 
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Brink). 
α * — (10) 
am 
(The intrinsic activity as such is not used since in practice it is not meas­
ured; whenever the term "intrinsic activity" is employed further on, a, the 
relative intrinsic activity is meant.) 
From equations 8, 9 and 10 follows that: 
SA
 ж
 aQRA
 = α
 ORA 
Sm a
m
Q
r
 Or 
therefore, from equation 7: 
SA α 
Sm
 1 + K ^ 
[Al 
(11) 
If the magnitude of the stimulus is linearly related to the size of the effect, 
it follows that: 
f^ --!4 (12) 
bm b
m 
and therefore: 
iÊ - ' -^ <13> 
where E A is the effect produced in the presence of, [A] and E m is the maximal 
possible effect that can be evoked via the same receptors. Equation 11 can 
now be written as: 
| A = —«L· - (14) 
E m ι
 + ^ A
 v
 ' 
[A] 
It should be mentioned that there is often apparently no linear relationship 
between stimulus and effect; this complication is discussed extensively in 
literature (Ariëns 7,9; van Rossum 6, 7). The method of choice for evaluating 
the type of interference caused by a second drug on the effect produced by the 
agonist is the interpretation of changes in the log concentration-response curve 
of the agonist caused by the presence of the interfering drug. This will be dis-
cussed further on in this chapter. It should be pointed out here, though, that the 
changes in the log concentration-response curve of the agonist by various types 
of interfering drugs remain essentially the same, whether or not a linear r e -
lationship exists between stimulus and effect. A competitive antagonist always 
causes a parallel shift to the right in the log concentration-response curve 
of an agonist, while a decrease in the maximal height and slope of the curve is 
in all cases the essential phenomenon caused by a non-competitive antagonist. 
Since a linear relationship is assumed between stimulus and effect, it fol-
lows that: 
EA
 = SA „ Ом. 
EAm SAm Qr 
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and therefore, from equation 7 that: 
1 E A 
E Am 1 + K A 
[A] 
(15) 
(SAm and EAm i ß t h e maximal stimulus and maximal effect respectively 
that can possibly be obtained by A; these maxima are reached when all recep-
tors are occupied.) 
3. CONCENTRATION-RESPONSE CURVES 
Different ways of plotting concentration-response curves can be employed, 
but usually the clearest picture of different types of drug interaction is found 
when plotting the percentage effect on a linear scale against the concentration 
of the agonist in the biophase on a logarithmic scale. Curves plotted in this 
way are symmetrically S-shaped, and can be calculated from equation 14 or 
15. That concentration at which 50% of the maximal effect obtainable by drug 
A is reached (the ED50). corresponds with Кд, if the various assumptions 
made hold, since: 
when 
therefore 
lA 
EAm 2 
[A] = KA 
1 + KA [A] (from eq.14) 
Curves obtained from equation 14 by calculating ^ 1 at different values for 
Em 
[A], using other values for KA or α for each curve, show that the height of the 
curve is dependent on the value of α while the position of the curve above the 
log dose axis depends entirely on KA (see fig.l). 
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Fig.l. Theoretical log concentration-response curves for compounds with varying values 
for the affinity (І/Кд) and the intrinsic activity (a) (Equation 14). Note the parallel shift in 
the curvee with a variation in Кд, and the decrease in maximal height and in the elope with a 
decrease in a. 
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The negative logarithm of that molar concentration of an agonist whereby 
Δϋΐ equals χ may be called the pD
x
 (Ariens 7,10). The pD2 value, that value 
E A с E A ι for which _ л г п equals 2 or ^г^- equals -тг, is therefore the negative logarithm 
Ед
 EAm 2 ι 
of the dissociation constant, Кд, or the logarithm of the affinity constant ^—. 
The pD2 values will be used to indicate the receptor affinities of the agonists 
examined on isolated organs. In practice, the pD2 values are found from that 
concentration of drug in the bath fluid at which 50% of the maximal effect for 
the drug tested is reached. It is, however, not known whether the concentra­
tion in the bath fluid equals the concentration in the biophase, therefore one 
should keep in mind that pD2 values presented in the next chapter represent 
"apparent affinities" which may differ from the actual affinities. When the 
relationship between stimulus and effect is not a linear function as was as­
sumed in equation 12, the pD2 value, even if the concentration of drug in the 
biophase is known, may not be the logarithm of the affinity constant. Even in 
that case, though, pD2 values are preferred above other pD values, since the 
slope of the concentration-response curve is the steepest at the point where 
50% of the total effect is reached, whereby experimental error in fixing this 
point from a curve plotted from experimental results, is the least. 
4. DRUGS ACTING ON THE SAME RECEPTORS 
E 
ι 
R 
Λ 
А Б 
When two drugs compete for the occupation of the same receptors one can 
speak of "competitive interaction". In the above model one has to do with two 
dissociation constants, KA for the complex RA, and KB for the complex RB. 
Analogous to equation 5, these constants are: 
Q R [ A ] Q R [ B ] 
KA = ?i and KR = я 
QRA Ь QRB 
(QRB i e t h e quantity of drug-receptor complex RB.) 
The total quantity of receptors - Or - equals Q R + QRA + QRB a n c l t h e r e -
sultant effect - Е д в - is the total of the effects E A produced by [A] and Ев pro­
duced by [Β], therefore: 
E A B
 =
 EA + E B 
Em Em Em 
If now the relative intrinsic activity of drug В is β, equation 13 can be ap­
plied to both the latter terms, whereby: 
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EAB QRA ^ . QRB 
aQRA + ßQRB 
QR + QRA + QRB 
QR[A] , „QRLB] 
а
~кГ
+ р
- і^-
n
 , Q R [ A ] , Q R [ B ] 
a M ρ-M-
KA KB 
KA к в KA KB ι 
Е
АВ a β 
[Β] KA + 
КВ^А] 1 + ( 1 + Κ Χ ' Ϊ Β ] 
Em =
 1 + ( 1 + Щ К А
+
 1+а+[АІКВ (16) 
Inequation 16 the first term gives the contribution of A to the effect and the 
second term gives the contribution of В to the effect. 
a. C o m p e t i t i v e a n t a g o n i s m 
As mentioned previously, a competitive antagonist of a certain agonist is a 
drug which has affinity towards the receptors of the agonist but has no intrinsic 
activity. In this case equation 16 can be applied, taking β as zero. The third 
term in the equation then falls away, leaving: 
EAB α „-ν 
Em "
 1 + i 1 + £ ä x K A <17) 
Log concentration-response curvee for drug A in the absence and in the 
preeence of varioue concentrations of the competitive antagonist В can be 
calculated from this equation. A set of theoretical curves are presented in figure 
2. It will be noticed from this figure that increasing concentrations of В shift 
the concentration-response curve of A progressively towards higher doses. It 
appears as if В decreases the receptor affinity of A, but, by applying higher 
doses of A, a maximal effect can always be obtained; the antagonism is sur­
mountable. 
To indicate the affinities of competitive antagonists, ρ Αχ valuee according 
to Schild are often used. The ρΑχ value of a competitive antagonist can be de­
fined as the negative logarithm of that molar concentration of the competitive 
antagonist in the presence of which the concentration of agonist has to be in­
creased by a factor χ in order to obtain an equal effect. When the effect E A B 
produced by a concentration of drug A in the presence of a competitive anta­
gonist B,[Aj B· i s Çqual to the.effect EA produced by a concentration of drug 
À alone, [Α], one finds from equations 14 and 17: 
[А] В [В] 
[A] = KB 
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[A] [A] 
Fig.2. Theoretical log concentration-response curves for an agonistic compound A combined 
with various concentrations of a competitive antagonist В (Eq.17; Кд • KB = 1, α « 1). Note 
the parallel shift in the curves for A. 
Fig.3. Theoretical log concentration-response curves for an agonist A combined with various 
concentrations of a second agonist B, acting on the same receptors (Eq.16; Кд - Κβ • 1» α • 
β • 1). Note the synergistic effect. 
The relation -τ—γ equals χ and gives the shift of the concentration-response 
curve of A produced by the presence of B. If [BJ equals Κβ there is a shift of 
a factor 2; therefore the pA2 value is thenegative logarithm of Κβ (Ariens 10). 
b. C o m p e t i t i v e s y n e r g i s m 
Concentration-response curves for various combinations of two full agonists, 
A with a= 1 and В with β= 1, can be calculated from equation 16. The effect 
at every point is a summation of the effects of drugs A and B; this is shown in 
figure 3. 
c. C o m p e t i t i v e d u a l i s m 
vVhen a full agonist A ( a= 1) is combined with a partial agonist В (0 < β < 1), 
equation 16 can also be applied. Log concentration-response curves can be 
calculated for the effect produced by A in the absence of and in the presence 
of various concentrations of B, or for the effect produced by В in the absence 
of and in the presence of various concentrations of A. These two sets of curves 
are presented in figure 4. 
It is interesting to note in figure 4 that В behaves as a synergist for low 
concentrations of A, but as an antagonist for higher concentrations. 
5. DRUGS ACTING ON DIFFERENT RECEPTORS 
One drug can also change the effect produced by another drug through acting 
on receptors other than those of the second drug. This type of interaction is 
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ЕАВ/Е; 
Е
АВ/Е 
Fig.4. Theoretical log concentration-response curves (4a) for an agonist A combined with 
various concentrations of a partial agonist B, acting on the same receptors, and (4b) for a 
partial agonist В combined with various concentrations of an agonist A, acting on the same 
receptors (Eq.16; Кд • Kß • 1, α = 1, β « 0.5). Note that В acts as a synergist in lower con­
centrations of A and as a competitive antagonist in higher concentrations of А; В shows a 
dualistic effect. 
not competitive, and a very large range of drug interactions may fall in this 
category. A definable group of interactions under this heading is, for instance, 
the so-called non-competitive type of interactions. 
a. N o n - c o m p e t i t i v e i n t e r a c t i o n 
E 
I R' 
l в 
A 
By this type of interaction is meant that the stimulus produced by the non-
competitively acting drug, when interacting with its receptors, causes some 
interference on or between the receptor occupation of the agonist and the ef­
fect of the latter. It should be stressed that the non-competitive drug inter­
acts with receptors other than those of the agonist. The non-competitive in­
teraction may lead to a decrease of the effect of a certain dose of the agonist 
(antagonism), but may in some cases lead to an increase (sensitization). Some 
cases whereby an antagonism towards the agonist is found will mainly be dis­
cussed here. 
(i) Non-competitive antagonists causing an apparent decrease in the intrinsic 
activity of the agonist* 
A drug В can presumably change the effect brought about by interaction 
* Note: The derivation of the equations in this way for this type of non-competitive antagonism 
is done after van den Brink. 
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of drug A with i ts r e c e p t o r s R by causing an interference somewhere in the 
stimulus-effect chain of A. This change o r interference caused by В a r i s e s 
from interaction of В with the r e c e p t o r s R'; В therefore has an intr ins ic a c ­
tivity (Ariens 4, 6, 7). The "effect" of Β, E ß ' · is actually an alteration of the 
effect of A. The effect produced by A in the presence of such a concentration of 
a substance В giving the maximal stimulus, S'm, via the receptors R', may 
be written as being some factor of the effect of [A] alone: 
„ -
 E A S ' m EAS' PEA EA 
Analogous to equation 11, the proportion of the maximal stimulus produced 
by [B] can be written as : 
SJB 
S m 
ß' 
1 + [В] 
If a l inear proportionality between stimulus and the alteration in the effect 
of A caused by В is assumed, 
S^B _ E A - EAB' 
S V EA - EAS'm 
S^B
 =
 Ε Α Β · _ - _ Ε Α 
S'm EAS'm " E X or 
(if the effect of A is decreased) 
(if the effect of A i s increased) 
For further calculation either of these equations can be used, s ince: 
E A ^ E A B ^ _ E A B ' - E A 
E A - E A S ' m 
therefore: 
E A B ' - E A 
EAS'm -"ЁА 
E A S '
m
-
 E A 
ß' 
1 + [В] 
F r o m this equation follows that: 
E A B ' = • 1 + ( EAS'r EA 1 ) ' 
EAB' 
EAB' 
Em 
1 + (p - 1) 
1 + (p - 1) 
[B] 
β' 
[B] 
i + ^ a [B] 
EA 
Em 
• E A 
ι + 
KA 
[A] 
(18) 
In this equation ρ descr ibes the ability of the system on which В is acting 
to cause an apparent change in the intr insic activity of A. Just as Em - the 
maximal effect possible on the receptor-effector system of the agonist - may 
have different values for different sys tems (for instance, the Em for his tamine-
like drugs on the guinea-pig ileum may be different from the Em for acetyl-
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choline-like drugs on this organ), ρ may also have different values for different 
non-competitive systems. When the value of ρ is changed, it implies that one 
then has to do with a different group of non-competitively acting drugs, acting 
on the receptors of a different non-competitive system. The values· Em and ρ 
aredrug independent. The non-competitive system in question is an antagoniz­
ing one if ρ for this system has a value between 1 and 0, full antagonism via 
this system only being possible when ρ equals 0. If ρ for a certain system is 
larger than 1, that system is a sensitizing one. 
The intrinsic activity β' describes the ability of the drug В to produce 
antagonism or sensitization of the effect of the agonist A when В interacts 
with the receptors R' of the non-competitive system. Just like α, β! is a drug 
constant. Full antagonism with В can only be obtained if В has an intrinsic 
activity β' equalling 1 and if В interacts with the receptors R' of a non-
competitively antagonizing system for which ρ equals 0. Equation 18 then be­
comes: 
(19) 
This seems to be the case for the majority of non-competitive antagonists 
encountered in practice. Log concentration-response curves for A in the pre­
sence of various concentrations of a non-competitive antagonist B, calculated 
from equation 19, are presented in figure 5. 
EAB' 
Em 
1 α 
" 1
 +
 [ B ]
 ' i +
K A 
K'B [A] 
Fig.5. Theoretical log concentration-reeponse curves for an agonist A combined with various 
concentrations of a non-competitive antagonist В (Eq.18; Кд » К'в - 1. α - 0'· 1, ρ • 0). 
Note the difference between the curves of non-competitive and competitive antagonism. Com­
pare with figure 2. 
As seen from figure 5, a non-competitive antagonist apparently decreases 
the intrinsic activity of the agonist (compare with figure 1) without affecting 
its affinity. 
The affinities of non-competitive antagonists are often indicated by pD'x 
values according to Ariens and van Rossum (Ariens 10). In the case of a full' 
36 
non-competitive antagonist (examples of partial non-competitive antagonists 
are not known to us) the pD'x value may be defined as the negative logarithm 
of that molar concentration of the non-competitive antagonist В that reduces 
the effect Ед to Едв ' . the effect of A in the presence of B. 
From equations 14 and 19 the following equation can be found: 
E A [B] 
EAB* " K'B 
EA 
In this equation — — | equals x. When [B] equals K ' B , the negative logarithm 
of [Bj i s t h e p D ^ value, this value then being an indication of the affinity between 
В and the receptors R'. From the above equation can be seen that: 
pD'x = - log K ' B - log(x-l) 
and 
pD'2 » - log K ' B = log 771—. the logarithm of the affinity con-
і^  В 
stant. 
The negative logarithm ofthat concentration of a non-competitive antagonist 
В with which 50% of the maximal suppression of the effect of A obtainable with 
Bisproduced, i s thepD^ valueofB. This value ie used to indicate the receptor 
affinity of В to R'. 
(ii) Non-competitive antagonists producing a decrease in affinity between the 
agonist and its receptors 
This is a special type of non-competitive antagonism, whereby a non-com­
petitive antagonist B, when interacting with its receptors R', produces a de­
crease in the affinity between the agonist A and its receptors R. At the same 
time A, when interacting with R, would also cause a decrease in the affinity 
between В and R' (Ariens 4,7). This type of drug interaction is schematically 
represented as follows: 
1 Î 
A В 
In this case the receptors R and R' are interdependent and the dissociation 
constants for the drug-receptor complexes ARCR' and RcR'B are Кд and K ' B 
respectively. The dissociation constants change to КдК'в (1 -/Сдд') when 
ARcR'B is formed. The mutual interference with the affinities of the drug 
molecules on their receptors is represented by /Сдв'. When there is a mutual 
inhibition of receptor affinity, /Сдв' is negative; when there is a mutual fur­
therance /CAB' ίβ positive. 
The following equation has been given for this type of interaction: 
EAB' α 
im - -7Ζ7ΚΪ ( 2 0 ) 
1 + / A B , t [ A ] 
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in which 
1 +icTt" 
ƒ AB' ^ (21) 
l+l-KAB< K ' B 
Theoretical log concentration-response curves for drug A in the presence 
of a drug В producing this kind of antagonism are presented in figure 6a. Note 
that a parallel shift to the right occurs when increasing concentrations of В 
are used, until a limit is reached. The limit is set by the value of ΚΑΒ'Ί when 
/CVB' equals - oo there is no limit, equation 20 then becoming the same as 
equation 17 which was presented for the case of competitive antagonism. The 
curves in figure 6a resemble those presented for competitive antagonism 
(figure 2) to some extent, since both types of antagonism produce a parallel 
shift in the curves. In figure 6b curves which demonstrate a mutual further­
ance in affinities are given. 
Compounds acting in the way described here have also been called "de­
sensitizing agents" and "sensitizing agents" respectively (Ariens 7). 
[A] [A] 
Fig.6. Theoretical log concentration-response curves for an agonist A combined with various 
concentrations of a desensitizing compound В (6a) and a sensitizing compound В (6b) (Eq.20 
and 21; KA = 1, α = 1, in (6а)К
А
в· » - 999, К'в - 1, in (6Ь)К
А
в' = 0 . 9 9 , Κ · Β ' 100). Note the 
parallel shift in the curves to higher or lower concentrations, depending on the value of 
KAB'. 
b. F u n c t i o n a l a n t a g o n i s m 
The term "functional antagonism" is used to classify a group of diverse 
types of antagonistic drugs which cannot be classified under familiar types 
of antagonism. This group therefore includes all drugs which are not chemical 
antagonists, competitive antagonists, non-competitive antagonists or physical 
antagonists, but which, in some unknown way, counteract the effect of an ago­
nist. It may well be that some types of functional antagonists produce an ef­
fect of their own, opposite to and interfering with the effect of the agonist; if the 
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own effect of the antagonist could be indentified, it would be classified as a 
physical antagonist. Some functional antagonists may even cause a parallel 
shift in the log concentration-response curve of the agonist by interacting in 
some unknown way. 
This group should be seen as a "remainder group". 
The shift produced by some catecholamines like d-isopropylarterenol, on 
the dose-response curves of acetylcholinomimetics, like furtrethonium, has 
been quoted as a possible example of a functional antagonism (Ariens 7). These 
results, however, could fit the theoretical curves for a non-competitive anta-
gonist producing a decrease in affinity between the agonist and its receptors 
(see figure 6a), but this case can also be classified as a type of functional an-
tagonism (Ariens 7). 
6. DRUGS ACTING ON MORE THAN ONE RECEPTOR SYSTEM 
Of various possibilities, one especially needs to be considered in connection 
with this study, this being the case when a drug A can cause an effect through 
interaction with its receptors R, but causes an inhibition of its own effect by 
acting in a non-competitive fashion via other receptors R'. 
a. N o n - c o m p e t i t i v e a u t o - i n h i b i t i o n 
E 
l - R ' 
V 
Since, in this case, the drug A acts as its own non-competiti ve antagonist, an 
equation for the effect, analogous to equation 18, can be derived: 
EAA' 
Em 1 + (p-1) 
[A] 1 + S 4 · i + î ^ 
(22) 
[A] 
If an auto-inhibitive effect is to be produced, ρ is smaller than 1. For com­
plete auto-inhibition ρ equals 0 and a' equals 1. In the latter case equation 22 
becomes: 
EAA' 
1 + 
K'A [A] 
(i) Competition on the auto-inhibitive receptors 
R' 
В 
In the presence of a drug B, having no intrinsic activity, and competing for 
the "auto-inhibitive" receptors R' with drug A, the following equation, which 
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is a combination of equations 17 and 22, can be written: 
EAA'B' 
Em 
= . 1 + ( P - 1 ) 
1 (
 К ' в
)
 [A] 1 + 
KA 
[A] 
(23) 
From this equation concentration-response curves can be calculated for the 
effect produced by A in the presence of various concentrations of B. These 
curves are presented in figure 7. Note that increasing concentrations of В 
produce a shift of the auto-inhibitive part of the curve towards higher doses 
of A while at the same time the maximal height of the bell-shaped curve is in­
creased. The increase in maximal height only takes place if the difference be­
tween KA and K'A is smaller than about a factor 10,000. When this difference 
is bigger, only a parallel shift of the declining part is obtained in the described 
situation. 
E A A' 'B'/E 
Fig.7. Theoretical log concentration-response curves for a compound A, exhibiting auto-
rnhibition, combined with various concentrations of a competitive antagonist В which in­
teracts with the receptors on which the auto-inhibition is induced (bq.23; Кд = 1, К'д = 
0.4, К'в = 1, α = α'« 1, 0' » 0). Note the increase in height and the shift in the descending 
part of the curves. 
b. D r u g s e x h i b i t i n g c o m p e t i t i v e a s w e l l a s n o n - c o m p e t i t i ve 
a n t a g o n i s m 
R 
Λ/ 
A В 
In this group drugs which act as competitive antagonists, but also as non-
competitive antagonists of the effect of an agonist through interaction with other 
receptors, are classified. The equation for the effect of an agonist A in the 
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presence of such a dualistic compound В is derived from combination of equa­
tions 17 and 18: 
tfM1^-1»^! T S T i u <2·" 
(In this equation ρ is smaller than 1.) Curves calculated for the effect of A 
in the presence of different concentrations of drug В with different Kg : К'в 
ratios are presented in figure 8a, b and c. It should be mentioned that in prac­
tice many competitive antagonists behave also as non-competitive antagonists 
when employed at higher doses, corresponding with curves in figure 8. 
ι — = — — — ι — 1 - 1 1 1 1 
10"2 to"1 1 10 102 to3 to4 105 [A] 
Fig.8. Theoretical log concentration-response curves for an agonistic compound A combined 
with various concentrations of a competitive antagonist В exhibiting non-competitive antago­
nism at higher doses (Eq.24; Кд »Κβ = 1.α =P'=1, for (8a) К'в • 10, for (8b) К'в - 100, for 
(8c) К'в * 1,000). Note the shift in the curves as a result of competitive antagonism, com­
bined with a decrease in maximal height and slope sooner or later, dependent on the difference 
between K B and K'g. 
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7. IRREVERSIBLY ACTING DRUGS 
So far only drugs which act in a reversible fashion with their receptors have 
been considered, but it is also possible that a drug might combine with its re­
ceptors in an irreversible way: 
R + В RB 
In practice this means that it is impossible or virtually impossible within 
the time allowed by the experimental situation to remove the drug from the 
receptors by washing repeatedly. The amount of receptors occupied within a 
certain time is in this case dependent upon the rate of reaction of the drug 
with its receptors, and this in turn is dependent on the association rate con­
stant and the concentration of drug present in the biophase. Even a concen­
tration of drug so low that there are just as many drug molecules as recep­
tors would afford complete occupation of all receptors if allowed sufficient 
time to interact. 
In the case of irreversible interaction we are primarily concerned with ir­
reversible antagonists, either "competitive" (acting on the same receptor as 
the agonist) or "non-competitive" (antagonizing via other receptors). Since 
the rates of reaction of these compounds with the receptors are complicated 
by many variables, the reactions cannot simply be presented in equations 
holding true for most cases; the following discussion is therefore more phe-
nomenological than the preceding text. 
An irreversible competitive antagonist would block a certain fraction of the 
receptors of an agonist within a certain time. The total stimulus that can then 
result from a given concentration of agonist therefore is smaller than the total 
stimulus produced by the same concentration before employing the irreversible 
antagonist. When incubating an isolated organ for a certain time with an irre­
versible competitive antagonist, an agonistic curve obtained thereafter is de­
creased in height. The same effect is produced, however, by an irreversible 
non-competitive antagonist. The latter drug produces the same effect as a 
reversible non-competitive antagonist except that the irreversible drug cannot 
be washed out. 
A number of theoretical concentration-response curves, calculated for an 
agonist after different periods of incubation with a fixed concentration of a 
competitive irreversible antagonist B, are presented in figure 9a. The equa­
tion used for the calculation is the following: 
EAB
 =
 SAB _ α .
 e
 -Ш
В
г 
E
m
 S
m
 KA y ' 
[A] 
In this equation t is the incubation time, e is the base of natural logarithms 
and equals 2.718, кв is the association rate constant for the drug-receptor 
complex RB where drug В is an irreversible competitive antagonist. The equa­
tion was derived by van Rossum and Ariens (van Rossum 6). In practice, how­
ever, this equation has a limited applicability, since, to find kß, the diffusion 
rate of drug В in the experimental system has to be known. 
One can, however, discern between competitive and non-competitive i rre­
versible drugs experimentally in some cases. The difference between these 
two types is that the rate of receptor occupation of a competitively acting ir­
reversible drug may be hindered by employing, during incubation, high doses 
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of the agonist in question or of a competitive antagonist of the latter, since 
the irreversibly acting drug then has to compete with one of the latter drugs 
for occupation of the same receptors. This means that inhibition of the ago-
nistic effect is smaller when an incubation is done with an irreversible com-
petitive antagonist in the presence of an agonist, than when exactly the same 
experiment is performed in the absence of the agonist. The agonist actually 
"protects" its receptors against the action of the irreversible drug. This forms 
the basis for the so-called "receptor protection" experiments. When using a 
non-competitive irreversible antagonist, no difference should be seen between 
incubation experiments done in the presence and in the absence of an agonist. 
A reversible competitive antagonist can also be used instead of the agonist in 
the above-mentioned experiments. 
a. N o n - s p e c i f i c r e c e p t o r b l o c k i n g a g e n t s and r e c e p t o r p r o -
t e c t i o n 
Some drugs, notably dibenamine and dibenzyline, have been shown to react 
in an irreversible fashion with the specific receptors of the biological amines 
acetylcholine, noradrenaline, histamine and serotonin (Furchgott 1; Ariens 7, 
9). By incubating an isolated organ with such a non-specific blocking agent in 
the presence of high concentrations of an agonist or one of its reversible com-
petitive antagonists, the receptors for other agonists are blocked while the r e -
ceptors which are "protected" are affected much less by the blocking agent. 
After washing out the drugs, the organ responds virtually only to agonists acting 
on the receptors which were protected. 
8. RECEPTOR RESERVE 
In discussing relationships between receptor occupation and effect pro-
duced by an agonist, it was assumed that a linear relationship exists between 
the quantity of receptors occupied, the size of the stimulus and the effect for 
a certain dose of an agonist: 
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This assumption was made to present the most simple model of relation-
ship between receptor occupation and effect, but in reality there is most prob-
ably often no linear relationship, and the effect might be some other function 
of the stimulus. Various possibilities have been pointed out by others (van 
Rossum 6, 7). It is also possible that a maximal effect can be brought about 
on an isolated organ when still only a fraction of the total number of receptors 
are occupied. This, for instance, is the case when the contractile possibility of 
an organ sets a limit before the actual maximal stimulus, Sm· is reached, per-
haps byother tissue forming a mechanical hindrance for further contraction of 
the muscle fibres. There can also be other reasons for this phenomenon (Ariens 
7) but anyhow, when a maximal effect ie reached before total receptor occupa-
tion, one has to do with a so-called "receptor reserve", i.e. receptors not 
needing to be occupied to produce a full effect. This is discussed extensively 
in literature (Ariens 7, 9; van Rossum 6, 7). In the case of a receptor reserve 
one can find a shift of the dose-response curve to the right without a decrease 
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in height when employing some types of non-competitive antagonists, and it 
becomes more difficult to distinguish between competitive and non-competitive 
antagonism (van Rossum 6). When incubating an organ with a fixed concentra­
tion of an irreversibly blocking agent for a number of equal incubation pe­
riods and obtaining agonistic curves between these periods, it is possible to 
ascertain whether receptor reserve plays a role. In the case of a receptor re­
serve being present, the curve is shifted to the right first and is then depress­
ed by treatment with the blocking agent (see figure 9b); in the absence of re­
ceptor reserve only a depression of the curve takes place (see figure 9a). 
Fig.9. Theoretical log concentration-responee curves for an agonistic compound A on a system 
(9a) without and (9b) with receptor reserve, after incubating for various times with an Irre­
versible receptor blocking agent or irreversible competitive antagonist В (Eq.25, Кд » 1, 
0 = 1 , И к ц « 0·1). Note the decime m the curves without any shift in the absence of a re­
ceptor reserve (9a) and the shift in the curve preceding the decline in the presence of a re­
ceptor reserve (9b). 
The general principles summarized in this chapter will be used as a basis 
for drawing conclusions in the following chapter, and will be extended in spe­
cial cases. 
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CHAPTER IV 
STRUCTURE AND ACTIVITY OF SEROTONIN 
AND RELATED COMPOUNDS 
1. ISOLATED ORGAN PREPARATIONS AS TEST OBJECTS FOR SEROTONIN­
LIKE AND ANTISEROTONIN ACTIVITY 
A number of different isolated organ preparations on which serotonin (5-
hydroxytryptamine; 5-HT) elicits a measurable response have been employed 
in connection with studies on 5-HT or its antagonists. The isolated rat uterus 
and isolated guinea-pig ileum, on which 5-HT causes contraction, have per­
haps been used the most frequently, but many other test systems have also 
been described. The compound 5-HT and some 5-HT antagonists have, for 
instance, been investigated on the hearts of various species of molluscs (Gad-
dum 8; Welsh) (whereon 5-HT produces an increase of the amplitude of the 
individual contractions) and on the isolated artery rings of the sheep or rabbit 
(Reid; Furchgott 1), rat colon (Benditi), rat ileum (Levy) and rat stomach fundus 
(Vane 1, 2; Barlow) (on which 5-HT causes contraction). 
As was mentioned in the previous chapter, it is mostly preferable in studies 
on structure-activity relationships to use isolated test systems instead of in­
tact animals, since factors like distribution and metabolism of the compounds 
tested are then largely avoided. 
After investigating some isolated systems described before and also trying 
out some new possibilities like the isolated tracheal muscle of the calf, rat 
vas deferens, rat spleen, rat urethra, oesophagus of the chicken and frog rectus 
abdominis muscle, the rat fundus strip was chosen as the most suitable for 
our purposes. The facts that this sytem is one of the more sensitive prepara­
tions towards 5-HT, and that it lends itself to the making of cumulative dose-
response curves, were the most important considerations. The isolated tracheal 
muscle of the calf and the oesophagus of the chicken also proved to be of value, 
but these are less sensitive than the fundus strip. 
a. M e t h o d s 
(i) Rat fundus strip preparation 
A slight variation on the method of Vane (Vane 2) is used in preparing the 
fundus strips. Stripe are obtained from adult male Wistar rats, having had no 
food for 48 hours, but water ad l i b i t u m . After killing a rat by a blow on the 
head, the stomach fundus is removed and carefully cleansed with Ту rode so­
lution at 37° C. The fundus is then stretched over the rounded end of a plastic 
rod about the thickness of a pencil, whereby the direction of the external 
layer of longitudinal muscle fibres is clearly visible. The fundus is halved 
by carefully cutting in the direction of these fibres. Along side of this incision 
two strips of about 2 mm width are cut, one from each half of the fundus. The 
mucosa is then carefully removed; this seems to facilitate the washing out 
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Fig.l. Diagram showing the method of cuttmg the rat fundus strip preparation. 
Note that strips containing the maximal straight stretches of longitudinal muscle fibres in 
the fundus are eventually used. 
of added drugs. The strips thus obtained are the maximal straight stretches 
of longitudinal muscle strips that can be obtained from the fundus. It is often 
not necessary to use the whole length of these strips; a length of 2 cm is usu-
ally sufficient. During the whole time of preparation the tissue is kept moist with 
Tyrode solution. The technique described here is schematically presented in 
figure 1. 
The slight variation on the method of Vane seemed necessary in order to 
obtain smooth log concentration-response curves. With strips prepared ac-
cording to Vane's method irregularities in the curve often appeared at higher 
doses, presumably resulting from contraction of the small lengths of circular 
muscle which ha ve a sensitivity to wards 5-HT which is different from that of the 
longitudinal muscle fibres (as was described by Vane). 
Each muscle strip is suspended in a 10 ml organ bath filled with Tyrode so-
lution and kept at 37° C, one end of the strip being affixed to a lightly loaded 
isotonic lever giving about 20 times magnification. Pure oxygen is bubbled 
through the bath fluid. A strip is allowed at least 45 minutes to acclimatize 
before starting with experiments and during this period the Tyrode solution 
is refreshed every 15 minutes. The cumulative technique, adding consecutive 
doses of spasmogen whereby each dose is 10 times as high as the previous 
one, is usually employed. Contraction is registered on a slowly rotating sooted 
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drum of a kymograph. For the evaluation of agonists this procedure is followed 
for every agonist including a reference agonist (5-HT in most cases) for the 
sake of eventual comparison of the curves obtained. The same procedure is 
followed for the evaluation of antagonists, whereby curves are obtained with 
the reference agonist in the absence (control curves) and in the presence of 
various concentrations of possible antagonists. The organ bath and technique 
for making cumulative dose-response curves was described in detail by van 
Roseum and van den Brink (van Rossum 3, 4). 
Between two cumulative registrations obtained with serotonin-like com-
pounds, one maximal contraction was produced with furtrethonium, a pro-
cedure which also facilitates the washing out process, whereby the number 
of curves that can be obtained from one strip is increased. 
Control curves are obtained regularly during an experiment to ascertain 
whether any change in sensitivity of a strip towards the spasmogen employed, 
ensues. 
A set of consecutive cumulative registrations obtained with 5-HT on a fundus 
strip, is presented in figure 2a. 
(ii) Calf tracheal muscle preparation 
This preparation has been used for the evaluation of ß-sympathomimetic 
and ß-sympatholytic drugs (Ariëns 1; Waelen), and also proved suitable for 
obtaining cumulative dose-response curves with 5-HT. The trachea of a young 
calf is removed directly after slaughtening at the abattoir, placed in Krebs-
Henseleit solution and kept at 4° C. Pieces of trachea can be cut off and used 
up to three days after the trachea was obtained. 
The isolated tracheal muscle preparation consists of a piece of muscle r e -
moved from the inside of one ring of the trachea. This strip of muscle is sus-
pended in an organ bath, one end being affixed to a lightly loaded isotonic lever 
giving about 20 times magnification. The organ bath is filled with Krebs-Hen-
seleit solution and kept at 37° C. A gas mixture consisting of 95% oxygen and 
5% carbon dioxide is bubbled through the bath fluid. The preparation is allow-
ed 45 minutes for acclimatization before starting with experiments, and dur-
ing this period the bath fluid is refreshed every 15 minutes. 
The procedure for obtaining dose-response curves is the same as described 
for the rat fundus strip under (i) above, except that each consecutive dose of 
spasmogen added is three times as high as the preceding one. 
The calf tracheal muscle preparation has the drawback of contracting re -
latively slowly in response to added spasmogens, thereby limiting the number 
of dose-response curves that can be made within a certain time. Because of 
this slow contraction, the kymograph on which registration is made is stopped 
while the contraction progresses, but is started to ascertain whether the con-
traction of the muscle has ceased. The kymograph is stopped again before ad-
dition of the next dose of the drug. 
A set of cumulative registrations obtained with 5-HT on this preparation 
is presented in figure 2b. When comparing figure 2b with figure 2a, it can be 
seen that 5-HT causes contraction of the rat fundus strip at lower doses than 
is the case for the calf tracheal muscle. This constitutes one of the reasons 
for preferring the former preparation for routine experiments. 
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contraction calf tracheal muscle cont rac t ion chicken oesophagus 
Fig.2. Registrograms of ser ies of cumulative doee-responee curves for 5-HT on the rat fundus 
strip preparation (2a), the calf tracheal muscle preparation (2b) and the chicken oesophagus 
preparation (2c). 
Note that each consecutive dose is added at the moment that the contraction induced by the 
foregoing dose ceased. 
Note further that the rat fundus strip preparation responds to lower doses of 5-HT than the 
other two preparations. 
(iii) Chicken oesophagus preparation 
It has recently been reported that the crop of the young chick contracts 
strongly in response to minute amounts of 5-HT (Everett 1). Although the crop 
is also suitable, we have found that the oesophagus of one-, two- or three-day-
old chicks responds more consistently to 5-HT. 
The oesophagus is removed from a young chick killed by pithing, suspended 
in an organ bath filled with Krebs-Henseleit solution through which an oxygen-
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carbon dioxide mixture (95 : 5) is bubbled. The organ bath is kept at 37° C. 
The procedure followed further is the same as that described for the rat 
fundus strip under (i) above. 
The chicken oesophagus preparation is less sensitive towards 5-HT than 
the rat fundus strip preparation, and can generally not be used for more than 
four hours. The fundus strip often shows no great change in response even 
after being in use for six hours. For these reasons the fundus strip is routinely 
used, while the chick oesophagus is used more as a control for results found 
on the fundus strip. 
A set of consecutive cumulative registrations obtained with 5-HT on a chick 
oesophagus is presented in figure 2c. 
(iv) Rat vas deferens preparation 
This preparation has often been employed for the evaluation of α-sympatho­
mimetic and a-sympatholytic compounds (Ariens 1,7; Koopman; van Rossum 2; 
Waelen). 
After killing a rat by a blow on the head, a vas deferens is removed and 
suspended in an organ bath filled with Tyrode solution. The procedure followed 
further is exactly the same as described for the rat fundus strip under (i) 
above, except that each consecutive dose of spasmogen added is 3 times as high 
as the previous one. 
This preparation has a limited applicability in the study of 5-HT. It has a 
low sensitivity towards 5-HT and has been used in this study only to demonstrate 
an action of 5-HT on α-sympathetic receptors (see figure 4), to determine 
whether some 5-HT antagonists synthesized by us also exhibit antagonism 
towards noradrenaline, and to demonstrate sensitization on the action of nor­
adrenaline (see figures 18a and 19a, b). 
2. THE ACTION OF SEROTONIN AND RELATED COMPOUNDS 
a. T h e a u t o - i n h i b i t i v e e f f e c t of 5-HT on t h e r a t f u n d u s s t r i p 
It has been reported that 5-HT exhibits an auto-inhibitive effect at higher 
doses when tested on smooth muscle preparations (Gaddum 1). This effect is 
also seen when using the fundus strip as test object, whereby the dose-response 
curve for serotonin, after reaching a maximal height at about 10"5м, shows 
a decline for higher doses (see figure 3). It was noticed that noradrenaline, 
which is assumed to have a relatively pure a-sympathomimetic action (Ahl-
quist; Ariëns 1), produces relaxation of a strip already contracted with 5-HT. 
Innes reported an action of 5-HT on the α-sympathetic receptors of the 
cat spleen (Innes 1). We found that the contraction produced by 5-HT on the 
rat vas deferens can be competitively antagonized by α-sympatholytics (see 
figure 4). 
Furthermore, in experiments conducted on the isolated tracheal muscle of 
the calf, no auto-inhibition in the action of 5-HT is found. It is known that this 
organ does not respond with a relaxation to α-sympathomimetics. In his paper 
on receptor protection, Furchgott has remarked that high concentrations of 
5-HT can protect the a-sympathetic receptors in the rabbit aorta strip pre­
paration against the action of irreversible receptor blocking agents (Furch-
gott 1). 
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Fig.3a. A registrogram of a cumulative dose-response curve for 5-HT tested on the rat fundus 
strip preparation, employing also high doses of 5-HT. 
Fig.3b. The cumulative log concentration-response curve from figure 3a. 
Note the auto-inhibitive effect with high doses of 5-HT. 
% contraction rat vas deferens 
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Fig.4. Cumulative log concentration-response curves for (-) noradrenaline (4a) and 5-HT 
(4b) in the presence of various concentrations of the α-sympatholytic Droperidol, tested on 
the isolated rat vas deferens. 
Note the parallel shift in the curves which indicates competitive antagonism for both cases; 
compare with figure 2 of chapter HI. (Figure 4a after van Rossum (van Roesum 2).) 
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The chemical structures of noradrenaline and 5-HT are related to some 
extent, as is shown by presenting the formulas in the following way: 
он 
' -Ος^
Ν Η
Η
0
0Χ^
0Η
 Е О ^ 
5-HT n o r a d r e n a l i n e 
It was decided to produce some dose-response curves with 6-HT in the pre­
sence of a-sympatholytic compounds. With some of these compounds, like 
nylidrine and phentolamine, a non-competitive type of antagonism towards the 
contraction produced by 5-HT is seen. Especially, however, in the presence of 
piperoxane, the maximal height of the 5-HT curve is increased and the de­
scending part is shifted to the right on the log concentration axis (see figure 
5). This agrees with results expected when combining a spasmogen, which 
inhibits its own effect in a non-competitive fashion at higher doses, with a 
competitive antagonist for the action of the agonist on the non-specific re­
ceptors. This situation can be schematically presented as follows: 
E 
5-HT piperoxane 
In figure 5a and b the results obtained when producing 5-HT curves In the 
presence of various concentrations of piperoxane, are presented. This figure 
gives an experimental example of the theoretical model as discussed in the 
preceding chapter (compare figure 5b with figure 7 of chapter III). These re­
sults suggest strongly that the auto-inhibitive effect found for 5-HT on various 
isolated organs may be the result of an interaction with α-sympathetic recep­
tors at higher doses. 
For obtaining the results represented in figure 5a, the cumulative dose 
technique was not used. When the curve is obtained by plotting the contractions 
at various individual doses, there is no difference in the shape and position 
of the curve when using the cumulative method as compared to the individual 
dose method. Producing relaxation with the cumulative method (as is the case 
with the descending part of the curve), however, gives a curve differing in po­
sition to that found when obtaining this part of the curve also by producing 
contractions at the various doses (individual dose method). Using the former 
method, the position of the latter curve is approached when increasing the 
weight on the lever. This dependency of the curve-position on the lever load 
in the case of curves obtained by relaxation was mentioned earlier (Ariens 
7). When the lever load becomes large a fading effect is seen, so that in the 
case of relaxation, measurement of the point of maximal effect for a specific 
dose becomes uncertain. For these reasons it was decided to use the indivi­
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Fig.Sa. A registrogram of contractions produced by 5-HT on the rat fundus strip preparation 
in response to various individual doses of 5-HT, whereby the drug is washed out after each 
contraction, in the presence of various concentrations ofthe α-sympatholytic compound piper­
oxane. 
Fig. 5b. Cumulative log concentration-response curves from figure 5a. 
Note that the maximal height of the curve is increased and that the auto-inhibition sets in 
at higher doses in the presence of piperoxane. Compare with figure 7 of chapter III. 
dual dose technique (washing out after each contraction produced by a single 
dose) when declining curves were encountered. 
b. Receptor reserve in the preparations used 
The fact that the presence of a receptor reserve in the preparations used 
to study different properties of drugs may make interpretation of the results 
more difficult was discussed in the previous chapter. It was mentioned that 
in the presence of a receptor reserve some amount of shift in the dose-response 
curve, instead of only a depression, may be seen when employing irreversible 
competitive antagonists. A certain amount of shift in the presence of a receptor 
reserve may also be noticed when employing non-competitive antagonists inter­
fering near the point of stimulus formation by the agonist (Ariens 7). Since 
shifting the dose-response curve to the right is used as an indication for com­
petitive antagonism, it seemed desirable to determine the amount of shift at­
tributable to receptor reserve beforehand, thereby avoiding the chance of per­
haps classifying some non-competitive antagonists as exhibiting some com­
petitive effect. 
To determine the receptor reserve, the preparations were incubated for 
consecutive equal periods with a fixed concentration of a non-specific i r re­
versible receptor blocking agent like dlbenamine or dibenzyline. After each 
incubation period the preparation was washed well with Tyrode or Krebs-
Henseleit solution and a cumulative dose-response curve was produced. 
For the rat fundus strip virtually no shift, but only depression in height 
ofthe log concentration-response curve of 5-HT was found; no receptor re-
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Fig.6a and c. Regis trograms of s e r i e s of cumulative d o s e - r e s p o n s e c u r v e s for 5-HT tested 
on the rat fundus str ip preparation (6a) and for oxapropamum (dilvasène) tested on the i so la -
ted rat jejenum (6c) after incubation with constant concentrations of dibenamine for various 
t i m e s . Fig. 6b and d cumulative log concentrat ion-response curves from figures 6a and 6c 
respect ive ly . 
Note that there i s no shift, only a decl ine in the c u r v e s for 5-HT, while a shift precedes the 
decl ine in the curves for d i lvasène . The absence of a shift in the curves for 5-HT probably in-
d icates the absence of a receptor r e s e r v e . Compare with figures 9a and b of chapter 111. (Fig. 
6d after Ariene (Ariens 9).) 
serve could be indicated for this preparation when using 5-HT as spasmogen. 
Some curves found experimentally are presented in figure 6a and b. In figure 6c 
and d curves which were obtained in the same way for exapropanium (dilvasène) 
on the rat intestine are presented. The latter case demonstrates the presence of 
a receptor reserve. Compare the experimentally obtained figures 6b and d 
with the figures theoretically calculated for the case of an irreversible com-
petitive antagonism, presented in figures 9a and b in the previous chapter. 
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It may be argued that dibenamine does perhaps not act as a competitive ir­
reversible antagonist towards 5-HT, but as an irreversible non-competitive 
antagonist, whereby the presence of a receptor reserve might go by undetect­
ed when employing this drug to demonstrate receptor reserve. To show that 
dibenamine does interact with the specific 5-HT receptors in an irreversible 
way, one should be able to protect the 5-HT receptors from the action of di­
benamine when incubating with dibenamine in the presence of high concentra­
tions of 5-HT, It has been shown that the 5-HT receptors in a number of iso­
lated tissue preparations, also those in the rat stomach fundus, can be pro­
tected from the irreversible action of dibenamine when employing high doses 
of 5-HT (Innes 2, 3), These results indicate that dibenamine interacts with 
the specific 5-HT receptors, making it probable that the virtual absence of a 
receptor reserve, as indicated by our experiments, is real. 
The fact that there appears to be virtually no receptor reserve for 5-HT in 
the fundus strip preparation makes it much more probable that pD2 values 
found on this preparation correspond with the actual affinities of the drugs 
tested. When a receptor reserve is present, as is for instance the case for 
cholinomimetics on the isolated rat intestine, for α-sympathomimetics on 
the isolated rat vas deferens and for histaminomimetics on the guinea-pig 
intestine, the pD2 values are higher than those which would correspond with 
the actual affinities (Ariens 9; van Rossum 6). In this respect testing 5-HT 
on the rat fundus strip preparation has an important advantage. Furthermore, 
on a system with a receptor reserve, it is possible that a drug producing 
maximal contraction does not have a relative intrinsic activity equalling 1. 
This is not possible on a system without receptor reserve (Ariens 7, 9; van 
Rossum 6). 
In contrast with the situation for the rat fundus strip preparation, different 
calf tracheal muscle preparations exhibit varying amounts of receptor reserve 
when treated in the way discussed above. As will be shown later, 5-HT probably 
causes a contraction on this preparation via a release of acetylcholine (see 
section 4 of this chapter). Whether the receptor reserve observed for the calf 
tracheal muscle preparation is a reserve of 5-HT receptors or a reserve of 
acetylcholine receptors or a reserve of both, is not known. 
The receptor reserve found for the calf tracheal muscle may provide part 
of the reason for the steeper slope of the log concentration-response curves 
found for 5-HT like compounds on this preparation. In any case, the apparent 
absence ofreceptor reserve in the rat fundus strip preparation, thereby giving 
more weight to the presentation of pD2 values as representing affinities, con­
stitutes another reason for preferring the fundus strip preparation for routine 
studies. 
c. S p e c i f i c i t y of a c t i o n 
A large number of naturally occurring and synthetic indole compounds, 
structurally related to serotonin, are known. In this investigation a large num­
ber of these compounds were studied in an attempt to find specific, in this 
case implying competitive, antagonists of serotonin. 
If competition for the specific serotonin receptors is taken as a requirement 
for specificity of action, it is of course essential to know whether the recep­
tors in the fundus strip on which serotonin induces contraction of this prepara­
tion are specific serotonin receptors.The high affinity of 5-HT towards these 
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receptors is of course already an indication that this is the case, but it seemed 
necessary to ascertain what effects the other known biological amines produce 
on the fundus. It has already been mentioned that noradrenaline produces re­
laxation and not contraction of the rat fundus strip, and it was further ascer­
tained that histamine hardly produces contraction of this preparation. Acetyl­
choline, however, also contracts the fundus strip. Atropine, a competitive an­
tagonist of acetylcholine, has been found to antagonize the action of 5-HT on 
the guinea-pig ileum (Gaddum 6; Day 1). This antagonism was confirmed by 
us. It seemed essential to ascertain whether the serotonin effect on the fundus 
strip could be antagonized by atropine and lachesine, the latter being an even 
better acetylcholine antagonist (Ariens 7). In figure 7a curves obtained on the 
fundus strip by producing contfactions with serotonin and acetylcholine, in the 
absence and in the presence of various concentrations of atropine and lachesine, 
are presented. Note that the acetylcholine curve is shifted to the right on the 
log dose axis, exhibiting the competitive antagonism of atropine and lachesine, 
but that these latter two compounds have no effect on the position of the sero­
tonin curve in the concentrations used. Compare the parallel shift in the ace* 
tylcholine curves caused by the competitive antagonists atropine and lachesine 
with the theoretical set of curves calculated for competitive antagonism as 
presented in figure 2 of chapter III. (It should be mentioned that all the curves 
obtained on the fundus strip preparation were made in the presence of 10-5 M 
piperoxane in order to exclude the auto-inhibitive action of 5-HT on α-sympa­
thetic receptors in the dose ranges used). The possibility of 5-HT inducing its 
effect on acetylcholine receptors or through the release of acetylcholine is ex­
cluded in the case of the fundus strip since the competitive acetylcholine anta­
gonists cause no change in the curves of 5-HT. 
On the calf tracheal muscle preparation, atropine exhibits mainly a non­
competitive type of antagonism towards 5-HT (see figure 7b). It seemed pos­
sible that the spasmogenic action of 5-HT on this preparation may be due to 
an indirect type of action, perhaps by an acetylcholine release, as was reported 
for the guinea-pig intestine (Johnson; Day 1; Harry). 
As will be discussed in more detail in section 4 of this chapter, it appears 
as if the 5-HT receptors in the rat fundus strip preparation and those in the 
calf tracheal muscle preparation are two different types of 5-HT receptors, 
distinguishable by the way in which 5-HT acts in these two preparations. The 
5-HT receptors in the rat fundus strip appear to be "musculotropic" recep­
tors while those in the calf tracheal muscle appear to be "neurotropic" re­
ceptors, 5-HT causing contraction of the calf tracheal muscle by releasing 
acetylcholine. In the latter case one would therefore expect that antagonists 
of acetylcholine also act as antagonists of 5-HT, since release of acetylcholine 
and interaction of the latter compound with its receptors then constitutes part 
of the stimulus-effect chain of 5-HT. This fact constitutes yet another reason 
for preferring the rat fundus strip preparation in investigations on 5-HT an­
tagonists, since compounds that antagonize acetylcholine do apparently not 
interfere with 5-HT on the fundus strip. Furthermore, as can be seen when 
comparing the log concentration-response curves for 5-HT found on the rat 
fundus strip preparation with those found on the calf tracheal muscle prepa­
ration, 5-HT apparently has a higher affinity towards the receptors in the rat 
fundus strip (compare the control curves for 5-HT in figure 7a with that in 
figure 7b). 
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Fig.7a. Cumulative log concentration-response curves for 5-HT and acetylcholine (ACh) in the 
presence of various concentrations of the cholinolytic compounds lachesine and atropine, 
tested on the rat fundus strip preparation. Fig. 7b. Cumulative log concentration-response 
curves for 5-HT in the presence of various concentrations of the cholinolytic compound atro­
pine, tested on the calf tracheal muscle preparation. 
Note the parallel shift in the curves for acetylcholine which indicates a competitive anta­
gonism (compare with figure 2 of chapter HI), while the curve for 5-HT remains unchanged 
(7a). This indicates that 5-HT does not act on the acetylcholine receptors in the rat fundus 
strip preparation. 
Note the decline of the curves without a clear preceding shift (7b), Indicating that 5-HT 
does not act directly on the acetylcholine receptors in the calf tracheal muscle preparation, 
but may act by liberation of acetylcholine. See section 4 of this chapter. 
d. E f f e c t of s t r u c t u r a l v a r i a t i o n of s e r o t o n i n 
Serotonin and the other compounds to be discussed here, can all be classi­
fied as tryptamine related compounds and it seems proper to discuss the ac­
tion of tryptamine (in relation to serotonin) first. 
Ca 
t ryptamine 
Tryptamine, like 5-HT, produces contraction of the fundus strip. It seemed 
acceptable to assume for the time being that tryptamine and serotonin act on 
the same receptors, as described by Gaddum (Gaddum 6). A test for this as­
sumption shall be presented later on. From comparison of the log concentra­
tion-response curves of these two compounds it can be seen that tryptamine 
has the same intrinsic activity ( a = 1) but an apparently lower receptor af­
finity than 5-HT (see table II for pD2 values). The difference in affinity is 
about a factor 100, indicating that the 5-OH group does apparently not play 
an essential role in the induction of the effect, but does contribute to the re­
ceptor affinity. 
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It has been reported that the effect of tryptamine on the rat fundus strip is 
potentiated by treatment with inhibitors of monoamine oxidase, while the effect 
of serotonin is unaffected (Vane L; Maxwell). (As mentioned before, monoamine 
oxidase (MAO) is responsible for the enzymatic breakdown of these amines.) 
This has been ascribed to the fact that tryptamine, not possessing the 5-OH 
group, has a higher lipid solubility than 5-HT and therefore readily passes the 
cell membranes to be broken down by MAO which is presumably only located 
intracellularly. On the other hand 5-HT would not pass the cell membranes 
readily. It is assumed that the contractile receptors on which both amines act 
are located extracellularly (Vane 1). In experiments done in the course of this 
investigation it has been found that the log dose-response curve of tryptamine 
is shifted to the left in a parallel fashion when adding a MAO inhibitor to the 
bath fluid. The curve of 5-HT is unaffected. This may be an indication that 
tryptamine in fact has a higher receptor affinity than that usually found in the 
experimental situation, but the affinity would still be lower than that of 5-HT. 
This sensitizing effect is discussed in more detail further on (see section 
5 of this chapter). 
It is also possible that tryptamine acts via liberation of 5-HT stored in the 
fundus strip. It is known that some compounds, as for instance reserpine, 
cause a depletion of 5-HT stores in the animal body (Pletscher 3; Shore 3, 4). 
Depletion experiments were not done by us, since it is known that 5-HT is 
poorly released from the rat gastro-intestinal tract, especially from the fundus, 
by reserpine (Erspamer 8; West 1; Pletscher 4). A number of consecutive 
dose-response curves were obtained with tryptamine to see whether tachy-
phylaxis could be proved, but no tachyphylaxis was noticed. It was therefore 
considered probable that tryptamine acts directly on the 5-HT receptors. This 
probability is strengthened by the fact that competitive antagoniste later found 
for 5-HT are competitive antagonists towards tryptamine just as well. An as-
sumption that tryptamine and serotonin and their closely related structural 
derivatives act directly and on the same receptors, at least in the rat fundus 
strip, did not seem unreasonable. 
The reason why the difference in receptor affinity between 5-HT and trypt-
amine is pointed out here, is that a large number of indole derivatives without 
the 5-OH group could be obtained, and that the latter are easier to synthesize 
than corresponding 5-OH derivatives. Since competitive 5-HT antagonists with 
a good receptor affinity are of great interest, corresponding 5-OH compounds 
should be made of those 5-OH free indole derivatives with the best affinities. 
(i) Substitution on the amino group 
Substitution on the amino group in 5-HT and tryptamine seemed to be in-
dicated in the first place, keeping in mind the structural relationship between 
5-HT and two other biological amines, noradrenaline and histamine. All three 
these compounds have a -C-C- chain between an amino group and an aromatic 
ring, and for noradrenaline competitive antagonists have been prepared by 
aralkyl substitution on the amino nitrogen. 
Competitive antagonists for histamine, too, have been found by aralkyl sub-
stitution on the amino nitrogen of ß-2-pyridylethylamine, a histamine-like com-
pound structurally closely related to histamine (Ariens 2, 7; van den Brink). 
In studying series with progressive alkyl chain lengths and eventually aral-
kyl groups as substituents it was shown that, in the case of noradrenaline, 
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T A B L E Ia 
Relative Intrinsic Activities and Affinities (pD2, pA2 and pD'2) 
of Derivatives of Arterenol, Tested cm the Isolated Vas Deferens of the Rat a 
1 
H O - / S - C - C - N - R 
HO OH 
R 
-H 
-c 
-c-c 
-
c
-c 
-c-c-c-c 
-¿-C-Ç-C 
t c 0) 
-g-c-c4J 
-H_> 
Relative 
Intrinsic 
activity с 
1 
1 
0.94+0.05 
0.4 + 0.1 
0 
0 
0 
0 
Affinity 
Specific 
p D 2 c 
5.4 + 0.2 
5.7+0.2 
5.2+0.2 
2.8+0.6 
pA2C 
3.5 
4.4 + 0.4 
5.1+3.0 
5.9 + 0.5 
Non­
specific 
рО'гС 
2.0+0.2 
2.8 
Est/Org b 
23/12 
19/10 
24/11 
27/19 
6/3 
4/3 
34/17 
19/12 
38/24 
a From Ariens 7. 
b Est/org: number of estimations / number of organs used therefor, 
с The + figures are the P95 values, indicating the 95% confidence limits for 
the mean. 
there is a decrease in intrinsic activity rather early in the series, whereby 
the noradrenaline derivatives with larger substituents behave as competitive 
antagonists of noradrenaline on the α-sympathetic receptors. The receptor 
affinity first shows a slight increase (adrenaline) and then a decrease, but this 
decrease does not parallel the decrease in intrinsic activity. When the sub­
stituents are aralkyl groups, receptor affinity is regained (Ariens 1, 2, 6, 7; 
Koopman) (see table la). In an analogous β-2-pyridylethylamine series the 
same phenomena can be seen (Ariens 2, 7; van den Brink) (see table lb). Note 
that in both these series there is a loss in affinity towards the specific re­
ceptors when alkyl substituents are employed but that affinity is increased 
again by employing aralkyl substituents. This phenomenon has been ascribed 
to a gain in affinity on so-called "additional receptor areas". It was postulated 
that since an agonist usually contains one or more polar groups, the receptor, 
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T A B L E Ib 
Relative Intrinsic Activities and Affinities (pD2, pA2 and рО'г) of a Series 
of ß-2-Pyridylethylamme Derivatives, 
Tested on the Isolated Ileum of the Guinea-Pig a 
Rl 
Hydrogen 
Methyl 
Ethyl 
Isopropyl 
Propyl 
Butyl 
Hexyl 
Octyl 
Decyl 
Phenylpropyl. 
R2 - methyl ' 
Histamine 
Relative 
Intrinsic 
activity с 
1 
1 
0.9 
0 
0 
0 
0 
0 
0 
0 
1 
Affinity 
Specific 
PD2 C 
5.4+0.1 
5.5 + 0.1 
4.5+0.1 
6.6 + 0.1 
PA2C 
4.0+0.1 
4.2 + 0.1 
4.3 + 0.1 
4.7 + 0.1 
5.9+0.1 
5.3 
5.9 + 0.1 
Est/Orgb 
31/24 
36/29 
23/17 
6/2 
12/5 
26/13 
9/4 
10/3 
3/1 
16/6 
36/26 
Non­
specific 
PD'2C 
<2.0 
<2.0 
2.3 + 0.3 
3.0 + 0.4 
4.0 + 0.4 
4.9 + 0.8 
<2.0 
Est/Orgb 
12/7 
6/4 
5/3 
5/2 
a From Ariëns 7· 
Ъ Est/org: number of estimations/number of organs used therefor, 
с The + figures are the P95 values, indicating the 95% confidence limits for 
the mean. 
being structurally complementary to the agonist, must also have a number of 
polar groups. This may be cause that there is a relatively non-polar area in 
the direct vicinity of the actual receptor - the "additional receptor area". A 
drug having a planar non-polar group, like for instance a phenyl group, in the 
right distance from its polar or "active groups", may gain in affinity by an 
attraction between the non-polar group and the non-polar additional receptor 
area by van der Waal's forces and hydrophobic forces (Ariëns 1, 6, 7). 
When applying aralkyl substitution on the amino nitrogen of 5-HT, however, 
it did not lead to appreciable loss of either affinity or intrinsic activity in the 
case of monosubstitution (substitution of only one Η-atom of the amino group). 
A set of agonistic curves obtained with these compounds is presented in figure 
10a. This is of course not a novel experience; monosubstitution with relatively 
large groups on the amino group of noradrenaline does not lead to competitive 
antagonists on the ß-sympathetic receptors; the compounds in that way ob-
tained remain ß-sympathomimetics (Ariëns 1, 7). In table II a number of N-
aralkyl substituted serotonin derivatives are presented, with their affinities 
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T A B L E II* 
Relative Intrinsic Activities and Affinities (pD2) of N-Monosubstituted 
Derivatives of Serotonin and Tryptamine, 
Tested on the Rat Fundus Strip Preparation 
<jg- c " c " 
Compound 
5-HT 
N-Methyl 5-HT 
0 6 
0 5 
Tryptamine 
U-1217 
U-2296 
U-3371 
U-0018 
X 
5-OH 
5-OH 
5-OH 
5-OH 
R 
-H 
-C 
-C-C-C-C 
-ccc/S 
-H 
-c 
-c-c 
-c-c-c 
< 
Relative 
Intrinsic 
Activity a 
1 
0.98 (4) 
0.97 (8) 
0.78 + 0.87 
0.97 (5) 
0.76 + 0.06 
0.95 (7) 
0.76 + 0.08 
0 . 7 8 + 0 . 1 0 
Affinity 
pD2 a 
6.82+0.001 
6.60+0.28 
6.19+0.06 
5.97+0.19 
4.71+0.14 
4.60+0.09 
4.98+0.96 
4.99+0.20 
4.59+0.16 
No. Str ips 
108 
6 
11 
17 
11 
25 
12 
24 
8 
a
 The + figures given are P95 values, indicating the 95% confidence limits for 
the mean! 
*) In this table and in the tables further on sample means of relative Intrinsic activity, pD2, 
pA2 and pD'2 and the P95 values indicating the 95% confidence limits for the mean are pre­
sented. The values given are means of the mean values per fundus str ip. The 95% confidence 
limits a r e valid (approximately valid) if the distribution of the quantity considered is normal 
(approximately normal). In most cases the normality of the distribution could not be tested, 
asthenumber of values available was not sufficient, but the frequency distribution of the 108 
pD2 values for 5-HT does not deviate significantly from a normal distribution according to 
the tests of Geary and Pearson based on the standardized mean deviation and the coefficient 
of skewness (Pearson). 
For relative intrinsic activity values that frequently obtain the value 1 no P95 confidence 
limits were stated, as the distributions of these values are obviously very skew. In stead of 
P95 values the number of values equal to 1 is given m the latter cases, thereby indicating 
how often the intrinsic activity of the compound equals that of 5-HT. 
Conclusions about differences in intrinsic activity or affinity were drawn according to the 
following rules-
1. RELATIVE INTRINSIC ACTIVITY OF A COMPOUND WITH RESPECT TO 5-HT 
The values of these relative intrinsic activities were always equal to 1 or smaller. If all 
values for a particular compound were smaller than 1, and their number was at least 6, it 
is concluded that the relative intrinsic activity of this compound is smaller than that of 5-HT. 
In all other cases no conclusion was drawn. In this way it is guaranteed that (1) the result 
is significant at the 5% level according to the two-sided sign test (Siegel), and thus the hypo­
thesis ρ > 0.5, where ρ is the probability that the compound has a greater intrinsic activity 
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(given as pD2 values) and relative intrinsic activities. 
It can be seen from table II that there is an indication of loss of intrinsic 
activity when a large substituent is employed, but nevertheless incomparable 
to the situation with the derivatives of noradrenaline or ß-2-pyridylethylamine. 
Bufotenme(5-hydroxy-N1N-dimethyltryptamme)acts as a partial agonist on 
both fundus strip and calf tracheal muscle preparations. The competitive dua-
listic action of bufotenine is illustrated in figure 8a and b. Note in this figure 
that bufotenine acts as a synergist of lower concentrations of 5-HT, but as a 
competitive antagonist of higher concentrations of 5-HT. Compare this figure 
with figure 4a of chapter III. 
The fact that bufotenine behaves as a partial agonist indicates to the possibi-
lity that the intrinsic activity might be suppressed by substituting both H atoms 
of the amino nitrogen in 5-HT by larger groups. 
Gyermek (Gyermek 4) has reported that some quaternary tryptamine de-
rivatives act as antagonists of serotonin; the two most active of these are in-
cluded in table III. He has noted in his series that the best antagonists are 
found when only one of the substituents is larger than a methyl group, and 
when an OH-group is present in the S-position. On this latter observation will 
be remarked further on. The former observation is to some extent supported 
by the results represented since compound U-2030, a compound with two larger 
substituents on the amino nitrogen, proved to have a low affinity compared to 
bufotenine which has only two methyl groups as substituents (see table III). 
A number of N-methyi,N-aralkyl substituted tryptamines were synthesized 
by us (see chapter VI) and tested on the rat fundus strip. These compounds 
proved indeed to possess no intrinsic activity, and behave as competitive an-
tagonists of 5-HT (see table III). It seems as if the most favourable distance 
between the aromatic ring in the side chain and the amino group for a rela-
tively high affinity towards the specific receptors and a relatively low affinity 
towards non-specific receptors is three carbon atoms for the compounds stu-
died. Compound О 10, containing four carbon atoms between the amino group 
and the phenyl group, has a relatively high affinity towards non-specific re­
ceptors as shown by its p D ^ value (see table III), while compound U-0678, 
than 5-HT if there is any difference, can be rejected. (The two-sided ρ value for η values 
smaller than 1 is 2- n +l, which is smaller than 0.05 for η > 6.) (ii) There is a probability of 
95% that the intrinsic activity of the compound will be smaller than that of 5-HT in at least 
60% of the cases where it will be determined. (The 95% lower confidence limit for the proba­
bility that the compound has a smaller intrinsic activity is (0.05)l/n, which is greater than 
0.60 for η > 6.) 
2. INTRINSIC ACTIVITY OF ONE COMPOUND WITH RESPECT TO ANOTHER 
If all values found for the intrinsic activity of a compound A were positive and all values for 
a compound В were 0, and for both at least 4 values were obtained, it is concluded that the 
intrinsic activity of A is greater than that of B. In other cases no conclusions were drawn. 
This procedure guarantees that Р д is greater than Pg according to Fisher ' s exact test for a 
2x2-tableatthe 5% level (two-sided) (Siegel), where Рд or Pfl respectively is the probability 
that a value of the intrinsic activity for either A or В is positive. (If there a r e 4 values for 
A, every time larger than 0, and 4 values for B, every time equalling 0, the Ρ value of the 
two-sided test is 1/35.) 
3. DIFFERENCES IN pD2, pA2 OR рО'г VALUES OF TWO COMPOUNDS 
Conclusions are only drawn if the differences are significant according to the two-sided 
Wilcoxon (Mann and Whitney) two sample test at the 5% level (Siegel). 
(The author is indebted to Mr. Ph.van Eiteren, Director of the Department of Mathematical 
Services, University of Nijmegen, for his advice on the statistical evaluations.) 
61 
T A B L E III 
Relative Intrinsic Activities and Affinities (pD2, pA2 and pD'2) of Ν,Ν-Disubstituted Tryptamine Derivatives 
Tested on the Rat Fundus Strip Preparation 
X · 
•o? 
+ 
•C-C-N-
\ 
Д і 
-R2 
R3 
Compound 
Tryptamine 
U-2161 
U-0678 
X 
-
Ri 
-H 
-c 
R2 
-H 
-c 
-c 
R3 
-H 
-H 
-H 
Relative 
Intrinsic 
Activity * 
0.97 (5) 
0.57+0.11 
Affinity 
Specific 
pD2* 
4.71+0.14 
5.28+0.31 
pA2 * 
4.34 + 0.30 
Nonspecific 
pDx2* 
4.01+0.16 
No. 
Strips 
11 
7 
8 
0 7 
0 9 
0 8 
0 10 
5-HT 
Вufotenine 
U-2030 
Gyermek XI 
Gyermek XII 
-
-
-
-
5-OH 
5-OH 
5-OH 
5-OH 
5-OH 
-C-C-C-7S 
tc-c4J 
tc-°<J 
- C - C - C - C - H / ~ \ 
-H 
-e 
-c-c-c-c 
-4JC 
• ^
l 
-Q 
-e 
-e 
-e 
-H 
-e 
-c-c-c-c 
-e 
-e 
-H 
-H 
-H 
-H 
-H 
-H 
-H 
-e 
-e 
1 
0.66 + 0.07 
0.76 + 0.12 
6 .82+0.001 
6 . 3 8 + 0 . 1 8 
5.79 + 0.25 
4 . 8 9 + 0 . 1 7 
5.28 
5 . 5 8 + 0 . 3 0 
5.78 + 0.26 
4 . 8 1 + 0 . 3 6 
4.76 + 0.29 
3 . 5 0 + 0 . 1 8 
4.72 
4 . 3 4 + 0 . 5 1 
5.27 + 0.18 
4.21 + 0.24 
3.63 + 0.28 
12 
5 
6 
9 
108 
12 
6 
6 
7 
• The + figures are P95 values, indicating the 95% confidence limits for the mean. 
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Fig.8. Cumulative log concentration-response curves for the agonist 5-HT in the presence 
of various concentrations of the partial agonist bufotenine, tested on the rat fundus strip pre­
paration (8a) and the calf tracheal muscle preparation (8b). 
Note the dualistic character of bufotenine, which indicates a competitive dualism in effect. 
Compare with figure 4a of chapter III. 
containing only one carbon atom between the amino group and the phenyl group, 
has a relatively low affinity towards the specific receptors. The compounds of 
Gyermek, having a shorter side chain, exhibit about the same pA2 values as 
the compounds О 7, О 8 and О 9, in spite of the advantage of a 5-OH group on 
the indole nucleus in the former compounds. However, it should be kept in 
mind that one is comparing quaternary amines with tertiary amines in the 
latter case. 
From the compounds related to tryptamine presented in table III it can be 
seen that although they are competitive 5-HT antagonists (with no intrinsic 
activity) there is generally not a great difference between their pA2 and рО'г 
values, meaning that these compounds produce non-specific (non-competitive) 
antagonism in doses not much higher than those by which a specific, competi-
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м 5 - H T M 5 - H T 
Fig.9. Cumulative log concentration-response curves for the agonist 5-HT in the presence 
of various concentrations of the antagonistic compounds 5-hydroxyindole (9a) and 5-benzyl-
oxygramine (9b). 
Note a shift together with a decrease in maximal height of the curves, indicating that the 
antagonistic compounds exhibit a dualism in antagonism. Compare with figure 8 of chapter 
HI. 
tive antagonism is obtained. The same holds for the two quaternary compounds. 
Anyhow, there is a strong indication that the intrinsic activity is strongly de­
pendent on the character of the amino group. It seemed therefore interesting to 
test some indole compounds in which the amino group is absent, or has a po­
sition nearer to the indole nucleus. In this respect 5-hydroxyindole seemed 
to be indicated, as well as gramine and some of its derivatives which have 
been reported to antagonize serotonin (Gaddum 4; Quadbeck; Erspamer 7). 
Gramine has only one carbon atom between the indole nucleus and the amino 
group (which in this case has two methyl groups). Curves obtained with 5-HT 
in the presence of 5-hydroxyindole and 5-benzyloxygramine are presented in 
figure 9a and b respectively. Note that the latter two compounds, although being 
competitive antagonists of 5-HT, exert also a non-competitive antagonism. 
Compare figure 9a and b with figure 8a in chapter III. 
Results obtained with indole and gramine derivatives tested as 5-HT anta-, 
gonists are presented in table IV. 
The first two compounds of table IV, which contain no side chain with amino 
group have no intrinsic activity, also indicating that this latter property is 
strongly dependent on the character of the amino group. In the case of the 
gramines the amino group is "shielded" by two methyl groups, but this is also 
the case with bufotenine, which still exhibits some intrinsic activity. It is pos­
sible that the amino group of the grammes does not reach the correct position 
on the receptor to elicit intrinsic activity, since here the side chain is shorter. 
Here again these compounds have rather low affinities towards the 5-HT re­
ceptors and rather high affinities towards non-specific receptors, as shown by 
comparison of their pA2 and p D ^ values. 
It should also be pointed out that 5-hydroxyindole has a much lower affinity 
than 5-HT, indicating that the amino group not only plays a role in intrinsic 
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T A B L E IV 
Affinities (pA2 and pD'2) of Substituted Indole Derivatives 
Tested on the Rat Fundus Strip Preparation 
<ХГ 
Compound 
5-hydroxyindole 
U-1367 
(5-benzyloxyindole) 
Gramine 
U-8273 
(5-benzyl-
oxygramine) 
U-11,028 
U-16,326 
X 
5-OH 
5 - O - C - H Q 
5-0-С-^~Л 
5-0-С-СЛ 
R 
-H 
-H 
XT 
Affinity 
Specific 
pA2* 
4.60 
4.27 
4.97 + 0.70 
5.32+0.25 
4.77+0.15 
5.07 + 0.26 
Nonspecific 
рО'г* 
3.26 
3.65 
4.29 
4.56 + 0.23 
3.52 + 0.21 
3.89+0.19 
No. 
Strips 
4 
4 
5 
15 
9 
6 
* The + figures are P95 values, indicating the 95% confidence limits for the 
mean; 
activity, but also in affinity. This is also seen when comparing the affinities 
of bufotenine and 5-HT (table III) although in the latter case the difference is 
not so great, bufotenine still having its amino group in the same relative po­
sition as in 5-HT, but the affinity is apparently slightly hindered by the pre­
sence of the two methyl groups. 
To study the effect of substituents of increasing size in series of N-methyl, 
N-alkylor N-methyl,N-aralkyl derivatives of 5-hydroxytryptamine, a number 
of 5-HT derivatives were synthesized. The synthesis is described in chapter 
VI. 
In such aser ies wherein one substituent on the amino group is a methyl group, 
while the other substituent is increased in size, there is apparently a pro­
gressive loss in intrinsic activity with increase in size of the latter substituent. 
The intrinsic activity is decreased to zero when the second substituent is an 
aralkyl group, like for instance phenylpropyl. The compound N-methyl,N-
phenylpropyl 5-HT behaves as a competitive antagonist (sçe table V). Note in 
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table V that there ie not such a sharp decrease in receptor affinity when alkyl 
substitution is employed, and that there is also no significant increase in af-
finity when aralkyl substitution is employed as is the case for the noradrena-
line and ß-2-pyridylethylamme series presented in table la and b. This in-
dicates that in the case of these 5-HT antagonists, little, if any, affinity is 
gained on the so-called additional receptor areas. 
The decrease in intrinsic activity with increase in size of a substituent on 
the amino group of N-methyl-5-hydroxytryptamme, contrasts with the situa-
tion found for the N-monosubstituted 5-hydroxytryptamines. This contrast is 
illustrated in figure 10a and b. 
M M 
Fig.lO. Cumulative log concentration-response curves for 5-HT and some N-monosubstituted 
5-HT derivatives (10a), and for 5-HT and some corresponding N,N -disubstltuted 5-HT deriva-
tives (10b). 
Note that with the monosubstltuted compounds there is virtually no decrease In the maximal 
height ofthe curves, while with corresponding disubstltuted compounds a gradual change from 
active to "inactive" compounds takes place with an increase in the size of one substituent. 
Note in figure 10a that there is practically no decrease in intrinsic ac-
tivity for the N-monosubstituted 5-HT derivatives tested, but, as can be seen 
in figure 10b, the corresponding N.N-disubstituted 5-HT derivatives whereby 
one substituent is a methyl group, do exhibit a decrease in intrinsic activity. 
The compound N-methyl,N-phenylpropyl-5-hydroxytryptamine (O 12) does not 
exhibit any intrinsic activity any more (figure 10b) but behaves as a competi-
tive antagonist of 5-HT (figure 11a and b). 
The compounds О 12, О 16 and 018 proved to be the competitive antagonists 
of 5-HT with the highest receptor affinity found during the course of this in­
vestigation. Log concentration-response curves obtained with 5-HT in the 
presence of various concentrations of 0 12 and О 18 on the rat fundus strip 
preparation as well as on the calf tracheal muscle preparation are presented 
in figure 11a, b, с and d. 
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T A B L E V 
Relative Intrinsic Activities and Affinities (pD2, pA2 and pD'2) of Ν,Ν-Disubstituted 5-Hydroxytryptamine 
and 5-Benzyloxytryptamine Derivatives, Tested on the Rat Fundus Strip Preparation 
Οσ 
/ R i 
C-C-N 
Ν-
 R 2 
Compound 
5-HT 
Bufotenine 
0 14 
O 2 0 
X 
5-OH 
5-OH 
5-OH 
5-OH 
Rl 
-H 
-C 
-C-C-C-C 
-C-C-C-Ç 
C-C-C-C 
R2 
-H 
-c 
-c 
-c 
Relative 
Intrinsic 
Activity * 
1 
0.66 + 0.07 
0 .58+0 .12 
0.19 
Affinity 
Specific 
pD2* 
6.82 + 0.001 
6 .38+0 ,18 
6.45 + 0.40 
6.54 
pA2 * 
Nonspecific 
ро'г* 
No. 
Strips 
108 
12 
11 
3 
0 12 
0 18 
0 16 
U-2030 
0 19 
0 11 
0 17 
5-ОН 
5-ОН 
5-ОН 
5-ОН 
5-0-C-/~~Y 
5-0-С-/~Л 
5-0-С-/~Л 
-C-C-C-/S 
ссс/О 
Ό 
-с-с-с-с 
-C-C-C-Ç 
С-С-С-0 
-с-с-с-/) 
-с 
-с 
-с 
-с-с-с-с 
-с 
-с 
-с 
0.76 + 0.12 5.79 + 0.25 
6.25+0.15 
6.44 + 0.06 
6.32+0.17 
6.05 + 0.29 
4.50+0.23 
5.85+0.19 
4.22 + 0.16 
4.31+0.19 
4.32+0.30 
4.61 + 0.57 
3.50 + 0.17 
4.46 + 0.30 
19 
15 
6 
6 
4 
6 
4 
* The + figures are Р95 values, indicating the 95% confidence limits for the mean. 
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Note in this figure that О 12 and О 18 cause a parallel shift to the right of 
the log concentration-response curves of 5-HT on both preparations, indicating 
competitive antagonism. Compare figure 11a, b, с and d with figures 2 and 8c 
of chapter III. 
% contraction rat fundus strip 
100 
τ calf tracheal muscle 
M 5-HT 
% contraction rat fundus strip 
100-|H0-r<^¡]—¡T-C-C-N-Ç-C-0-<^ 
Ч ^ м ^ c c ^ · 
calf tracheal muscle 
M 5 - H T M 5-HT 
Fig.U. Cumulative log concentration-response curves for the agonist 5-HT in the presence 
ofvarious concentrations ofthe antagonistic compounds О 12 and О 18, tested on the rat fundus 
strip preparation (11a and c) and tested on the calf tracheal muscle preparation (libandd). 
Note the parallel shift in the curves which indicates a competitive antagonism. Compare 
with figure 2 of chapter III. 
A registrogram of cumulative concentration-response curves obtained with 
5-HT on the rat fundus strip preparation in the presence of various concentra­
tions of О 12 is presented in figure l i e . The competitive antagonism by О 12 
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and О 18 was also confirmed on the chicken oesophagus preparation. 
As has been shown in figure 11, О 12 and О 18 behave as competitive antago­
nists towards 5-HT on both rat fundus strip preparation as well as on the calf 
tracheal muscle preparation. It will be pointed out later (section 4 of this 
chapter) that the 5-HT receptors in the calf tracheal muscle are probably of a 
different type than those of the rat stomach fundus. 
contraction rot fundus strip 
Ar« 
НО'
7
 ь,п-8 
IO" 8 1 0 IO"8 10-8 ю- 7 
5-HT 5-HT 5-HT 5-HT 5-HT 5-HT м 
О 12 О 10' 3 10' 10" 3 IO' 5 м 
Fig.l le. Registrogramof cumulatlveconcentration-response curves for 5-HT in the presence 
of various concentrations oftheantagonistO 12, tested on the rat fundus preparation, for which 
the curves are given in figure 11a. 
It should also be mentioned that no difference in pA2 values for the com­
pound О 12 could be shown, whether 5-HT or tryptamine was the agonist em­
ployed. This could be interpreted as an indication that tryptamine and seroto­
nin act on the same receptors. If tryptamine acts by means of a 5-HT release 
one would have to assume that the amount of 5-HT released is not bound to a 
limit, or else one would expect the competitive antagonist to exhibit at least 
a higher pD'2 value when tested against tryptamine. Since this is not the case, 
and since no tachyphylaxis to the effect of tryptamine could be shown, it seems 
plausible to assume that tryptamine acts directly on the specific 5-HT recep­
tors in the rat fundus strip preparation. 
The compounds О 12 and 0 18 were also tested to determine whether they 
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T A B L E VI 
Affinities (pA2 and рО'г values) of the competitive serotonin antagonists Ό 12 and O J8 
Tested against various agonistic compounds on different isolated tissue preparations 
Antagonist 
Ç 
HO-|^N » -C-C-N-C-C-C-/~~\ 
0 12 
Agonist 
H 0 O^r c - c ' N 
5-HT 
H O ^ ^ - C - C - N 
ноХ/6 н 
noradrenaline 
histamine 
Tissue 
preparation 
rat fundus strip 
calf 
tracheal muscle 
isolated 
rat vas deferens 
isolated 
guinea-pig ileum 
Affinity 
Specific 
pA2* 
6.25+0.15 
6.45 + 0.43 
<4 
5.80 + 0.25 
Nonspecific 
pD'2* 
4.22 + 0.16 
<3.5 
<4 
5.36 + 0.23 
No. 
preparations 
19 
9 
6 
6 
H O - j ^ 1 -C-C-N-C-C-0-/~~\ 
О 18 
^O^-C-N—С 
С 
furtrethonium 
"Од-"™ 
5-НТ 
но-М
5н 
noradrenaline 
, f-C-C-N 
histamine 
^Cr^C-N—С 
furtrethonium 
rat fundus strip 
isolated 
rat jejunum 
rat fundus strip 
calf 
tracheal muscle 
isolated 
rat vas deferens 
isolated 
guinea-pig ileum 
rat fundus strip 
isolated 
rat jejunum 
5.55 + 0.22 
5.03 + 0.41 
6.44 + 0.06 
5.86+0.04 
<4 
5.51+0.28 
5.76 + 0.50 
5.03 + 0.48 
4.59 + 0.46 
4.77+0.37 
4.31+0.19 
4.51 + 0.08 
<4 
4.49 + 0.44 
4.58 + 1.01 
4.62 + 0.29 
7 
5 
15 
7 
6 
6 
6 
6 
ω * The + figures are P95 values, indicating the 95% confidence limits for the mean. 
exhibit antagonistic properties towards other biological amines as well. These 
determinations were done on the isolated rat vas deferens employing noradre­
naline as agonist, on the isolated guinea-pig ileum using histamine as agonist 
and on both the rat fundus strip preparation as well as on the isolated rat je­
junum employing the cholinomimetic compound furtrethonium as agonist. The 
compounds 012 and 018 produced no change in the curve of noradrenaline in 
concentrations up to 10-4 м . Against histamine as well as against furtretho­
nium 012 and 018 exhibit some antagonism, but the pA2 values for both com­
pounds tested against 5-HT are higher, indicating that these compounds anta­
gonize 5-HT in lower concentrations than those needed to antagonize the other 
amines. The pA2 values for О 12 and О 18 found in experiments with the ago­
nistic compounds mentioned, have been summarized in table VI to give some 
idea on the specificity of these two 5-HT antagonists. 
(ii) Substitution on the a-carbon atom 
The compounds a-methyltryptamine and a-ethyltryptamine (Monase) first 
synthesized by Heinzelman et al. (Heinzelman 2), have been described as mono­
amine oxidase inhibitors (Greig). Since these substances both have a sub­
stituent in close proximity to the amino group, it seemed interesting to examine 
the possible influence of these substituents on the intrinsic activity and affinity. 
The results of experiments with some a-substituted tryptamines are represented 
in table VII. 
Here again an influence on intrinsic activity is shown, this time by substi­
tuents in the proximity of the N-atom. A larger substituent, as in Monase, 
causes bigger suppression of the intrinsic activity, but also hinders the 
affinity more. It is interesting to note that a-methyltryptamine and MP 809 
apparently have better affinities than tryptamine, whereas a-methylserotonin 
(U 7729) has lower affinity than serotonin (see table VII). This discrepancy 
will be discussed later (section 5b of this chapter). 
(iii) Various substitutions on the indole nucleus 
It has been mentioned earlier that absence of the 5-OH group leads to a de­
crease in receptor affinity but not to a change in intrinsic activity when com­
paring 5-HT and tryptamine. Since tryptamine is potentiated (the log concen­
tration-response curve is shifted to the left) by monoamine oxidase inhibitors 
(MAO inhibitors), the pD2 value found for tryptamine in the absence of a suf­
ficient concentration of a MAO inhibitor is quite probably too low. The same 
holds true for N-methyltryptamine. Because of this potentiation of tryptamine 
and N-methyltryptamine by MAO inhibitors, pD2 values for these compounds 
in the presence of 10-5 м pargyline are also presented (see table VIII). With 
this concentration of pargyline no potentiation of N,N-dimethyltryptamine 
could be shown. 
In table VIII the relative intrinsic activities and affinities (as pD2, pA2 and 
ρΌ'2 values) of some corresponding 5-HT, tryptamine and 5-benzyloxytrypt-
amine derivatives are summarized. Note in this table that the 5-hydroxy de­
rivatives invariably have the highest affinities towards the specific receptors, 
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T A B L E VII 
Relative Intrinsic Activities and Affinities (pD2) of α-substituted Tryptamine 
and 5-Hydroxytryptamine Derivatives, 
Tested on the Rat Fundus Strip Preparation 
I*^4! rC-C-N 
R 
Tryptamine 
U-14,164 E 
(a-methyltryptamine) 
MP 809 
U-17,312 E 
(Monase) 
5-HT 
U-7729 
(o-methyl 5-HT) 
X 
4-C 
5-OH 
5-OH 
R 
-H 
-C 
-C-
-C-C 
-H 
-c 
Relative 
Intrinsic 
Activity * 
0.97 (5) 
0.64 +0.13 
0.71 + 0.09 
0.25 + 0.07 
1 
0.84 + 0.07 
Affinity 
pD2* 
4.71 +0.14 
5.38 + 0.21 
5.65+0.17 
5.03 + 0.73 
6.82 +0.001 
6.45 +0.18 
No. 
Strips 
11 
11 
18 
7 
108 
14 
* The + figures are P95 values, indicating the 95% confidence limits for the 
mean. 
no matter whether the compounds compared are agonists or competitive anta­
gonists, for instance not only does 5-HT have a higher pD2 value than trypt­
amine, but the antagonists 0 12 and 0 18 also have higher pA2 values than 
О 7 and О 8 or О 11 and О 17 respectively. 
Some very interesting compounds are known with substituents in a position 
other than 5; in this respect 4-eubstituted compounds shall be discussed first. 
Psilocybine, a hallucinogenic compound (Isbell) described as a serotonin anta­
gonist (Erspamer 1), and the closely related psilocine are examples in this 
category. The parameters of some 4-substituted compounds are represented 
in table VIII. 
Psilocybine proved to be a competitive antagonist of 5-HT, although being 
only Ν,Ν-dimethyl substituted, like bufotenine which is still a partial agonist. 
This observation is perhaps the least obscure indication found that there is a 
tendency for compounds without a 5-OH group to exhibit not only a lower affi­
nity but also generally a slightly lower intrinsic activity than corresponding 
agonistic compounds containing the 5-OH group. Although something else ex­
cept the absence of the 5-OH group, for instance some type of hindrance by 
the large phosphate ester group, may play a role in depriving psilocybine from 
its intrinsic activity, it is interesting to note that the 4-OH compounds gener­
ally exhibit not only a lower affinity but also a lower intrinsic activity than 
corresponding 5-OH compounds (see table VIII and figure 12). 
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T A B L E Vili 
Comparison of Relative Intrinsic Activities and Affinities (pD2, pA2 and ρΌ'2) of some 5-Hydroxytryptamine 
Derivatives with corresponding Tryptamine Derivatives, 4-Hydroxy and 5-Benzyloxytryptamlne Derivatives. 
Values are for the Rat Fundus Strip Preparation. 
<Ххс-£<. 
Compound 
5-HT 
Tryptamine 
Tryptamine + 
pargyline 10-5 M 
4-HT 
N-Methyl 5-HT 
U-1217 
U-1217 + 
pargyline 10-5 M 
N-Methyl 4-HT 
Bufotenlne 
U-2161 
U-2161 + 
pargyline 10-5 M 
X 
5-OH 
4-OH 
5-OH 
4-OH 
5-OH 
Rl 
-H 
-H 
-H 
-c 
-c 
-c 
-c 
-c 
R2 
-H 
-H 
-H 
-H 
-H 
-H 
-c 
-c 
R3 
-H 
-H 
-H 
-H 
-H 
-H 
-H 
-H 
Relative 
Intrinsic 
Activity * 
1 
0.97 ( 5) 
0.99 (11) 
0.85 ( 1) 
0.98 ( 4) 
0.76 + 0.06 
0.80 + 0.12 
0 .76+0 .11 
0.66 + 0.07 
0 .57+0 .11 
0 .79+0 .12 
Affinity 
Specific 
pD2 * 
6.82 + 0.001 
4 . 7 1 + 0 . 1 4 
5.26 + 0.07 
5.36 + 0.19 
6.60 + 0.28 
4.60 + 0.09 
5.60 + 0.23 
4.82 + 0.34 
6 .38+0 .18 
5 .28+0 .31 
5.13 + 0.27 
P A 2 * 
Non-
specific 
р О ' г * 
No.Strips 
108 
11 
12 
7 
6 
25 
5 
7 
12 
7 
6 
Psi locine 
О 12 
О 7 
О 11 
О 18 
О 8 
О 17 
О б 
U-3370 
U-7729 
(α-methyl 5-НТ) 
U-14.164E 
(a-methyl-
tryptamine) 
6-НТ 
Psilocybine 
4-ОН 
5-ОН 
5-0-C-/S 
5-ОН 
5-0-C-/S 
5-ОН 
5-ОН 
6-ОН 
ОН 
4-О-Р-ОН 
-С 
-с-с-с-^Л 
-c-c-cVS 
-С-С-С-Г~\ 
Ω
-
Ω
 
Ω
-
Ω
 
Ω
-
Ω
 
Ω
 
Ω
 
Ω
 
ι
 
ι
 
ι
 
Ο
 
Ο
 
Ο
 
ÓÒ
Ó 
- C - C - C - C 
- C - C - C - C 
-Η 
-Η 
-Η 
-C 
-C 
- C 
-C 
-C 
-C 
-C 
-C 
-Η 
-Η 
-Η 
-Η 
-Η 
-C 
-Η 
-Η 
-Η 
-Η 
-Η 
-Η 
-Η 
-Η 
-Η 
-C 
-C 
-Η 
-Η 
0.26 + 0.11 
0.97 ( 8) 
0.27 
0.84 + 0.07 
0.64 + 0 . 1 3 
0.68 + 0.07 
4.47 + 0.56 
6 . 1 9 + 0 . 0 6 
4.43 
6 . 4 5 + 0 . 1 8 
5.38 + 0.21 
3.95 + 0.48 
6 : 2 5 + 0 . 1 5 
4 . 8 9 + 0 . 1 7 
4.50 + 0.23 
6.44 + 0.06 
5 . 5 8 + 0 . 3 0 
5 . 8 5 + 0 . 1 9 
5 . 2 7 + 0 . 1 8 
4.22 + 0.16 
3 . 5 0 + 0 . 1 8 
3 . 5 0 + 0 . 1 7 
4.31 +0.19 
4.34 + 0.51 
4.46 + 0.30 
3.30 + 0.27 
10 
19 
12 
6 
15 
6 
4 
11 
4 
14 
11 
7 
16 
iä * The + figures given are P95 values, indicating the 95% confidence limits for the mean. 
- с - с 
- H - С 
Relative i-ntrinaic a c t i v i t y 
LO 
e-c-c-c -c-e-c-O -c-c-o-(3 
• χ . S - O H 
* x=4-OH 
« x. - H 
x= -H . , 
(•PargyhneiO*'J 
x, 5-O-C-0 
Ri 
Rz -H -H - c -c-c-e-c -c-c-c-^> -c-c-o^ 
Flg.12. Curvee to indicate the changes in affinity (pD2 or pA2 value) (12a) and in relative In­
trinsic activity (12b), in corresponding series of amino substituted 5-HT, 4-HT, tryptamine 
and 5-benzyloxytryptamme derivatives as found for the rat fundus strip preparation. 
Note that the pD2 values for tryptamine and N-methyltryptamine are enhanced in the pre­
sence of the MAO inhibitor pargyline, indicating that metabolic break-down of these two com­
pounds by MAO may interfere with the measured pD2 values (12a). Note the decrease in re­
lative intrinsic activity accompanying an increase in size of a substituent (12b). 
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It is interesting to note that 6-hydroxytryptamine exhibits a lower affinity 
than even tryptamine. It seems as if an OH-group in the 6-position works de­
trimentally on receptor -affinity, an OH-group in the 4-position of tryptamine 
enhances affinity, but the most favourable position for the OH-group remains 
the 5-po6ition. The intrinsic activity is also influenced by the OH-group in the 
6-position (see table VIII). 
A number of 5-HT antagonists containing substituents in the 1 position of the 
indole ring have been reported. The best known antagonists of this type are 
BAS and related compounds, first reported to exhibit 5-HT antagonism by 
Woolley and co-workers (Woolley 4, 5, 12; Shaw 1). The structural formulae 
for these compounds are the following: 
A 
X
"^jirjL Z 5-ОСНз -H BAS 
^ ^ ψ
 с
 S-ОН -H BAS-phenol 
С S-OCHj -CHj BAB 
'Ò 
It was mentioned earlier in this chapter that substitution on the amino ni-
trogen of noradrenaline and ß-2-pyridylethylamine has been demonstrated to 
lead to competitive antagonists of the respective agonistic compounds (see 
table I). It may be possible to view substitution in the 1 position of 5-HT as 
analogous to amino substitution in noradrenaline and ß-2-pyridylethylamine, 
on the basis of the following analogy in structure: 
TioradrenaHne ß-2-pyridy]- 5-HT 
ethylamine 
It should be noted that the BAS-like compounds contain no methyl group (BAS 
andBAS-phenol)oronlytwo methyl groups (BAB) as substituents on the ethyl-
amino group; yet they are known to behave as 5-HT antagonists. This situation 
maybe viewed as analogous to the series of choline esters, studied by Ariens 
and van Rossum, in which the higher homologues were shown to be competitive 
antagonists of acetylcholine (Ariens 12,7; van Rossum 1). In the latter series 
there are also no substituents on the quaternary amino group of the esters. 
In experiments done on the rat fundus strip the BAS-like compounds act as 
irreversible antagonists of 5-HT. After treatment with one of these compounds 
the sensitivity of the isolated fundus preparation towards 5-HT could not be 
restored by washing the preparation with Tyrode solution. Surprisingly, though, 
the BAS-like compounds, especially BAS-phenol, exhibited contraction of the 
fundus strip in a number of experiments. Relaxation could be brought about 
after washing, but the ability of the muscle to respond with a contraction to the 
BAS-like compounds for a second time, was impaired. 
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In an attempt to ascertain whether the irreversible antagonism exhibited by 
the BAS-like compounds was competitive, in other words an irreversible 
blockade of the specific 5-HT receptors, receptor protection experiments were 
carried out. The theoretical background of this procedure was discussed in the 
previous chapter (see sections 7 and 8, chapter III). 
For this investigation two strips obtained from the same rat fundus were 
employed for every experiment. A high concentration of 5-HT or competitive 
antagonist of 5-HT (concentrations of IO" 4 and 10-3 M 5-HT as well as I O - 4 
and 10-3 M О 12 in the bath fluid were used) was added to the bath fluid of one 
of the strips, the other strip was to serve as a control. Both preparations were 
incubated with a concentration of 10-5Mof BASorBAS-phenolfor a fixed period 
of time (5, 10 and 15 min. periods were employed)* After incubation with the 
BAS-like compounds, 5-HT curves were obtained on both strips. Had the BAS-
like compounds produced their antagonistic action on the specific 5-HT recep­
tors, one could have expected that the strip in which the receptors were "pro­
tected' with a high concentration of a drug acting reversibly on these recep­
tors, would produce a higher maximal effect than the unprotected strip. This 
could, however, not be shown. 
Protection in this way against the irreversible blocking actions of diben-
amine and dibenzyline could also not be shown by us. These two compounds 
have been shown to interact in an irreversible way with the receptors of bio­
logical amines (Furchgott 1), therefore it cannot be concluded here that the 
BAS-like compounds do not produce their antagonism on the specific 5-HT 
receptors. 
(iv) Lysergic acid derivatives 
It is generally assumed that the most potent 5-HT antagonists are to be found 
in this group of compounds. The drugs D-lysergic acid diethylamide (LSD), 
2-bromo-LSD (BOL) and methysergide (UML; Deseril) are some of the best 
known 5-HT antagonists of this group. The lysergic acid derivatives could be 
seen as structural analogues of 5-HT because both structures contain the in­
dole ring. For the structural formulas the reader is referred to table II of 
chapter II. The three compounds mentioned here have been examined on the 
fundus strip preparation. They behave as irreversible antagonists against 5-HT 
on this preparation. It could also not be determined whether the irreversible 
interaction is competitive, since receptor protection experiments with these 
drugs, done in the same way as described under (iii) above, could not allow 
conclusions to be drawn. 
It was surprisingly found that LSD, in concentrations of I O - 4 M, did not ex­
hibit antagonism towards 5-HT on the calf tracheal muscle preparation. This 
will be discussed further under section 4. 
3. STRUCTURALLY NON-RELATED SEROTONIN ANTAGONISTS 
a. P h e n o t h i a z i n e s and a n t i h i s t a m i n i c s 
Of the phenothiazines tested, chlorpromazine has been reported to be the 
most potent 5-HT antagonist (Gyermek 7, 8; Erspamer 1). This compound was 
found to be a reversible non-competitive antagonist of 5-HT, both on the rat 
fundus strip as well as on the chicken oesophagus. Concentration-response 
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% contraction rat fundus strip 
M 5-HT м 5-HT 
Flg. 13. Cumulative log concentration-response curvee for the agonist 5-HT in the presence 
of various concentrations of the irreversibly antagonistic compounds LSD (13a) and UML 
(methysergide) (13b), tested on the rat fundus strip preparation. 
Note the depression in maximal height of the curves. 
% contraction rat fundue strip 
M 5-HT M 5-HT 
Fig.14. Cumulative log concentration-response curves for the agonist 5-HT in the presence 
of various concentrations of chlorpromazine (14a) and the musculotropic drug papaverine 
(14b), tested on the rat fundus strip preparation. 
Note the depression in maximal height and slope of the curves, indicating non-competitive 
antagonism in both cases. Compare with figure 5 of chapter HI. Note the difference between 
the curves for this non-competitive antagonism and those for competitive antagonism. Com­
pare with figure 11. 
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curves obtained with chlorpromazine on the rat fundus strip are presented 
in figure 14a. 
In figure 14b curves are presented for 5-HT in the presence of various con­
centrations of the musculotropic drug papaverine. 
Note that chlorpromazine, just like papaverine, causes only a depression in 
height and slope, but no shift in the log concentration-response curves for 5-HT. 
Compare the sets of curves presented in figure 14 with those theoretically cal­
culated for non-competitive antagonism and presented in figure 5 of the pre­
vious chapter. 
Cyproheptadine has been described as the antihistaminic drug which exhibits 
the strongest anti-5-НТ action (Erspamer 1). This compound was found in our 
experiments to be an irreversible 5-HT antagonist on the rat fundus strip. 
b. C i n n a m a m i d e s 
Recently some cinnamamides, especially 2' - (3- dimethylaminopropylthio) 
cinnamanilide (compound SQ 10,643), have been described as potent 5-HT an­
tagonists (Krapcho 1, 2; Rubin 1; Dombro 1). Compound SQ 10,643 and also 
N-(ß-dimethylaminoethyl)-N-benzyl-m-methoxycinnamamide (compound no. 
VII described by Dombro and Woolley (Dombro)) were found not to exhibit an-
tagonism in doses lower than IO -4 M on the rat fundus strip in our experi-
ments. 
с S y m p a t h o m i m e t i c s 
The fact that 5-HT possibly reacts with α-sympathetic receptors at high 
doses, thereby causing an auto-inhibitive effect, has already been discussed 
(section 2a). It was remarked that noradrenaline causes relaxation of a fundus 
strip brought into contraction with 5-HT. One would expect that noradrenaline, 
being known as an a-sympathomimetic compound, would behave as a non­
competitive antagonist of 5-HT. Surprisingly, though, noradrenaline causes a 
parallel shift in the log concentration-response curve of 5-HT, an action de-
monstratable for low doses (10-7 щ of noradrenaline. On further investiga­
tion of this phenomenon it was found that this property of noradrenaline is 
shared by the ß-sympathomimetic compound isopropylnoradrenaline. 
The shift in the log concentration-response curve caused by noradrenaline 
could be antagonized by the β-sympatholytic compound nethalide (see figure 
15a), but not by an α-sympatholytic compound. It appears, therefore, that the 
shift takes place by a ß-sympathomimetic action of noradrenaline. When 5-HT 
curves were obtained in the presence of larger doses of noradrenaline, com-
bined with the ß-lytic compound nethalide (to prevent the agonistic curve from 
shifting into such high ranges of concentration that 5-HT would not dissolve 
any more) a non-competitive type of depression was exhibited on the agonistic 
curve. Various imidazoline compounds have recently been shown to exhibit 
specific α-sympathomimetic properties, devoid of ß-sympathomimetic actions 
(Mujic). One of these compounds, oxymetazoline, was tested as antagonist to-
wards 5-HT and was found to produce only a non-competitive antagonism of 
5-HT (see figure 15e). 
. The fact that the competitive antagonists of 5-HT found in this study do not 
cause a shift in the 5-HT curve by a ß-sympathomimetic action is illustrated 
for the compound 012 in figure 15b. Note in this figure that the shift in the log 
concentration-response curve for 5-HT caused by 012 is not antagonized by the 
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м 5-HT кг5-НТ 
% contract ion r a t f u n d u s s t r i p 
м 5-HT м 5-HT 
Fig.lSa and b. Cumulative log concentration-response curves for the agonist 5-HT m the ab­
sence and presence of a constant concentration of noradrenaline (15a) and the competitive 
antagonist О 12 (15b) tested in the absence and in the presence of the p-sympatholytic com­
pound nethalide. 
Note that the shift in the curve of 5-HT caused by noradrenaline is antagonized by the 0-
sympatholytic compound, while the shift produced by О 12 is not. This indicates that the shift 
caused by noradrenaline is due to a β-sympathomimetic action Fig.lSc and d. Cumulative 
log concentration-response curves in the presence of the competitive antagonists О 12 and 
О 18 and the combination of these two drugs (15c) and in the presence of the competitive an­
tagonist О 18 and noradrenaline, and the combination of the latter two drugs (15d). 
Note that with the combination of О 12 and 0 18 the shift obtained is hardly more than the 
shift with О 18 alone, as could be expected with such a combination of two competitive anta­
gonists. The shift produced by a combination of О 18 and noradrenaline is more than svould 
be expected from a combination of two competitive antagonists. 
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% c o n t r a c t i o n r a t f u n d u s s t r i p 
M 5-НГ 
Fig.lSe. Cumulative log concentration-response curves for the agonist 5-HT in the presence 
of various concentrations of the a-symathomimetic compound oxymetazoline. 
Note thedecrease in maximal height of the curves, indicating a non-competitive antagonism. 
Compare with figure 5 of chapter HI. 
β -sympatholytic compound nethalide, as is the case for the shift produced by 
noradrenaline. Compare figure 15b with figure 15a. 
'The fact that a ß-sympathomimetic compound can produce a parallel shift 
in the log concentration-response curve of a cholinomimetic compound when 
tested on the rat intestine has been previously demonstrated (Ariens 6, 7). The 
shift was ascribed to a kind of functional antagonism as it could be indicated 
that isopropylarterenol did not cause the shift by interacting with the same 
receptors as the agonist. 
It was shown that when using two competitive antagonists simultaneously, 
the amount of shift of the curve of the agonist on the log concentration axis 
was far less than a summation of the amounts of shift produced by the same 
doses of the competitive antagonists individually. When using a competitive 
antagonist and isopropylarterenol simultaneously, however, the amount of 
shift on the agonistic curve above the log concentration axis was nearly a 
summation of the amounts of shift produced by the same concentrations of 
the latter two drugs individually (Агіёпв 6, 7). • 
By comparing the antagonistic action of a combination of the two compe­
titive antagonists 0 12 and 0 18 with the antagonistic action of a combination 
of О 18 and noradrenaline, it can be shown in the same way as in the experi­
ments mentioned above that noradrenaline does not cause the shift in the 5-HT 
curve by competitive antagonism. 
When obtaining a dose-response curve with the agonist 5-HT in the pre­
sence of two competitive antagonists, 012 and 018, the amount of shift obtained 
is much less than a summation of the shift produced by each antagonist in the 
same concentration individually. When obtaining a curve with 5-HT in the pre­
sence of a combination of a competitive antagonist and noradrenaline, however, 
there is nearer a summation in the amount of shift produced by each antagonis­
tic compound individually. In figure 15c and d the described situation is pre­
sented. 
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It can be demonstrated that the results shown above are actually predicted 
by the theory. When two competitive antagonists are employed simultaneously, 
the situation can be schematically presented as follows: 
R 
A B C 
In this scheme the competitive antagonists В and С compete with the agonist 
A for occupation ofthe receptors R. Only the agonist A has an intrinsic activity 
and is able to cause an effect on the effector E. 
When A and В are present alone, equation 17 of chapter III, derived for com­
petitive antagonism, can be applied: 
|AB
 =
 α
 ( 1 ) 
E m
 ! + ( ! + [ § ] ) KA 
^ K B ; [A] (= eq.17, chapter III) 
(2) 
When A and С are present alone, the same equation applies: 
E A C α 
For the case when А, В and С are present simultaneously, an equation can 
be derived in a way similar to the deduction presented in chapter III section 
4a. This gives the following equation: 
EABC α .,. 
Em =
 1 + ( 1 + [ Β ΐ + ί α KJL ( 3 ) 
І + ( І +
К
В
+
К < У [Aj 
(An equation similar to the one above has been presented by Ariens and Simonis 
(Ariëns 6).) Demonstration ofthe amount of shift in the dose-response curve of 
A produced by the presence of В and С individually and the presence of both the 
latter two drugs at the same time can best be illustrated by an example. In equa­
tion 1 a concentration of В which would produce a shift in the curve for A by a 
factor 100, would be: 
[B] = 99 KB 
In equation 2 a concentration of С which would produce a shift of a factor 10, 
would be: 
[C] = 9 K c 
If these values for [B] and [C] are used in equation 3, the amount of shift in 
the curve of A caused by the simultaneous presence of В and С in these con­
centrations would amount to a factor 109. 
Let us now take an example whereby only one of the drugs causing the shift 
competes with the receptors for A, while the other causes a decrease in the 
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affinity between R and A by acting on other receptors. This might be repre­
sented by the following scheme: 
R O R ' 
/\ J 
A B C 
Here С acts on the receptors R', causing a decrease in affinity between A and 
R. В competes with A for occupation of R. When only A and В are present in 
this system, equation 1 can again be applied. 
When A and С alone are present in this system, equation 20 of chapter III 
may be applied: 
1 ^ "—кг W 
A C
 [A] (= eq.20, chapter III) 
When all three compounds are present, the following equation may be used: 
E A B C '
 =
 α /5) 
E m ι + ( ι + ! ^ ' · ^ 
Let us again give values that give the same shifts for В and С individually as 
in the first example. The concentration of В giving a shift in the curve for A of 
a factor 100 is again: 
[B] =99 KB 
When A and С are present alone, a concentration of С giving a factor 10 shift 
in the curve of A, is a concentration whereby / д с ' equals 10. 
"When these concentrations of В and С are now present simultaneously, how­
ever, equation 5 applies. The shift in the curve for A produced by the simul­
taneous presence of В and С is now a factor 1000, compared to a factor 109 
for the example whereby В and С both compete with A for occupation of R. 
Since the shift in the concentration-response curves is seen on a logarithmic 
scale, a shift of a factor 109, produced in the first example by combining В and 
С is hardly greater than the shift of a factor 100 produced by В alone. In the 
second example, however, the amount of shift on the logarithmic scale pro­
duced by В and С together (a factor 1000) is a summation of the amounts of 
shift produced by В alone (a factor 100) and by С alone (a factor 10). 
In the second scheme presented it is possible, however, that С does not only 
cause a reduction in affinity between A and R, but also between В and R. When­
ever the affinity between В and R is not decreased by the same amount as the 
affinity between A and R, combination of two drugs В and С acting in these ways 
• Note: By preeenting this equation in thie context the author does not wish to indicate that 
the receptors for 5-HT andíhe ones on which noradrenaline produces a shift of the curve 
of 5-HT are "coupled" in the way for which this equation was first presented (Ariens 4). 
"the function / А С ' т а У ^ 8 0 Ь е o f а пУ nature, not necessarily similar to equation 21 of 
chapter 111. Equation 4, as presented here, is used only to indicate change of Кд caused by 
С in a manner which is not competitive, leaving aside the further nature of this change. 
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will always produce a bigger shift than a combination of two competitive anta-
gonists. 
d. M o r p h i n e 
Morphine is known to possess antagonistic activity towards the action of 5-HT 
on the guinea-pig ileum, apparently blocking the contraction caused by 5-HT on 
the "M" recep tors (Gaddum 6). Probably 5-HT causes contraction via the "M" 
recep tors by a r e l ease of acetylcholine, whereby the recep tors for 5-HT would 
be situated in the ganglia o r postganglionic fibres of the cholinergic pathways 
(Day; Johnson; Brownlee). Bindler and Gyermek have already indicated that 
there may be differences between the 5-HT recep tors in the inferior mesenter ic 
ganglion of the cat and the M recep tors in the guinea-pig ileum; however, m o r -
phine also behaved as an antagonist of 5-HT acting on the former r ecep to r s 
(Bindler). 
On the ra t fundus s t r ip preparat ion, morphine did not exhibit any antagonis-
tic action towards 5-HT, even in concentrations as high as I O - 4 M. On the calf 
t racheal muscle preparation, however, morphine did exhibit antagonism, p r o -
ducing a non-competitive like depression of the dose- response curve . This an-
tagonism is i l lustrated in figure 16. 
Note that morphine suppresses the maximal height of the curve of 5-HT; 
there is a lso some shift but this might be due to receptor r e s e r v e . Compare the 
curves in figure 16b with the theoretical curves for non-competitive anta-
gonism as presented in figure 5 of chapter III. 
contraction calf tracheal muscle % contraction calf tracheal muscle 
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Fig.lóa and b. Registrogram (16a) and cumulative log concentration-response curves (16b) 
for 5-HT in the presence of various concentrations of the antagonistic drug morphine, tested 
on the calf tracheal muscle preparation. 
Note the depression in maximal height of the curves without a clear shift. 
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4. TWO TYPES OF 5-HT RECEPTORS 
As the investigation of the actions of 5-HT and its antagonists progressed, 
it became increasingly clear that the calf tracheal muscle preparation behaved 
somewhat differently than the rat fundus strip towards various 5-HT anta­
gonists. Whereas morphine and atropine do not antagonize the action of 5-HT on 
the fundus strip preparation, antagonism towards 5-HT is produced on the calf 
tracheal muscle by these compounds (see figures 7b and 16). Atropine is a 
well known antagonist of acetylcholine, and it has been reported that morphine 
blocks a liberation of acetylcholine by the cholinergic nerves of the guinea-pig 
intestine (Day 1). 
If the contraction produced by 5-HT on the calf tracheal muscle is due to 
liberation of acetylcholine one would expect a potentiation of the response to 
5-HT by acetylcholine esterase inhibitors. Such a potentiation of the effect of 
5-HT on the guinea-pig ileum, when employing an irreversible acetylcholine 
esterase inhibitor, has been shown (Harry; Johnson). 
We have employed the reversible acetylcholine esterase inhibitor physo-
stigmine (eserine) to determine whether the 5-HT curve on the calf tracheal 
muscle or rat fundus strip is changed in the presence of an acetylcholine es-
terase inhibitor. Physostigmine in concentrations of up to 10-5 M does not cause 
any change in the dose-response curve of 5-HT on the rat fundus strip prepa­
ration, but the dose-response curve of 5-HT on the calf tracheal muscle pre­
paration is shifted to the left in a parallel fashion by physostigmine. The latter 
effect is illustrated in figure 17; a concentration of 10-7 M physostigmine al­
ready causes sensitization of the organ to 5-HT. 
% contraction calf tracheal muscle-
100 η 
M 5-HT 
Fig.17. Cumulative log concentration-response curves for 5-HT in the presence of various 
concentrationeofthe acetylcholine esterase inhibitor physostigmine tested on the calf tracheal 
muscle preparation. 
Note the sensitizing action of physostigmine, indicating that S-HT may act through a release 
of acetylcholine in this preparation. 
To review the differences found between the effects of 5-HT on the fundus 
strip preparation and the calf tracheal muscle in short: morphine and atropine 
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antagonize the response to 5-HT on the calf tracheal muscle but not on the rat 
fundus strip preparation in the same doses, LSD antagonizes the response of 
the rat fundus strip to 5-HT but not the response of the calf tracheal muscle, 
and finally, the effect of 5-HT on the calf tracheal muscle could be potentiated 
by an acetylcholine esterase inhibitor, while this potentiation does not take 
place on the rat fundus strip. 
On the grounds of these findings we conclude that 5-HT acts in different 
ways in the two preparations concerned. It seems as if the 5-HT receptors in 
the tracheal muscle correspond with the "M" receptors for 5-HT as described 
by Gaddum and Picarelli (Gaddum 6) or the "nervous receptors" for 5-HT as 
described by Bindler and Gyermek (Bindler). Morphine and atropine act as 
antagonists towards the effects of 5-HT produced via an action on these r e -
ceptors but not towards effects of 5-HT produced on "D" receptors (muscular 
receptors) (Gaddum 6; Gyermek 2; Day 1). 
A study on both preparations of various agonists and antagonists acting on 
the same receptors as 5-HT, to determine whether the receptors as such in 
the two preparations have distinctly different properties and are not merely 
different in location, is indicated. 
5. SENSITIZING AGENTS 
a. C o c a i n e , I m i p r a m i n e and a d a m a n t a n a m i n e 
It has recently been reported that the nictitating membrane of the cat is 
sensitized towards noradrenaline and 5-HT by treatment with Imipramine, 
desmethylimipramine and some structurally related compounds (Sigg). Other 
experiments done at this institute have shown that these drugs as well as co-
caine cause a shift to the left, viz. a shift towards lower concentrations of the 
log concentration-response curve of noradrenaline (van Rossum 5). A report 
that cocaine and desipramine potentiate noradrenaline on the isolated rat vas 
deferens also appeared recently .(Ursillo). These observations prompted us to 
investigate the effects of Imipramine and cocaine on the dose-response curve 
of 5-HT found on the rat fundus strip. Both these compounds produce a sensiti-
zation of the fundus strip preparation towards 5-HT. The log concentration-
response curve of 5-HT is shifted to the left by low doses of both Imipramine 
and cocaine. Cocaine produced sensitization towards 5-HT in concentrations 
between 10-9 and 3.10-7 M, imipramine in concentrations between 10-8 and 
10-6 M. The shift in the log concentration-response curve of 5-HT obtained 
in the presence of the lower concentrations of cocaine or imipramine increases 
when the concentrations of the latter drugs are increased, until a maximal 
sensitization is reached. When the concentration of the sensitizing drug is 
then further increased, the curve is shifted back until it reaches its original 
position. The amount of shift varies from preparation to preparation, but with 
cocaine shifts of nearly a factor 100 have been obtained, while imipramine 
rarely produces more than a factor 10 sensitization. An example of such a 
sensitization by cocaine is given by the curves presented in figure 18. 
The effect of the antiviral compound adamantanamine on the concentration-
response curve of 5-HT was investigated by us, and this compound also proved 
to have a sensitizing effect on the action of 5-HT on the rat fundus strip. In 
relatively high concentrations - usually higher than 10-5 M - adamantanamine 
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Fig.18. Cumulative log concentration-response curvee for (+) noradrenaline (18a) and 5-HT 
(18b) in the presenceof various concentrations of cocaine, tested on the isolated .rat vas defe-
rens and rat fundus strip preparation respectively. 
Note the sensitizing action of cocaine. (Fig.l8a after van Rossum (van Rossum 5).) 
shifts the log concentration-response curve of 5-HT to the left. In the presence 
of about 10-3 M adamantanamine the maximal shift (usually about a factor 100) 
is obtained. When employing still higher concentrations of adamantanamine, 
the ability of the fundus strip to contract in response to 5-HT is apparently 
lost and this ability cannot be restored by washing out the drugs. Concentra-
tion-response curves for 5-HT in the presence of adamantanamine are pre-
sented in figure 19c and d. 
Adamantanamine causes a sensitization of the rat vas deferens towards nor-
adrenaline as well. This is illustrated in figure 19a and b. 
The means by which cocaine, Imipramine and adamantanamine produce their 
sensitization is not known to us. It may be that an uptake of 5-HT and noradre-
naline by storage sites is inhibited by these drugs, thereby leaving a higher 
concentration of 5-HT and noradrenaline in the vicinity of the receptors, but 
this would not explain why the sensitization by cocaine and Imipramine lessens 
when the concentrations of these compounds in the bath fluid are further in-
creased. 
b . M o n o a m i n e o x i d a s e i n h i b i t o r s 
As mentioned earlier in section 2d. of this chapter, the effect of tryptamine 
on the rat fundus strip is potentiated by MAO inhibitors, while the effect òf 
5-HT is not. The reason for the potentiation of tryptamine and not 5-HT has 
been ascribed to the fact that tryptamine has a much higher lipid solubility 
than 5-HT, and would therefore be able to enter the cells readily, to be broken 
down by MAO. It is presumed that MAO is located intracellularly, and the re -
ceptors on which the contraction is induced are located extracellularly. Inhibi-
tion of MAO and thereby preventing the breakdown of tryptamine would pre-
sumably result in a higher concentration of tryptamine in the vicinity of the 
receptors, and therefore in a potentiation in the action of tryptamine. It was 
also shown that the rat fundus contains an enzyme which oxidizes 5-HT and 
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Fig.l9a and c. Reglstrograms of cumulative doee-responee curves for (+) noradrenaline tested 
on the isolated rat vas deferens (19a) and 5-HT tested on the rat fundus strip preparation 
(19c) In the presence of various concentrations of adamantanamine. 
Fig.l9b and d. Cumulative log concentration-response curves for (19a) and (19c) respectively. 
Note the sensitizing action of adamantanamine. Compare with figure 6b of chapter III. 
tryptamine. It was further shown that the potency of tryptamine is increased 
much more than the potency of N-methyltryptamine, the potency of the latter 
being increased more than the potency of N-ethyltryptamine by treatment of 
the fundus strip with a MAO inhibitor. Before treatment, tryptamine exhibited 
the lowest and N-ethyltryptamine the highest potency of the three compounds, 
which is just the reverse of what would be expected in analogy with the cor­
responding 5-HT derivatives. After treatment with the MAO inhibitor trypt­
amine exhibited the highest potency of the three tryptamine derivatives men­
tioned, and N-ethyltryptamine the lowest (Vane 1). 
Although full curves were not given, results presented by Maxwell e.a. (Max­
well) suggest a parallel shift to the left of the log concentration-response 
curve of tryptamine after the strips had been treated with MAO inhibitors. To 
ascertain whether this is in fact so, we have produced concentration-response-
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Fig.20. Cumulative log concentration-response curves for tryptamine, N-methyltryptamine 
and N-ethyltryptamine in the absence (20a) and in the presence (20b) of the MAO inhibitor 
pargyline, all curves obtained on the same rat fundus strip preparation. 
Note the sensitization for tryptamine and N-methyltryptamine while the curve of N-ethyl-
tryptamine is unchanged. The sensitization indicates that the metabolic break-down by MAO of 
the first two compounds may interfere with the position of their curves above the log con-
centration axis. 
curves with tryptamine in the presence of various concentrations of the re -
versible MAO inhibitor pargyline. A parallel shift to the left indeed resulted 
from these experiments as can be seen in figure 20. A decrease in the amount 
of potentiation with an increase in the size of the substituent on the amino group 
of tryptamine was also found by us (compare figure 20a with figure 20b). 
It was mentioned under section 2d (ii) of this chapter that tryptamine has 
a lower pD2 value (4.71 + 0.14) than a-methyltryptamine (5.38 + 0.21), while 
5-HT has a higher pD2 value (6.82+0.001) than a-methyl-5-hydroxytrypt-
amine (6.45 + 0.18). This discrepancy is also cleared by the fact that the pD2 
value of the MAO inhibiting compound a-methyltryptamine is not changed by 
the presence of pargyline, while the pD2 value of tryptamine changes to 5.26 
+ 0.07 in the presence of 10-5M pargyline. 
6. AN APPROACH TO THE 5-HT RECEPTORS 
In absence of knowledge about the chemical structure of the specific mole-
cular complexes, molecules or parts of molecules with which pharmacologically 
active compounds interact, these sites of interaction have been called "re-
ceptors". The chemical identification of receptors progresses very slowly, 
since receptors can practically only be studied in s i t u . In those cases where 
substances that are thought to be receptors have been destroyed or extracted, 
it will be difficult to prove that these are identical with the pharmacologically 
functional receptors especially since there are no means as yet to establish 
whether the response produced by the drug in living tissue is induced by in-
teraction with the substances destroyed or extracted. 
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Recently Woolley and Gommi have reported that the sensitivity of the isol-
ated rat uterus and rat fundus strip preparation towards 5-HT is diminished 
by incubating the preparations with the enzyme neuraminidase in the presence 
of ethylenediaminetetraacetic acid (EDTA). The response of these prepara-
tions towards other spasmogenic compounds were practically unaltered. By 
incubating the preparations desensitized in this way with gangliosides isolated 
from bovine brain, the sensitivity of the preparations towards 5-HT could be 
restored. The authors suggested that neuraminidase "selectively destroys" 
the receptors of 5-HT and that the 5-HT receptor is probably "one of the gan-
gliosides" (Woolley 13). 
It should be mentioned that the enzyme neuraminidase or sialidase cleaves 
the glycosidic bond joining the potential keto group of an N-acylated neuraminic 
acid (sialic acid) to an adjacent sugar residue (Gottschalk). Gangliosides are 
known to contain sialic acids linked to a side chain comprising a number of 
sugar molecules. 
The results obtained by Woolley and Gommi could to a certain extent be 
confirmed. When incubating a rat fundus strip for consecutive periods of 30 
minutes with 10 ml Tyrode solution containing 0.02 international units sial-
idase (RDE sialidase Behringwerke, Marburg, obtained from Vibrio cholerae) 
and 5 mg EDTA, a suppression of the log concentration-response curve for 
5-HT was observed. Responses of the preparation towards the cholinomimetic 
compound furtrethonium are markedly less affected than responses towards 
5-HT. Restoration of the original log concentration-response curve of 5-HT 
often ensues after a further incubation period of 15 to 30 minutes in the pre-
sence of 3.10-4 M N-acetylneuraminic acid (NANA), N-glycolylneuraminic 
acid (pure) or N-carbobenzoxyneuraminic acid. It appears, therefore, that the 
whole ganglioside is not necessary to bring about restoration of the effect, 
since incubation with only a sialic acid also restores the response of the pre-
paration. It should be remarked that the pD2 value found for 5-HT after res-
toration could not be shown to differ significantly from that calculated from 
the original log concentration-response curve. 
When incubating a preparation with only Tyrode solution for some time (2 
to 3 hours) after it has been desensitized by treatment with sialidase and 
EDTA, spontaneous resensitization towards 5-HT also ensues. Woolley and 
Gommi have also noticed this spontaneous restoration and have ascribed it to 
a "translocation of gangliosides from intracellular structures to the cell mem-
brane, or else to biosynthesis of new gangliosides at the membrane" (Woolley 
13). 
We noticed, however, in some of our preparations that incubation with EDTA 
alone in the above mentioned concentration also reduced the maximal height 
of the 5-HT curve, while this reduction is apparently enhanced by the presence 
of the enzyme sialidase. When incubating the rat fundus strip preparation with 
EDTA alone in higher concentrations (20 mg in 10 ml Tyrode solution) the 
response of the preparation towards 5-HT is strongly diminished, the response 
towards furtrethonium also being affected, but less so than the response to-
wards 5-HT. When incubating a preparation treated in this way with Tyrode so-
lution for some time, the response of the preparation towards 5-HT gradually 
returns to its original level within about 3 hours. The resensitization towards 
5-HT of a preparation treated with EDTA alone is apparently also enhanced 
by incubating for 15 minutes with 3.10-4 M N-carbobenzoxyneuraminic acid. 
These results do not seem to indicate that gangliosides are definitely involved 
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in the loss of sensitivity of the fundus strip preparation when treated in the 
ways mentioned. As it has been shown that calcium apparently plays an im­
portant role in muscle contraction (Podolsky; Weber 1, 2; Martonosi; Finkel; 
Fanburg; Kuriyama) it is quite possible that this type of inactivation of the 
fundus strip is entirely due to binding of the calcium in the systems by EDTA. 
It is possible that the contraction produced by furtrethonium is less affected 
byadecrease in calcium concentration than the contraction produced by 5-HT. 
Whatever the mechanism of this type of desensitization may be, these expe­
riments (including those of Woolley and Gommi) cannot be taken as indications 
for the nature of the 5-HT receptors in the rat fundus strip preparation. As 
mentioned in chapter III, there may be a whole chain of events taking place be­
tween the receptor occupation and the eventual effect. As a matter of fact, non­
competitive antagonists when interacting with their receptors, presumably 
cause an interference somewhere in this chain of events between receptor 
occupation and effect, as was mentioned in section 5 of chapter III. By in­
terfering anywhere in this stimulus-effect chain of 5-HT, a change in the ef­
fect brought about by 5-HT may ensue. When treating an isolated tissue in 
such a way that the effect brought about by 5-HT is subdued, does not neces­
sarily mean that the receptors for this compound have been destroyed, even 
if the effect of 5-HT is subdued and the effect of other spasmogens not. 
It is quite probable that the stimulus-effect chain of 5-HT is quite different 
from the stimulus-effect chains of other spasmogens, and that by interfering 
in this stimulus-effect chain of 5-HT the response brought about by 5-HT is 
"specifically" suppressed without any change occuring to the actual receptors. 
Breaking down a sialoside with an enzyme and then restoring the response 
with either added gangliosides or added sialic acids does not indicate that the 
receptor of 5-HT is a sialoside, unless it can be shown that 5-HT actually 
interacts with that sialoside in s i t u . 
A study on the chemical nature of receptors could perhaps best be done by 
making use of the principles of receptor protection. If an isolated tissue pre­
paration known to contain the receptors to be studied is incubated with an ir­
reversible receptor blocking agent in the presence of a receptor protecting 
agent (agonist or competitive antagonist) of the receptors in question, one has, 
after washing out the drugs, a preparation in which the desired receptors are 
largely intact while other binding sites of the receptor blocking agent are ir­
reversibly blocked. When incubating a tissue preparation treated in this way with 
a radioactively labelled receptor blocking agent, this latter compound would 
react irreversibly with those sites protected during the previous incubation, 
other sites of irreversible binding being blocked by the treatment with the un-
labelled receptor blocking agent. The excess labelled blocking agent could 
be removed by washing. It may then be possible to isolate and identify the 
sites with which the labelled drug has interacted, although it should be kept in 
mind that these sites may be not only the actual receptors, but also other bind­
ing sites like the "silent receptors". 
By applying the technique described above, Dikstein and Sulman (Dikstein 1) 
have found indications that adrenaline (acting as the receptor protecting com­
pound) prevents the interaction of the irreversible receptor blocking agent di-
benamine with the cephalin fraction of the rabbit aorta. They suggested that 
the α-receptors for adrenaline maybe proteophospholipids, further substanti­
ating their evidence by showing that the contraction exhibited by the isolated 
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rabbit uterus in the presence of noradrenaline is nullified by pretreating this 
organ with a 25% acetone solution, the preparation responding again to nor-
adrenaline after incubation with phosphatidylethanolamine or phosphatidyl-
serine (Dikstein 2). 
Q4 
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CHAPTER V 
SEROTONIN AND BEHAVIOUR 
Since serotonin (5-hydroxytryptamine; 5-HT) is present in relatively high 
concentrations in the brains of various animal species, and since it is probably 
synthesized in the brains of some species, it is highly probable that 5-HT has 
some or other function in the brain. As was mentioned in chapter II, there are 
indeed various indications that 5-HT plays a role in the central nervous system. 
A number of drugs which are structurally related to 5-HT manifest clear 
effects on the central nervous system. The most extreme example in this 
respect is perhaps the hallucinogenic effects produced in man by the indole 
nucleus containing compound lysergic acid diethylamide (LSD). Other com-
pounds structurally related to 5-HT which have been reported to exhibit psy-
chic effects are for example bufotenine(Evarts),psilocybine(Hollister^ Isbell), 
a-methyltryptamine (Murphree), ^N.N-dimethyltryptamine (Sai-Halasz) and 
N.N-diethyltryptamine (Böszörmenyi). 
Psychic effects can perhaps best be studied in human subjects since it is 
difficult to interpret these effects in animals. However, drug-induced changes 
in the behavioural patterns of animals are often used to study effects of drugs 
on the central nervous system; these tests may be particularly useful for 
screening compounds for an effect and for routine measurements after the 
effect has been established. Since the aim of the investigation described in 
this chapter was to establish whether some 5-HT antagonists found exhibited 
central effects, studies with these compounds on the behaviour of animals were 
indicated. 
Before discussing the central effects caused by 5-HT, it should be remarked 
that this amine, when given peripherally to animals, does not, or hardly, pass 
the blood brain barrier. The precursor amino acid of 5-HT, 5-hydroxytrypto-
phan (5-HTP) passes the blood brain barrier much more readily (Udenfriend 
1; Southern). The precursor 5-HTP is decarboxylated to 5-HT in the brain 
(Udenfriend 2,3). This situation has its analogy amongst the catecholamines; 
noradrenaline and dopamine also do not pass the blood brain barrier readily, 
but their precursor 3,4-dihydroxyphenylalanine (DOPA) does, and is decarbo-
xylated to dopamine in the brain, some dopamine in turn being hydroxylated to 
noradrenaline (Carlsson 1; Blaschko). 
Returning to the effects of 5-HT (administered peripherally as 5-HTP) on 
animal behaviour, it should be remarked that what is known seems to indicate 
towards a suppressive type of action. It has been reported that 5-HT causes 
sedation in various species of animals (Bogdanski; Monnier; Lewis 2; Costa 2) 
that it potentiates barbiturate narcosis (Holtz), that it antagonizes an increase 
in locomotor activity in mice and rats caused by treatment with cocaine or 
amphetamine (Brown; Matussek), etc. (By locomotor activity is here meant 
the tendency ofthe animals to exhibit movement, like walking or running about, 
without being forced to do so by their environment.) The only reproducible 
effect of 5-HTP in mice would be the "abolishment of intraspecific aggressive 
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behaviour" (Erspamer 3,1). (By intraspecific aggressive behaviour is meant 
aggressive behaviour between two animals of the same species.) It was also 
noticed that mice, treated from birth with a diet rich in phenylalanine and 
tyrosine (to induce phenylketonuria), have a 5-HT deficiency in their brains, 
and i n t e r a l i a , behave aggressively (Woolley 3). Aggressive behaviour was, 
however, not noticed in rats which were fed on a tryptophan-free diet, al­
though their brain 5-HT levels were lowered by 80%. One third of the rats 
treated in this way showed specific behavioural changes like backward cir­
cling, tremor, convulsions, etc. (Boullin). On the other hand Heller e.a. men­
tioned that destruction of the dorsomedial midbrain tegmentum of rats by 
electrocoagulation, causes a decrease in brain 5-HT levels. Rats treated in 
this way exhibit intraspecific aggressivity (Heller). 
It was noticed at this laboratory that mice treated with reserpine become 
irritable after giving DOPA (van RossumS). It is known that reserpine depletes 
both catecholamines (Holzbauer; Burn) and 5-HT (Brodie; Pletscher 3,5) from 
their respective stores in the central nervous system. By treatment with the 
catecholamine precursor DOPA, the catecholamine stores are replenished 
(Carlsson 1, 2; van Rossum 9, 10) but the 5-HT stores are, of course, still 
depleted. Everett and Wiegand also mentioned that reserpinized mice behave 
aggressively after treatment with DOPA, although they mentioned that the ag­
gressive behaviour is possibly caused by DOPA itself (Everett 2). However, 
treatment of unreserpinized mice with DOPA does not produce aggressive 
behaviour. 
Another indication that a shortage of 5-HT may have something to do with 
aggressive behaviour is the finding that an injection of 0.8 mg of the 5-HT an­
tagonist LSD into the lateral ventricle of the brain of a cat produces rage in 
this animal. When 5-HT is given by the same route, a taming effect is ob­
served. A subcutaneous injection of 3 mg LSD also produced rage in a cat 
(Gaddum 9). It has also been reported that LSD causes a short-lasting "rage 
reaction" in the Siamese fighting fish ( B e t t a s p l e n d e n s Regan) although 
the main action of LSD in this case seems to be a narcotic one (Evans, Abra-
hamson). 
An investigation of the effects of 5-HT on the aggressive behaviour of ani­
mals seemed to offer the most attractive possibilities in the line of behavioural 
studies with this amine. Hereby we preferred not to work with the Siamese 
fighting fish, but rather with some mammalian species. Thinking in this di­
rection, the choice eventually fell on the Chinese hamster ( C r i c e t u l u s 
b a r a b e n s i s g r i s e u s , Milne-Edwards) as the experimental animal offering 
the best possibilities. The adult female Chinese hamster behaves very aggres­
sively towards the male except during the period that she is in oestrus. When 
put together in an animal cage, the female attacks and in most cases eventually 
kills the male. The female animals have an oestrus cycle of 4 to 5 days dura­
tion. The oestrus always takes place two to three hours after nightfall and 
lasts for but a few hours (van Gaaien). 
We established that an intraperitoneal injection of 100 to 200 μmol/kg 5-HTP 
practically abolishes the aggressive behaviour of the female Chinese hamster 
towards the male. 
An apparatus was built wherewith changes in the intraspecific aggressive 
behaviour of the Chinese hamster as well as effects on spontaneous locomotor 
activity of this animal could be studied simultaneously. 
98 
1. APPARATUS FOR MEASUREMENT OF AGGRESSIVE BEHAVIOUR AND 
LOCOMOTOR ACTIVITY 
a. T h e a c t i v i t y c a g e 
Many devices to measure locomotor activity of animals have been described. 
The most suitable device for our purposes was considered to be the type of 
activity cage whereby interruptions of light beams, focussed through the cage 
on photo-electric cells, are counted. This method of measuring locomotor 
activity, first described by Winter and Flataker (Winter) and used often since, 
has been adapted at this laboratory to realize cumulative registration of the 
interruptions of the light beams by the animals, whereby the progress in lo­
comotor activity in time is not lost (van Rossum 9). 
It seemed desirable to build an animal cage for aggressivity measurements 
in which the male and female would be separated in such a way that they would 
not be damaged when trying to fight, in order to enable measurements over 
longer periods and the repeated use of the same animals. On the other hand 
the separation should not cause a too large suppression of the impulse to fight; 
this was the objection against using glass or very fine mesh-wire as separa­
tion. The solution proved to be a separation consisting of a grid of parallel 
vertical metal bars. 
It also proved to produce longer attacking periods if the cage segment of 
the male was made rather small in order to keep the male as near the grid 
as possible. 
It was mentioned that the intention was to study effects on locomotor ac­
tivity and aggressiveness simultaneously, whereby it is not meant that these 
would be two completely separable effects, as of course, some locomotor ac­
tivity must be exhibited to expect any aggressive response. 
A metal box was built, measuring 32 cm long, 18 cm wide and 12 cm deep 
and covered by a mesh-wire lid. This cage was divided into two compart­
ments by a frame bearing vertically placed metal bars of 1 mm diameter 
spaced 1 cm apart, the upper half of which was covered by a thin metal plate. 
This grid was vertically suspended from a flat spring at 6 cm from one end of 
the cage. 
The swing of the grid is restricted by two screws affixed to the cage bottom 
allowing 1 mm movement. The spring presses the grid against the screw on 
the side of the larger compartment. The spring provides just that amount of 
pressure on the grid whereby no signal is registered when the animals only 
gnaw on the bars, but pushing or jumping against the grid, as is done by the 
aggressive female hamster, is registered. The same considerations were kept 
in mind when 1 mm movement of the grid was chosen. The other screw serves 
as an electrical contact. When the grid is pressed against the latter screw, 
this contact, called "separation contact" in the further text, is closed. The 
contact was included in a circuit connected with the "operate" button of a pulse 
shaper. 
Two parallel light beams, focussed on two cadmium sulphide photo-electric 
cells (Philips LDR cadmium sulphide resistance type В 873103) over the width 
of the cage are situated in the larger compartment, 10 and 16 cm respectively 
away from the grid. Each photo-electric qell is included in a circuit which is 
connected with the input (operate button) of a pulse shaper. 
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b. T h e p u l s e s h a p e r s 
The transistorized pulse shapers used are essentially the same as those 
described by van Rossum e.a. (van Rossum 9). They convert resistance in­
creases of more than 40 КЛ. in the connected circuits into square pulses of 
80 millisec. duration (see figure 1). Such a change takes place every time 
when a separation contact is reopened after a closure (when the change is 
from 10 KLnto 110 K n ).The cadmium sulphide photo-electric cell has a re­
sistance of 10 K n while light falls on it, changing to more than 50 K/lwhen 
the light beam is interrupted. Such an interruption therefore also results in 
a pulse. 
Fig.l. Diagram of a transistorized pulse shaper which is used for the conversion of inter­
ruptions of a light beam or closures of a "separation contact" into square pulses of 80 mil­
lisec. duration (After van Rossum 9). 
The relais of the pulse shapers (Siemens relais Tris 154d/97d Τ Bv 65421) 
are kept in operation and are released over a period of 80 millisec. by every 
pulse. 
c. T h e r e c o r d e r s 
The counting mechanisms were specially designed to enable cumulative re­
gistrations of more than one phenomenon simultaneously on one record. A 
schematic representation of such a recorder is given in figure 2. Each re­
corder consists of an aluminium drum (1), 50 mm in diameter, having a spiral 
groove (2) of 5 mm wide and 3 mm deep on its outer surface, leading once 
arotmdthe drum from bottom to top. The top and bottom of the groove is con­
nected by a vertical groove (3) of the same depth and 7 mm wide. The height 
of the spiral is 50 mm. A metal block (4), sliding on two vertically placed 
metal bars (5) is moved upwards through a short projection of the block (6) 
sliding in the spiral groove, when the drum is rotated anti-clockwise. The 
block falls back through the vertical groove when the highest point of the spiral 
is reached. A horizontally swinging arm (7) with a pen (8) is attached to the 
block. A cog with 50 teeth (9) is affixed to the axle of the drum. A spring (10) 
operated by an electromagnet (Philips NF 28665-1-194-4500-0.17 Cu Em) (11), 
moves the cog one tooth forward every time when the electromagnet is powered. 
Since the spiral is 50 mm high, the pen makes 50 upward excursions of 1 mm 
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ι— Fig.2. Diagram showing the construction of a recorder used for regi -
t— stration of behavioural phenomena of animals. See text for description. 
before falling back to its lowest position, then starting on a new series of up-
ward excursions. In this way a continuous record is obtained. The pen can be 
brought to a zero position by turning the knob (12). 
Theelectromagnetoperatesona25V, 5 Amp. current delivered by a stabiliz-
ed power supply (Delta Electronics, Zierikzee, Netherlands. Type TPS 24-5). 
The relais of each pulse shaper operates a contact closing the circuit of a 
counting apparatus. One recorder is used to register the closures of the se-
paration contact, and is therefore operated by the pulse shaper for this con-
tact, while another recorder registering interruptions of the light beams, is 
operated by both pulse shapers connected to the photo-electric cells. 
The recorders have rather compact outer dimensions, enabling the mount-
ing of two or more on one kymograph. For the experiments described in the 
following text, the recorder registering pushes on the grid is mounted directly 
above the one registering the spontaneous locomotor activity, on a kymo-
graph (Jaquet 1108). 
The pens are kept on the paper by light springs. The paper is moved at a 
speed of 2 mm/min. The number of pulses per unit of time registered by the 
recorder can be estimated from the slope of the curve registered. 
In the following experiments two of the activity cages described above were 
connected with one "recording unit", consisting of two recorders mounted on 
one kymograph. One recorder therefore registers closures of the separation 
contacts of both cages, while the other recorder registers the interruptions of 
light beams in both cages. This was done to obtain, in fact, the average re -
sponses of two animals on one record. Some experiments were also performed 
whereby each cage had its own individual "recording unit". In the latter case 
the paper was moved at a speed of 1 mm/min. 
Note: A recorder with some broader applicabilities than the one described 
above was also built during the course of this investigation. In essence this 
second recorder includes also the possibility of registering a number of pulses 
produced during a set period of time, whereafter the pen falls back to the zero 
position and a new period of registration is begun. This was achieved by in-
troducing a second electromagnet (also Philips NF 28665-1-194-4500-0.17 
Cu Em) into the apparatus. This second electromagnet then, when empowered, 
releases the spring (10) and the other catch spring, whereby the weight of the 
block (4) and pen arm (7) causes the pen to fall back to zero while the drum is 
rotated clockwise by the projection of the block (6). Since the Jaquet 1108 ky-
mograph contains the possibility of closing an electrical contact after pre-
selected constant periods of time, use can be made of this system to produce 
the pulse enabling the recorder to fall back to zero. 
Another refinement in the second recorder was achieved by making use of 
two micro-switches, the one operated by the block when it reaches the zero 
position, switchingoff the current for the second electromagnet, and the other 
operated by the block when the latter reaches its maximal position, switching 
on the current to empower the second electromagnet and thereby causing the 
pen to fall back to the zero position. Because of the use of these two micro-
switches the vertical, groove (3) could be dispensed with, making it possible 
also to use a drum of still smaller diameter. It should be remarked that the 
projection of the block (6) in this latter apparatus was fitted with a ball race 
to minimize friction. 
To summarize, the first recorder described here enables one to obtain a 
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Fig.3a and b. Cumulative records of aggressive behaviour (3a) and locomotor activity (3b) 
of two female Chinese hamsters on 5 consecutive days. The consecutive records are marked 
1 to 5. The aggressive behaviour of both animals was registered by one recorder in each ex-
periment, while at the same time the locomotor activity of both animals was registered by 
a second recorder. 
Note that there is a decrease m both activities on consecutive days. 
cumulative record of a number of pulses per unit of time, the recorder etarting 
again at zero for each full set of 50 pulses obtained. Estimation of pulses per 
unit of time is found from the slope of the recorded curves. The second r e -
corder includes this same possibility of registration, but furthermore includes 
the possibility of registering the number of pulses obtained within consecutive 
equal periods of time. The description of the second recorder is presented 
merely as information. In the results presented further on in this chapter it 
is irrelevant which of the two types of recorder was used. 
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2. METHODS 
A mature male Chinese hamster is placed in the smaller compartment of the 
cage and a female one of at least six months old and not in oestrus, in the larger 
one. (Older females are usually more aggressive than younger ones). The ag­
gressive behaviour of the female consists of attempts at attacking the male, re­
sulting in pushes against the grid. These pushes or jumps are registered. The 
locomotor activity of the female animal results in interruptions of the light 
beams, which are registered by a second recorder. Measurements are made for 
periods of three hours. Control registrations are obtained by using untreated 
females, since it was ascertained that no significant differences could be found 
after injecting physiological saline solution. The female animals are not used 
within one week after a previous experiment, this period being longer when 
long-acting drugs are used. Drugs are dissolved m physiological saline solu­
tion unless stated otherwise, in such a concentration that the dose per gram 
bodyweight is contained in 0.01 ml. All drugs are injected intrapentoneally. 
It was found that the aggressivity, as measured by the number of pulses re­
sulting from pushes against the grid, varies much from animal to animal. 
Some animals produce counts as high as 1000 in three hours while others do 
not even produce 50. It might be advisable to select animals beforehand in 
order to use only those giving control values within certain limits, but this 
was not done in this investigation since this study was of a preliminary nature. 
It was decided in the beginning not to preselect animals on the basis of con­
trol experiments, but to use them at random, provided that they exhibit at least 
some aggressivity towards the male as can be seen when putting male and 
female together. 
To reduce extreme variations in results to some extent, pushes against the 
grids and interruptions of the light beams of two cages were registered si­
multaneously on one recording unit in later experiments. 
The control values for the same animals, as measured from time to time, 
also exhibited some variation, but less than the variation found between ani­
mals. It was noticed that when controls were determined frequently (every 
day) there was a tendency towards the aggressive activity becoming lower for 
each consecutive measurement. Longer intervals between experiments (at least 
1 week) were therefore used. The tendency towards a decrease in aggressive 
behaviour in control experiments done with the same animals on consecutive 
days is shown in figure 3a. Longer intervals were employed between the con­
trols presented in figure 4. As can be seen in figure 4a, the aggressive beha­
viour is influenced less when longer intervals between experiments are em­
ployed. 
Fig.4a and b. Cumulative records of aggressive behaviour (4a) and locomotor activity (4b) ot 
two female Chinese hamsters with intervals of 14 days between each determination. The con­
secutive records are marked 1, 2 and 3. The aggressive behaviour of both animals was r e ­
gistered by one recorder in each experiment, while at the same time the locomotor activity 
of both animals was registered by a second recorder. 
Note that there is no clear decrease in aggressive activity for consecutive controls with this 
interval between experiments. Compare fig.4a with fig.3a. 
Note that there appears to be a decrease in locomotor activity for consecutive controls as 
can be seen m fig. 4b. 
(These animals received 4μ mol/kg LSD one week after the first control and 60μ mol/kg О 18 
one week after the second control, for other experiments not presented here.) 
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The variation in measurements of locomotor activity between animals and 
between control experiments for the same animals is usually far less than the 
variation in measurements of aggressive activity, although also the locomotor 
activity decreases with consecutive control experiments, as can be seen in 
figure 3b and figure 4b. 
3. EFFECT OF DRUGS ON THE AGGRESSIVE BEHAVIOUR AND SPONTA­
NEOUS LOCOMOTOR ACTIVITY OF THE FEMALE CHINESE HAMSTER 
It was mentioned that some indications were found in the literature that too 
low a level of 5-HT in the central nervous system may result in aggressive 
behaviour in some laboratory animals, while injecting 5-HTP peripherally, 
thus causing an increase in 5-HT in the central nervous system, depresses 
intraspecific aggressive behaviour. The latter was confirmed by us by ob­
serving the aggressive behaviour of female Chinese hamsters after intra­
peritoneal injection of 5-HTP. 
a. I n f l u e n c e of an i n c r e a s e of s e r o t o n i n in t h e c e n t r a l n e r v ­
o u s s y s t e m 
Single intraperitoneal injections of 50 to 200 μ mol/kg 5-HTP regularly 
causes a decrease in aggressive behaviour as well as a decrease in spontane­
ous locomotor activity of the female Chinese hamster as measured by the ap­
paratus described before. This is illustrated in figure 5a and b. A dose of 100 
μ mol/kg 5-HTP reduces both measurements to below any control values found 
for each animal or pair of animals in more than 80% of the cases studied. (In 
using the same apparatus, registering only the spontaneous locomotor activity, 
it was determined that 200 μ mol/kg 5-HTP suppresses the increase in loco­
motor activity caused by 10 μ mol/kg amphetamine in mice. The latter con­
firms results recently reported by Matussek, using rats in his experiments 
(Matussek).) 
The decrease in aggressive behaviour of the female Chinese hamster caused 
by injecting 5-HTP could be strongly potentiated by pretreating the animals 
with a MAO inhibitor (500 μ mol/kg pargyline i.p. 2 hours before, or 100 μ 
mol/kg iproniazid 6 hours before injecting 5-HTP and startingthe experiment). 
These MAO inhibitors also caused depression of the aggressive behaviour 
without combination with 5-HTP. 
It is possible that a general suppressive effect on the phenomena discussed 
is produced by 5-HTP. Furthermore one cannot be sure to what extent the in­
crease in peripheral 5-HT, caused by injection of 5-HTP, interferes with the 
results. It was therefore decided to approach the matter from another angle, 
Fig.5a and b. Cumulative records of aggressive behaviour (5a) and locomotor activity (5b) L 
of two female Chinese hamsters given 100μ mol/kg 5 HTP intraperitoneally immediately ' 
before startingthe measurements (record 2), compared to control determinations of the same 
phenomena on the same animals one week before (record 1) and one week after (record 3) 
the 5-HTP treatment. The aggressive behaviour of both animals was registered by one re­
corder in each experiment, while at the same time the locomotor activity of both animals 
was registered by a second recorder. 
Note that 5-HTP causes a marked decrease in aggressive behaviour, compared to the con­
trol determinations, and also a decrease in locomotor activity of these animals. Compare 
record 2 with record 1 and 3 in both figures. 
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namely to investigate the influences of 5-HT depletion or an antagonism against 
5-HT on the aggressive behaviour and spontaneous locomotor activity. 
b. I n f l u e n c e of d e p l e t i o n of s e r o t o n i n in t h e c e n t r a l n e r v o u s 
s y s t e m 
If a low level of 5-HT in the brain would be responsible for an increase in 
aggressivity, it seemed reasonable to expect that perhaps a selective deple-
tion of 5-HT might lead to an increase in aggressive behaviour. A selective 
depletion of 5-HT in the brain only, with the aid of drugs, is perhaps not within 
reach, but as some compounds are known to cause i n t e r a l i a depletion of 
brain 5-HT, the matter could be persued to some extent. 
It has been demonstrated that reserpine is capable of causing a nearly com-
plete depletion of 5-HT in brain tissue (Brodie; Fleischer 3, 5; Shore 1). This 
drug, however, also causes a depletion of catecholamines in the central nervous 
system (Bum; Holzbauer). It is thought probable that the latter action of r e -
serpine is responsible for its sedative effect (Kärki 2; Pletscher 7). 
In an attempt to produce depletion of 5-HT in the central nervous system 
of female Chinese hamsters, these animals were given various small doses 
of reserpine twice daily, by intraperitoneal injection. It was assumed that se-
dation could be an indication that brain catecholamines and 5-HT were deplet-
ed. Most of the animals exhibiting sedation, however, died within a few days, 
even if the reserpine treatment was stopped. (The reserpine was dissolved in 
a minimal quantity of glacial acetic acid - about 1 drop per 5 mg - with the 
aid of gentle heat, and diluted further with a normal saline solution.) The se-
dation could not be abolished by treatment with the catecholamine precursor 
DOPA; the general condition of the animals appeared to be affected by treat-
ment with reserpine. Employing lower doses of reserpine whereby sedation 
is not seen, no change in aggressive behaviour or locomotor activity could be 
detected. 
The compound (+)-4-chloro-N-methylamphetamine(Ro 4-6861) has recently 
been reported to cause a decrease of 5-HT in the rat brain without affecting 
the level of catecholamines (Pletscher 6; Lippmann). Female Chinese hamsters 
pretreated with up to 30 μ mol/kg of this compound twice daily for three days, 
exhibited a decrease in both aggressivity and spontaneous locomotor activity. 
Too little is known about other effects of this compound to comment on this 
result. 
c. I n f l u e n c e of s e r o t o n i n a n t a g o n i s t s 
"Some drugs described as antagonists of 5-HT, like LSD and psilocybine, are 
Fig.óa and b. Cumulative records of aggressive behaviour (6a) and locomotor activity (6b) of 
two female Chinese hamsters given 4 μ mol/kg LSD intraperitoneally immediately before 
starting the measurements (records 1 and 3) compared to control determinations of the same 
phenomena on the same animals one week after the first experiment with LSD (record 2) and 
one week after the second experiment with LSD (record 4). The aggressive behaviour of both ani­
mals was registered by one recorder in each experiment, while at the same time the loco­
motor activity of both animals was registered by a second recorder. 
Note that LSD causes an increase in aggressive behaviour compared to the control deter­
minations, as well as an increase in locomotor activity of these animals. These effects pro­
duced by LSD are opposite to the effects produced by 5-HTP. Compare figure 6a and b with 
figure 5a and b. 
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known to be centrally active compounds. It seemed to be of interest to study 
the effects of these compounds on the aggressive activity and locomotor ac­
tivity. 
The 5-HT antagonist LSD produced an increase in locomotor activity when 
given in doses of 2 or 4 μ mol/kg in 20 out of 30 experiments. An increase in 
locomotor activity caused by LSD in test animals has been reported before 
(Koella). 
In 50% of our experiments LSD in the above mentioned doses also caused a 
marked increase in aggressive behaviour. The increase in aggressive behaviour 
and locomotor activity caused by LSD is shown in figure 6a and b. In some ex­
periments where there was no increase in aggressive behaviour after LSD 
treatment the animale walked backwards and sometimes exhibited tremor and 
convulsions. It is possible that the dose whereby an increase in aggressive 
behaviour is produced is rather critical for each individual animal. It is also 
possible that this effect of LSD is dependent on the age of the animals, since 
in our experiments LSD rarely caused an increase in aggressivity in animals 
older than 12 months.· This, perhaps, warrants a further investigation. The 
compound methysergide (UML; Deseril) structurally closely related to LSD, 
did not produce a clear change in aggressive behaviour in our experiments. 
This compound was used in doses of 2 or 4 μ mol/kg, and in these doses it 
caused an increase in locomotor activity in practically all cases. As pointed 
out in chapter II, UML, although being a more "potent" antagonist of 5-HT on 
isolated organs, does not cause hallucinogenic effects in man like LSD. 
Another substance known as an antagonist of 5-HT (Wiedman, Robson 2) and 
known to cause psychic symptoms in man reminiscent of those produced by 
LSD (Isbell), is the indole alkaloid psilocybine. In our experiments, however, 
psilocybine exhibited no effect in doses between 20 and 40 μ mol/kg, and when 
employed in larger doses it caused a decrease in both aggressive activity as 
well as in locomotor activity. This could be due to other effects of the drug 
when used in large doses. 
The compounds О 12 and О 18, shown in the previous chapter to be competi­
tive antagonists of 5-HT both on the rat fundus strip preparation as well as on 
the calf tracheal muscle preparation, were also tested to determine effects on 
intraspecific aggressive behaviour and locomotor activity of the female Chine­
se hamster. The compound О 12 caused an increase in aggressive behaviour 
when used in a dose of 20 μ mol/kg in three out of five experiments, as well 
as an increase in spontaneous locomotor activity. In figure 7a and b the in­
crease of aggressive behaviour and locomotor activity produced by the com­
pound О 12 is illustrated. A dose of 40 μ mol/kg of О 12 usually produces 
tremor and a tendency to walk backwards in the animals. 
Enough experiments to give an indication of the effects produced by the com­
pound О 18 have not yet been done at the time of writing. 
Experiments on the lines indicated here are to be continued. 
d. I n f l u e n c e of s o m e o t h e r c e n t r a l s t i m u l a t i n g d r u g s 
Although a representative group of other central stimulating compounds 
which produce their actions in various ways have not yet been tested, re­
sults obtained with a few of these compounds will be mentioned here. 
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Fig. 7a and b. Cumulative records of aggressive behaviour (7a) and locomotor activity (7b) 
of two female Chinese hamsters given 20μ mol/kg О 12 intraperitoneally immediately before 
starting the measurements (record 2) compared to control determinations of the same phe­
nomena on the same animals one week before (record 1) and one week after (record 3) the 
experiment with О 12. The aggressive behaviour of both animals was registered by one r e ­
corder in each experiment, while at the same time the locomotor activity of both animals 
was registered by a second recorder. 
Note that the compound О 12 causes an increase in aggressive behaviour compared to the 
control determinations as well as an increase in locomotor activity of these animals. These 
effects produced by О 12 are opposite to the effects produced by 5-HTP (compare figure 7a 
and b with figure 5a and b) but similar to the effects produced by LSD (compare figure 7a and 
b with figure 6a and b). 
(i) Monoamine oxidase inhibitors 
Of this group of compounds ipromazid (in a dose of 100 μ mol/kg given 6 
hours before putting the animals into the activity cage) caused a decrease in 
aggressive behaviour, without a clear change in the locomotor activity. Par-
gyline (in a dose of 500 μ mol/kg given 2 hours before putting the animals into 
the activity cage) caused, qualitatively, the same effect. 
(n) Amphetamine 
This compound, m doses between 5 and 15 μ mol/kg produced no measurable 
change in the locomotor activity. Doses of 15 μ mol/kg caused a depression in 
aggressive behaviour m five out of six experiments. 
The inability to produce an increase in locomotor activity with amphetamine 
in the Chinese hamster, is in contrast with results obtained when amphetamine 
111 
is given to mice. For the latter animals it has been shown that amphetamine 
causes an increase in locomotor activity by probably acting directly on the 
catecholamine receptors in the brain (van der Schoot). 
4. REMARKS 
The aim of this chapter is mainly to introduce a new technique for measuring 
aggressive behaviour in small laboratory animals like the Chinese hamster. 
The results obtained with the various drugs should not be taken as being com-
plete or final, but merely as indications that some drugs might influence not 
only the spontaneous locomotor activity, which is usually measured in loco-
motor activity studies, but also a more directed type of activity like, pos-
sibly, intraspecific aggressive behaviour. It is possible that 5-HT may play 
some role in the central nervous system connected with the intraspecific ag-
gressive behaviour in the Chinese hamster, but enough evidence to make such 
a claim is still lacking. 
112 
CHAPTER VI 
CHEMICAL SYNTHESIS OF SOME TRYPTAMINE 
AND 5-HYDROXYTRYPTAMINE ANALOGUES 
A number of investigators have recently synthesized and tested series of 
tryptamine and 5-hydroxytryptamine (5-HT) derivatives (Barlow 1; Brimble-
combe; Gyermek4; Chapman). The method of synthesis best suited for obtain­
ing N-alkyl and N-aralkyl tryptamines, is apparently the one described by 
Speeter and Anthony (Speeter). This method is based on the interaction of 
indoles with oxalyl chloride, conversion of the resulting 3-indole-glyoxalyl 
chloride to the appropriate amide and then reduction with lithium aluminium 
hydride to the corresponding tryptamine (see figure 1). 
H 
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Fig.l. Scheme for the syntheeie of N-monosubstituted or N.N-disubetituted tryptamine de­
rivatives. 
1. SYNTHESIS OF AMINO-MONOSUBSTITUTED AND AMINO-DISUBSTITUTED 
TRYPTAMINES 
The general method of preparation of compounds of these groups is given by 
the following prescriptions. 
a. S y n t h e s i s of t h e 3 - i n d o l e - g l y o x a l a m i d e s 
In a 500 ml round bottomed matrass of a Rotavap distilling apparatus, 0.01 
moles indole was dissolved in 20 ml ether and the solution was cooled to 0° C. 
To this was added 0.015 moles oxalyl chloride, dissolved in 20 ml ether, 
previously cooled to 0° C. A yellow crystalline precipitate of 3-indole-glyox-
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alyl chloride forms immediately. The ether was slowly distilled off at 36°C 
and 760 mm Hg with the aid of the Rotavap apparatus, and the residue was dried 
at 500C and 20 mm Hg. The yellow crystalline residue was dissolved in 50 
ml of a mixture of ether and tetrahydrofurane 1 : 1 , and 0.024 moles of the 
appropriate amine, dissolved in 50 ml of the ether and tetrahydrofurane 
mixture, was slowly added. The matrass was affixed to a reflux condenser, 
and the mixture was refluxed for 2^-hours on a water-bath. 
After refluxing, the flask was again affixed to the Rotavap apparatus and 
the ether-tetrahydrofurane mixture was distilled off. The residue was dis­
solved in 10 ml ethyl alcohol, 200 ml distilled water was added, followed by 
20 ml 1 N hydrochloric acid. This latter mixture was extracted thrice with 
ether and the combined ether layers were washed twice with a 1% sodium bi­
carbonate solution. The ether extract was dried, first for 8 hours with ex­
siccated calcium sulphate, followed by 8 hours drying with calcium hydride. 
After filtering the extract the ether was distilled off, leaving the light yellow 
3-indole-glyoxalamide. 
b. R e d u c t i o n of t h e 3- i n d o l e - g l y o x a l a m i d e s 
A desired 3-indole-glyoxalamide prepared by the method described above 
(the total quantity obtained) was dissolved in 50 ml tetrahydrofurane. This so­
lution was added dropwise to a suspension of 0.1 moles lithium aluminium 
hydride in 100 ml tetrahydrofurane, already refluxing on an oil bath at 7(PC. 
This mixture was refluxed at 70° С for 72 hours. After refluxing, the excess 
lithium aluminium hydride was bound by adding dropwise a small excess of 
ethyl acetate, followed by dropwise addition of distilled water to destroy the 
lithium aluminium hydride. To this suspension 500 ml ethyl alcohol was added 
and the aluminium hydroxide was filtered off in a Büchner funnel. The pre-
cipitate of aluminium hydroxide was washed twice, each time with 250 ml 
ethyl alcohol. The filtrates were added together and the liquid was distilled 
off to leave a dry residue, which was dissolved in 100 ml ether and dried with 
calcium hydride. After removing the calcium hydride by filtration, the trypt-
amine derivative was precipitated, either as the oxalate by addition of a solu-
tion of oxalic acid in ether, or as the hydrochloride by addition of a water-free 
solution of hydrogen chloride in ether or, as creatinine sulphate by addition of 
a solution of creatinine sulphate in ether. The oxalate, hydrochloride or creati-
nine sulphate salt of the tryptamine derivative was purified by recrystalliza-
tion from ethyl alcohol. 
The compounds 0 7 ,08 and О 9 were synthesized according to the procedure 
described above (see table I). 
(Note: the ether and tetrahydrofurane used in the above syntheses were pre­
viously made absolutely water-free and peroxide-free by consecutive reflux­
ing with ferrous sulphate, calcium hydride and sodium for three hours. The 
liquids were used directly afterwards. The ethyl alcohol used was of a chemi­
cally pure grade.) 
2. SYNTHESIS OF AMINO-MONOSUBSTITUTED AND AMINO-DISUBSTI-
TUTED 5-BENZYLOXYTRYPTAMINES 
The same procedure as described under la and b above was followed, ex-
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cept that 5-benzyloxyindole was used instead of indole. The compounds O i l , 
О 13,0 15,0 17 and О 19 were synthesized according to this method (see table 
I). 
3. SYNTHESIS OF AMINO-MONOSUBSTITUTED AND AMINO-DISUBSTI-
TUTED 5-HYDROXYTRYPTAMINES 
These compounds were synthesized by debenzylation of amino-substituted 
5-benzyloxytryptamines. The following procedure was adopted. 
The free base of the desired amino-substituted 5-benzyloxytryptamine 
was obtained by dissolving the salt in distilled water and adding a small ex­
cess of sodium hydroxide solution. The resulting suspension was extracted 
twice with ether and the combined ether layers were dried and distilled to 
remove the ether. The free base was dissolved in 20 ml ethyl alcohol, 0.1 g 
of palladized charcoal was added and reduction was carried out with hy­
drogen at 760 mm Hg and 18° C. The theoretical quantity of hydrogen was 
taken up by the mixture after two hours. The 5-hydroxytryptamine derivative 
was isolated as oxalate as described above, purified by recrystallization and 
eventually converted, if desired, to the hydrochloride by conventional methods. 
The compounds О 5, О 6, О 12, О 14, О 16, О 18 and О 20 were synthesized 
according to this method (see table I). Determination of the melting points as 
well as determination of nitrogen and chlorine was done to obtain an indication 
of the purity of the compounds synthesized. Nitrogen and chlorine determination 
seemed preferable, since these two elements are generally present in small 
quantities in the compounds synthesized, and would therefore perhaps best 
serve as indicators of purity. 
The compounds generally exhibited reasonably sharp melting points except 
О 6 and О 20, for which a melting traject of two or three degrees was found, 
indicating impurities. For the compounds crystallized as hydrochlorides the 
nitrogen and chlorine found by analysis generally did not deviate much from 
the theoretical values, but for the compounds crystallized as oxalates or as 
creatinine sulphates the nitrogen found by analysis differs rather much from 
the theoretical value. This may be due, in the case of the oxalates, to water of 
crystallization being present, and in the case of the creatinine sulphates either 
water of crystallization or contamination with excess creatinine sulphate might 
have influenced the results. 
The fact that the analysis of the hydrochloride was generally satisfactory 
makes it improbable that the syntheses of the other compounds were not suc­
cessful, since the same method of synthesis was followed for all compounds. 
When following the method of synthesis prescribed, it is also improbable that 
a pharmacologically active compound could be present as impurity. Anyhow, 
it should be stressed that pD2, pA2, pD'2 and intrinsic activity values for the 
compounds О 5, О 6, О 16 and О 20 as presented in chapter IV, have been given 
with some reserve. 
115 
ON 
T A B L E I 
Tryptamine and 5-Hydroxytryptamine derivatives synthesized 
»HOÇT0-0^. 
No. 
0 5 
0 6 
0 7 
0 8 
О 9 
Ri 
5-OH 
5-OH 
-
-
-
R2 
-C-C-C^Q 
-с-с-с-с 
-C-C-C-Q 
-&C-0-Q 
-tc-c^Q 
R3 
-H 
-H 
-с 
-с 
-с 
Salt 
Creatinine 
sulphate 
Creatinine 
sulphate 
HCl 
HCl 
HCl 
Melting 
point 0 C 
155-156 
160-162 
182-183 
Formula 
C23H31N5O6S 
C18H29N5O6S 
C20H25N2CI 
C20H25N2OCI 
C21H27N2CI 
cale. 
13.85 
15.79 
8.52 
8.12 
8.17 
% N found 
16.72-16.90 
14.94-14.95 
8.10 
7.96 
%ci 
cale. 
10.78 
10.28 
10.34 
% Cl found 
OIO 
o n 
0 1 2 
0 1 4 
0 1 6 
0 1 7 
0 1 8 
0 1 9 
O20 
-
5-0-C-/~N 
5-OH 
5-OH 
5-OH 
5 - 0 - C - Q 
5-OH 
5-0-C^3 
5-OH 
-с-с-с-с-/~Л 
-с-с-с-/~Л 
-с-с-с^~Л 
-c-c-c-c 
/O 
¿«.-o 
-c-c-c-ç 
c-c-c-c 
-c-c-c-ç 
c-c-c-c 
-c 
-c 
-c 
-c 
-c 
-c 
-c 
-c 
-c 
HCl 
HCl 
HCl 
oxalate 
oxalate 
HCl 
oxalate 
HCl 
oxalate 
105-106 
112-113 
202-203 
90- 92 
103-104 
125-126 
122-123 
138-139 
63- 66 
C21H27N2CI 
C27H31N2OCI 
C20H25N2OCI 
C17H24N2O5 
C28H30N2O5 
C27H31N2O2CI 
C22H26N2O6 
C26H36N2OCI 
C21H32N2O5 
8.17 
6.44 
8.12 
8.33 
5.90 
6.21 
6.76 
6.55 
7.14 
7.77- 7.92 
6.12- 6.26 
7.74- 7.75 
7.88- 7.93 
5.52- 5.56 
6.04- 6.09 
6.69- 6.81 
6.25- 6.31 
6.79- 6.83 
10.34 
8.15 
10.28 
7.86 
8.28 
10.38-10.39 
8.12- 8.31 
10.29-10.30 
8.04- 8.06 
8.42- 8.47 
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CHAPTER VII 
SUMMARY 
The primary aim of this investigation was to ascertain whether a change from 
agonists via partial agonists to competitive antagonists exists in homologous 
series of serotonin (5-hydroxytryptamine; 5-HT) and tryptamine derivatives 
with substituents of increasing size. It has been shown for other biogenic 
amines (noradrenaline, acetylcholine) that the introduction of especially 
aralkyl substituents in certain positions produce compounds which are compe-
titive antagonists of the respective amines. In the course of this investiga-
tion various known antagonists of 5-HT were also investigated, as well as a 
number of compounds exhibiting 5-HT like activity. Some compounds causing 
sensitization of isolated tissue preparations towards 5-HT or tryptamine also 
received attention, as well as the probability that more than one type of 5-HT 
receptors exist. A possible technique for the evaluation of some central ef-
fects of some hallucinogenic compounds was discussed. 
CHAPTER II 
A summary of the biochemistry, distribution in the mammalian body and 
possible physiological and pharmacological actions of 5-HT is given. A num-
ber of different types of the more generally known 5-HT antagonists are dis-
cussed, especially those which may, on basis of structural relationships, be 
expected to be competitive antagonists of 5-HT. The probable existence of 
more than one type of 5-HT receptors is pointed out. It is furthermore point-
ed out that the methods generally followed in investigations on drug antago-
nism and for obtaining "potency ratios" for agonistic compounds, are un-
satisfactory in a quantitative study on structure-activity relations. For these 
reasons a molecular pharmacological approach was preferred. 
CHAPTER III 
Those principles of molecular pharmacology which are applied in the eva-
luation of drugs in chapter IV are discussed in this chapter. It is pointed out 
that various uncertainties make a quantitative evaluation of drugs on intact 
animals inadvisable, therefore isolated tissue preparations are to be pre-
ferred. 
A drug has to have two properties in order to behave as an agonist, namely 
a f f i n i t y towards specific receptors and the ability to cause an effect when 
interacting with these specific receptors. This latter ability is termed i n -
t r i n s i c a c t i v i t y . Drugs having only affinity towards the specific recep-
tors, but no intrinsic activity, are competitive antagonists of agonists acting 
on the receptors in question. 
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Non-competitive antagonists cause a decrease in the effect of an agonist 
by interacting with receptors other than those of the agonist. This type of an­
tagonism is generally produced by an interference in the stimulus-effect chain 
of the agonist, but in special cases the non-competitive antagonist may cause 
a decrease in the receptor affinity of the agonist. Sensitizing drugs may cause 
an increase in affinity between the agonistic receptors and the agonist. 
Some compounds may interact with more than one type of receptors, for 
instance, auto-inhibiting drugs may cause the auto-inhibition by producing a 
non-compel iti ve antagonism of their own effect when employed in high con­
centrations. Some competitive antagonists may simultaneously act as non­
competitive antagonists when employed in high concentrations. 
Irreversible antagonists maybe either competitive or non-competitive. The 
antagonism caused by a competitive irreversible antagonist is hindered by the 
presence of high concentrations of an agonist or of a reversible competitive 
antagonist. This is the basis for receptor protection experiments, whereby the 
irreversible competitive antagonist (receptor blocking agent) is also an irre­
versible competitive antagonist on the receptors of other agonistic drugs. By 
protecting the receptors of the agonist in question with high concentrations of 
the agonist itself or with a reversible competitive antagonist, the receptors 
for other agonists can be irreversibly blocked by a receptor blocking agent 
while the receptors for the agonist in question remain largely unaffected. 
In the presence of a receptor reserve a distinction between competitive 
and non-competitive antagonism is less sharp in some cases. To make the 
distinction more certain, the amount of receptor reserve of a preparation can 
be estimated by determining the amount of shift of the log concentration-re­
sponse curve of the agonist caused by treatment with an irreversible com­
petitive antagonist. 
CHAPTER IV 
The methods of preparing the isolated tissue preparations used in this study 
are described. It is shown that the rat fundus strip preparation exhibits prac­
tically no receptor reserve when 5-HT is employed as spasmogen, and that the 
auto-inhibitive effect of 5-HT on this preparation may be due to an interaction 
of 5-HT with α-sympathetic receptors at higher concentrations. It is further 
shown that the contraction of the fundus strip produced by 5-HT is probably 
a direct action, in contrast with the probably indirect action of 5-HT on the 
calf tracheal muscle preparation. 
Tryptamine probably acts directly on the 5-HT receptors of the rat fundus 
strip preparation. 
In a series of 5-HT derivatives with substituents of increasing chain lengths 
on the amino group, there is little change in intrinsic activity in the case of 
monosubstitution. With N-methyl,N-alkyl and -aralkyl substitution on trypt­
amine and 5-HT, there is a gradual change from agonists via partial agonists 
to competitive antagonists with increase in size of the substituents. Some N-
methyl.N-aralkyl 5-HT derivatives proved to be the most active competitive 
antagonists found during this study. (A number of tryptamine derivatives with 
substituents in positions other than only on the amino group, as well as some 
other indole derivatives, were also investigated in this connection.) 
Most of the generally known 5-HT antagonists could not be proved to be 
120 
competitive. The compounds LSD and BAS behave as irreversible. 
Some difference exists between the actions of 5-HT on the rat fundus strip 
preparation and on the calf tracheal muscle respectively. The contraction of 
the latter preparation produced by 5-HT is probably caused by a release of 
acetylcholine. The receptors in these two preparations may be of the mus-
culotropic and neurotropic types respectively. 
Some compounds behave as sensitizers of the rat fundus strip and the rat 
vas deferens towards 5-HT and noradrenaline respectively. Amongst these 
sensitizers are compounds like cocaine, Imipramine and the antiviral com-
pound adamantanamine. Monoamine oxidase inhibitors behave as sensitizers 
of the rat fundus strip towards tryptamine and tryptamine derivatives with 
small substituents on the amino nitrogen. 
The claim that treatment of the rat fundus strip with the enzyme neuramini-
dase in the presence of EDTA causes destruction of the 5-HT receptors, is 
criticized. The chemical structure of receptors could perhaps rather be ascer-
tained by using an adaptation of the receptor protection technique. 
CHAPTER V 
Indications that 5-HT may play a role in intraspecific aggressive behaviour 
of animals, led to an investigation of means to register changes in this type of 
behaviour in a quantitative way. An apparatus was built wherewith changes 
in the aggressive behaviour of the female Chinese hamster towards the male of 
the same species could be studied. New types of recorders used for the r e -
gistration of behavioural phenomena are described. 
The precursor amino acid of 5-HT, 5-hydroxytryptophan (5-HTP), appa-
rently causes a decrease in the aggressive activity of these animals, while 
some 5-HT antagonists, like LSD and N-methyltN-phenylpropyl-5-HT, seem 
to cause an increase in aggressivity in some cases. 
CHAPTER VI 
The method according to which a number of 5-HT and tryptamine derivatives 
were synthesized is described and the results of the chemical analysis of these 
compounds are given. 
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SAMEVATTING 
Die primêre doel van hierdie ondersoek was om vas te stel of 'n oorgang 
van agoniste via gedeeltelike agoniste na kompetitiewe antagoniste plaasvind 
in homoloë reekse van serotonien (5-hidroksietriptamien; 5-HT) en tripta-
mien-derivate met steeds grotere substituente. Dit is reeds bewys vir ander 
biogene amiene (arterenol, asetielcholien) dat introduksie van veral aralkiel 
substituente in sekere posisies, verbindings oplewer wat kompetitiewe anta-
goniste is van die ooreenstemmende amiene. Gedurende hierdie ondersoek is 
ook die wer kings van verskeie algemeen bekende antagoniste van 5-HT onder-
soek, asook die werking van 'n aantal stowwe met 5-HT-agtige eienskappe. 
Aan 'n aantal verbindings wat geïsoleerde weefselpreparate tenoor arterenol, 
5-HT of triptamien sensitiseer is ook aandag geskenk, asook aan die moont-
likheid dat meer as een soort 5-HT reseptore bestaan, 'n Moontlike tegniek 
om sekere sentrale effekte van sekere 5-HT-antagoniste te evalueer, is be-
spreek. 
HOOFSTUK II 
'η Opsomming van die biochemie, verspreiding in die dierlike liggaam en 
moontlike fisiologiese en farmakologiese werkings van 5-HT is gegee. 'n Aan­
tal verskillende tipes van die meer algemeen bekende 5-HT-antagoniste is be­
spreek, veral die wat, op basis van struktuurooreenkomste, moontlik as kom­
petitiewe 5-HT-antagoniste magoptree. Die moontlikheid dat meer as een soort 
5-HT-reseptore bestaan, isaangedui. Daar is verder op gewys dat die metodes 
wat algemeen gevolg word in ondersoeke op geneesmiddelantagonisme en om 
"potensieverhoudings" tussen agoniste vas te stel, onbevredigend is in 'n on­
dersoek op struktuurwerkingsverband. Om hierdie redes is 'n molekulêr-far-
makologiese benadering verkieslik. 
HOOFSTUK III 
Die prinsipes van molekulêre farmakologie wat aangewend is vir die besy-
fering van die eienskappe van geneesmiddels in hoofstuk IV, word in hierdie 
hoofstuk bespreek. Daar word op gewys dat verskeie onsekerhede 'n kwanti-
tatiewe bepaling van geneesmiddelwerking op intakte proefdiere bemoeilik, 
daarom word verkieslik van geïsoleerde weefselpreparate gebruik gemaak. 
'n Geneesmiddel moet twee eienskappe besit om as 'n agonis te kan optree, 
nl. a f f i n i t e i t tot spesifieke reseptore en die vermoë om 'n effek te produ-
seer wanneer dit met die spesifieke reseptore in interaksie tree. Hierdie ver-
moë word i n t r i n s i e k e a k t i w i t e i t genoem.Verbindings met alleen affi-
niteit tot, maar geen intrinsieke aktiwiteit op die spesifieke reseptore nie, is 
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kompetitiewe antagoniste van agoniste wat op hierdie reseptore hul effek tot 
stand bring. 
Nonkompetitiewe antagoniste veroorsaak 'n verkleining van die effek van 'n 
agonis deur interaksie met reseptore anders as die van die agonis. Hierdie 
wyse van antagonisme word in die algemeen teweeggebring deur 'n interfe-
rensie in die stimulus-effek skakeling van die agonis, maar in sommige ge­
valle kan 'η nonkompetitiewe antagonis 'η verlaging in affiniteit tussen 'η 
agonis en sy reseptore teweegbring. Sensitiserende verbindings mag 'n ver­
hoging in affiniteit tussen 'n agonis en sy reseptore veroorsaak. 
Sommige verbindings mag met meer as een soort reseptore in interaksie 
tree, bv. outo-inhiberende geneesmiddels mag die outo-inhibisie veroorsaak 
deur 'n nonkompetitiewe antagonisme van hul eie effek wanneer huile in hoë 
konsentrasies gebruik word. Sommige kompetitiewe antagoniste mag tegely-
kertyd as nonkompetitiewe antagoniste optree as hoë konsentrasies gebruik 
word. 
Onomkeerbare antagoniste kan of kompetitief of nonkompetitief wees. Die 
antagonisme veroorsaak deur 'η kompetitiewe onomkeerbare antagonis kan 
teengegaan word deur die teenwoordigheid van hoë konsentrasies van 'n agonis 
of omkeerbare kompetitiewe antagonis. Dit is die basis vir reseptor-besker-
mingseksperimente, in welke die onomkeerbare kompetitiewe antagonis (resep-
torblokkeerder)ook ,n onomkeerbare kompetitiewe antagonis is van reseptore 
van ander agoniste. Deur die reseptore van die agonis te beskerm met 'n hoë 
konsentrasie van die agonis self of van 'n omkeerbare kompetitiewe antagonis, 
kan die reseptore van ander agoniste onomkeerbaar blokkeer word deur 'n r e -
septorblokkeerder terwyl die beskermde reseptore tot 'n groot mate onaangetas 
bly. 
In teenwoordigheid van 'n reseptorreserwe is die onderskeid wat gemaak 
word tussen kompetitiewe en nonkompetitiewe antagoniste in sommige gevalle 
minder skerp. Om hierdie onderskeid meer seker te stel kan die reseptorre-
serwe in 'n preparaat bepaal word deur vas te stel in welke mate die log kon-
sentrasie-effekskrommenaregsverskuifna behandeling met 'n onomkeerbare 
kompetitiewe antagonis. 
HOOFSTUK IV 
Die metodes waarvolgens die geïsoleerde weefselpreparate wat in hierdie 
ondersoek gebruik is geprepareer is, is beskryf. Daar is aangetoon dat die rot 
fundusstrook-preparaat prakties geen reseptorreserwe vertoon wanneer 5-HT 
as spasmogeen gebruik word nie, en dat die outo-inhibitiewe effek van 5-HT 
op hierdie preparaat moontlik te wyte is aan 'η interaksie van 5-HT met α-sim-
patiese reseptore. Verder is aangetoon dat die kontraksie van die fundusetrook 
deur 5-HT teweeggebring waarskynlik'n direkte werking is, in teenstelling met 
die waarskynlik indirekte werking van 5-HT op die kalf tracheaspierpreparaat. 
Triptamien reageer waarskynlik op'η direkte wyse met die 5-HT-reseptore 
van die rot fundusstrook-preparaat. 
Daar ie weinig verandering in intrinsieke aktiwiteit in 'n reeks van N-mono-
substitueerde 5-HT-derivate, maar in reeks van N-metiel.N-alkiel of -aralkiel 
gesubstitueerde triptamien- en 5-HT-derivate met steeds groterwordende sub-
stituente tree 'n graduele verandering op vanaf agoniste via gedeeltelike agonis­
te na kompetitiewe antagoniste. Sommige N-metiel,N-aralkiel-5-HT-derivate is 
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die mees aktiewe kompetitiewe antagoniste gedurende hierdie ondersoek gevind. 
('η Aantal triptamien-derivate met substituente in posisies anders dan alleen 
op die aminogroep, sowel as sommige ander indol-derivate, is ook in hierdie 
verband ondersoek.) 
Vir meeste van die algemeen bekende 5-HT-antagoniste kon nie bewys word 
dat hulle kompetitiefis nie. Die verbindings LSD en BAS is onomkeerbare anta­
goniste. 
Daar bestaan verskille tussen die werking van 5-HT op die rot fundusstrook 
en die werking op die kalf tracheaspier. Die kontraksie van laasgenoemde pre­
paraatdeur 5-HT word waarskynlik teweeggebring deur 'n asetielcholienlibe-
rasie. Die reseptore in hierdie twee preparate is waarskynlik muskulotroop en 
neurotroop respektiewelik. 
• Sommige verbindings tree op as sensitiseerders van die rot fundusstrook en 
rot vas deferens teenoor 5-HT en arterenol respektiewelik. Onder hierdie 
groep van stowwe val kokaien, imipramien en die antivirusstof adamantana-
mien. Monoamien-oksidaseremmere sensitiseerookdierot fundusstrook teen­
oor triptamien en triptamien-derivate met klein substituente aan die amino­
groep. 
Die aanspraak dat behandeling van die rot fundusstrook met die ensiem neu­
raminidase in teenwoordigheid van EDTA 'n afbraak van die 5-HT-reseptore 
teweegbring, isgekritiseer. Die chemiese struktuur van reseptore kan eerder 
bestudeer word deur gebruik te maak van 'n aangepaste reseptorbeskermings-
tegniek. 
HOOFSTUK V 
Aanduidings dat 5-HT'n rol mag speel by onderdrukking van intraspesifieke 
aggressiewe gedrag van proefdiere het gelei tot 'n ondersoek na moontlikhede 
om veranderinge in hierdie gedrag op 'n kwantitatiewe wyse te registreer, 
'n Apparaat waarmee veranderinge in die aggressiewe gedrag van die wyfie Sji-
nese hamster teenoor die mannetjie bestudeer kon word, is gebou. Nuwe tipes 
rekordere vir die registrasie van gedragsfenomene is beskryf. 
Die voorganger-aminosuur van 5-HT, 5-hidroksietriptofaan (5-HTP), ver-
ooreaak 'n verlaging van die aggressiewe gedrag van die wyfie Sjinese ham­
ster, terwyl sommige 5-HT antagoniste soos LSD en N-metiel,N-fenielpropiel-
5-HT, waarskynlik in sommige gevalle 'n verhoging in aggressiwiteit veroor-
saak. 
HOOFSTUK VI 
Die metode waarvolgens 'n aantal 5-HT- en triptamien-derivate berei is, 
is beskryf, en die resultate van die chemiese analiese van die gesintetiseerde 
verbindings is gegee. 
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